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 Preface 
This E-book is the fifth volume of a series that compiles contributions 
from different areas of the multidisciplinary field of Pharmaceutical 
Sciences. The E-book  consists  of 11 chapters that  cover the areas  of 
organic chemistry, health and environmental management, plant 
physiology, food science, toxicology, botany, parasitology, physiology, 
biochemistry and molecular biology, microbiology, and pharmacology. 
The key role of sphingolipids in the regulation of a number of cellular 
functions has boosted important research endeavors towards the 
development of analogs thereof and their use for shedding light on their 
biological and biophysical mechanisms. Chapter 1 describes the design 
and synthesis of particular classes of sphingolipid analogs, namely 
ceramidase inhibitors, of potential interest in the treatment of 
chemoresistant forms of prostate cancer, and sphingolipid-based 
fluorogenic probes with specific applications in structural and cell 
biology. Chapter 2 deals with the assessment of the human health risk 
resulting from exposition  to groundwater contaminated by chlorinated 
hydrocarbons using the so-called Risk Based Corrective Action (RBCA) 
model, a useful tool developed by the American Society of Testing and 
Materials (ASTM) for determining the amount and urgency of necessary 
actions for a polluted site regarding human health. In vitro culture 
techniques using plant cell and organ cultures are promising tools for the 
production of valuable plant secondary metabolites, with important roles 
in plant defense and as a source of phytochemicals for human health and 
nutrition. Chapter 3 describes different in vitro culture techniques and 
reports the development of two biotechnological systems for improving 
the production of two high-value compounds such as the anticancer 
diterpene alkaloid taxol in cell suspension cultures of Taxus spp and 
ginsenoside in hairy root cultures of Panax ginseng. Dietary and physical 
activity strategies have been reported to be useful for  improving  the 
social, cognitive and academic performance of children and adolescents 
with Attention Deficit and Hyperactive Disorder (ADHD), the most 
common neurobehavioral disorder of childhood. In Chapter 4, the role of 
diet and physical  activity in  the management  of ADHD are critically 
discussed. Chapter 5  reviews  the  applicability  of  the  zebrafish 
embryo model in some relevant areas of human toxicology as developmental 
 toxicity, cardiovascular toxicity and neurotoxicity, as an alternative 
model to the laborious and costly traditional in vivo mammalian 
screening approaches. Recent molecular phylogenetic studies have 
shown that the radiation of the genus Cheirolophus in the 
Macaronesian archipielagos was an extraordinarily recent and rapid 
process, with its diversification in the Canary Islands being among the 
top ten explosive plant radiations in this oceanic archipelago. In 
Chapter 6, the main potential patterns and processes involved in the 
explosive diversification of Cheirolophus in the Canary Islands and 
Madeira are reviewed. Chapter 7 summarizes the ultrastructural 
knowledge on spermiogenesis and on the spermatozoon in 
cyclophyllidean cestodes, as a widely accepted valuable tool for the 
elucidation of the phylogenetic relationships in the Platyhelminthes. 
This chapter describes the pattern of spermiogenesis and the type of 
sperm cell for each family of cyclophyllideans and provides new 
spermatological data on some species of the Anoplocephalidae and the 
Taeniidae cyclophyllidean families. Intestinal and bronchoalveolar 
mucosae contribute to homeostasis by preventing the entrance of 
biological and  chemical  agents that  could alter the stability of the 
system. Chapter 8 reviews the main effects of dietary supplementation 
with spray-dried plasma (SDP), a complex mixture of biologically 
active functional components, on mouse models of acute intestinal and 
lung inflammation, highlighting the contribution of an SDP-induced 
increase of regulatory T cell response and enhanced release of anti- 
inflammatory cytokines. Chapter 9 provides an overview of the 
current knowledge about the nutritional regulation of alanine 
aminotransferase expression in fish and its potential use as a 
biotechnological target for enhancing carbohydrate catabolism for 
energy purposes, and preserving dietary amino acids for growth, with 
the aim of sparing protein and improving the sustainability of 
aquaculture. In Chapter 10, the production of oxylipins, a class of 
differently hydroxylated fatty acids, by Pseudomonas aeruginosa 
42A2 grown in submerged culture with oleic or linoleic acid is 
reported, as well as their potential applications as lubricants or 
fungicides against phytopathogenic fungal strains. Finally, chapter 11 
summarizes novel insights into the crosstalk between heart chronic 
low-grade inflammatory processes and metabolic disturbances that are 
involved in the pathogenesis of diabetic cardiomyopathy. 
 We hope that this E-book may be of interest for a broad readership, 
not only for those working in the field of pharmaceutical sciences, but 
also for medical, biological and chemical science researchers. 
 
Dr. Diego Muñoz-Torrero 
Dr. M. Pilar Vinardell 
Dr. Javier Palazón 
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Abstract. Sphingolipids are an important group of biomolecules 
that play important roles in the regulation of many cell functions. 
Many efforts have been made in recent years to design analogs 
suitable for a better understanding of the biological and biophysical 
roles of sphingolipids. In this review, some of the most relevant 
contributions in the field from our group are collected. In particular, 
this review deals with the development of new sphingolipid analogs 
as acid ceramidase inhibitors, and the design of fluorogenic probes 
to screen enzyme activities and to the study of biophysical 
properties. 
 
Introduction 
 
 Sphingolipids (SLs) represent an important group of natural products 
that play crucial roles in cell survival and regulation [1]. Chemically, SLs in  
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mammals contain a lipophilic 2-amino-1,3-diol backbone of eighteen 
carbon atoms, as found in sphingosine (So). Acylation of the 2-amino 
group with fatty acids affords ceramides (Cer), responsible for grow 
inhibition and apoptotis. The so-called complex SLs arise from 
functionalization at the primary hydroxyl group of Cer. In this case, 
glucosylation leads to glucosyl ceramide (GlcCer), the precursor of higher 
glycosphingolipids (GSLs), which play important roles in cell-cell 
recognition events at the outer membrane [2]. Esterification with 
phosphorylcholine leads to sphingomyelin (SM), while both Cer and Sph 
can be also phosphorylated in cells to the corresponding phosphate esters, 
ceramide-1-phosphate (CerP) [3] and sphingosine-1-phosphate (S1P) [4], 
which are important as second messengers and also in cell regulation as 
proliferative agents (Fig. 1).  
 
 
 
Figure 1. Some of the most representative sphingolipids in mammals. 
 
 The effective control of the cellular functions requires a delicate balance 
of SL levels, which is regulated by finely tuned complex metabolic pathways 
with the help of specific enzymes However, the enzymatic processes by 
themselves are not enough to understand this intricate scenario, whose 
operability depends on the cellular compartmentalization of the different 
pathways involved (Fig. 2) [1]. This cellular organization is especially 
relevant for signaling events mediated by SL that are often spatially 
separated in particular organelle. Since the subcellular distribution of lipids 
is not uniform [5], local changes in lipid concentrations can be responsible 
for diverse downstream effects. 
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Figure 2. Metabolic pathways and compartmentalization in sphingolipid 
biosynthesis. (CERT: ceramide transporter protein; dhCer: dihydroceramide; dhKSo: 
ketosphingosine; dhSo: dihydrosphingosine; GSL: glycosphingolipids; NCDase: 
neutral ceramidase; NSmase: neutral sphingomyelinase; SK: sphingosine kinase; 
FAPP2: GlcCer transfer protein). 
 
 The fact that the expression of SL metabolizing enzymes is deregulated 
in many diseases has boosted the design of SL biosynthesis modulators as a 
rational approach to define new targets and new small molecule chemical 
entities with potential therapeutic applications [6].  
 In recent years, the interest on the biophysical properties of SLs, in 
particular So, Cer and their phosphorylated derivatives, has emerged as a 
major field of research. In this context, So is known to increase membrane 
permeability, while Cer increase lipid chain order, induce “flip-flop” motion 
of lipids and segregate laterally into rigid domains, among other effects [7]. 
Interestingly, it is the ability of these SL to aggregate into microdomains 
what accounts for the formation of high local concentrations of secondary 
messengers that are ultimately responsible for the triggering of some cellular 
effects. 
 
1. Sphingolipid analogs as enzyme inhibitors 
 
 Abnormal SLs metabolism is known to occur in some diseases, such as 
certain sphingolipidoses [6], cancer [8], diabetes [9], and aterosclerosis [10]. 
The cellular contents of the various SLs species are controlled by enzymes 
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involved in their metabolic pathways. In this context, the search for potent 
and selective inhibitors of SL metabolizing enzymes offers new insights for 
the discovery of alternative therapeutic agents. Our interest in SL enzymes 
as potential targets led us to investigate on ceramidases, a type of 
amidohydrolases that catalyze the cleavage of Cer into So and fatty acids. 
According to their optimal pH, ceramidases fall into three groups, acidic 
(aCDase), neutral (NCDase) and alkaline ceramidases (alkCDase). While 
aCDase is ubiquitously expressed, NCDase is highly expressed in the small 
intestine along the brush border, where it is involved in the catabolism of 
dietary sphingolipids thus regulating the levels of bioactive sphingolipid 
metabolites in the intestinal tract. On the other side, alkaline ceramidases are 
expressed in the endoplasmic reticulum, where three different types have 
been identified, based on their localization and the encoding genes [11].  
 The role of CDases in human disease is well documented. In general, 
increased CDase activity leads to reduced levels of ceramides and increased 
amounts of S1P, which results in increased resistance to cytotoxic signals. 
This situation is often found in cancer progression and resistance to 
treatments. On the other hand, a decrease of ceramidase activity provokes 
cell death. A number of reports point to important roles of ceramidases, 
mainly aCDase, in the initiation and progression of cancer, and the response 
of tumours to therapy [12]. Overexpression of aCDase is found in several 
cancer cell lines and cancer tissues [13], which appears to contribute to 
decreasing the levels of Cer and increasing those of S1P, thereby resulting in 
resistance to cell death and enhancement of cell proliferation. In most cases, 
aCDase inhibition induces apoptosis. Multiple reports confirm the 
relationship between aCDase activity and radio- or chemotherapy resistance, 
as well as the interest of aCDase inhibitors as anticancer drugs, either alone 
or in combination with other therapies [11]. The research in this field has led 
to implicate an over-expression of acid ceramidase (aCDase) in metastatic 
prostate cancer [14]. Many tumor types express high levels of acid 
ceramidase (aCDase). Specifically, the expression levels of aCDase in 
prostate cancer have been reported to be elevated relative to normal prostate 
tissue [15]. With these considerations in mind, a rational design of an 
aCDase inhibitor was undertaken. Taking into account that aCDase is a 
cysteine hydrolase, a small family of Cer analogs modified at the amide 
linkage with thiol reactive functions was generated and tested. These 
compounds were inspired in reported cysteine protease inhibitors [16] and 
included two β-haloamides and several α,β–unsaturated amides as Michael 
acceptors, as shown in Fig. 3. 
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Figure 3. New acid ceramidase inhibitors. 
 
 The best inhibitors in intact cells were compounds RBM1-12, RBM1-13, 
RBM1-18 and SABRAC, with percentages of inhibition ranging from 50 to 
70%. Compounds RBM1-12, RBM1-13, and SABRAC were selected for 
further studies and were shown to be selective aCDase inhibitors in light of 
their lack of activity on NCDase, the enzyme that hydrolyses Cer in the cell 
membrane. In vitro dose-response determinations showed that SABRAC 
was the best inhibitor, with an IC50 value of 52 nM, followed by RBM1-12 
(IC50 = 0.53 µM) and RBM1-13, which exhibited the lowest potency (IC50 = 
11.2 µM). Furthermore, in the presence of SABRAC and RBM1-12, the 
enzyme activity showed an exponential decay versus incubation time at two 
protein concentrations, this indicating an irreversible type of inhibition. The 
above observations confirmed aCDase as a therapeutic target in advanced 
and chemoresistant forms of prostate cancer and suggested that our new 
potent and specific inhibitors could act by counteracting critical growth 
properties of these highly aggressive tumor cells. 
 
2. Sphingolipid analogs as fluorogenic probes 
 
 The perception that SL metabolism is composed of a highly intricate, 
interrelated system of enzymes, whose relative activities determine the 
intracellular concentration of SLs and, ultimately, the cell fate, has boosted 
the development of methods to monitor SL enzyme activity. In this context, 
the use of fluorogenic substrates (substrates that give rise to a fluorescent 
readout subsequent to a particular enzymatic reaction) represents a 
breakthrough in the design of probes suitable for determining enzyme 
activities. Guided by these interests, our group has been working actively in 
the development of new fluorogenic probes for the development of HTS 
methods for the screening of several SL metabolizing enzymes. With our 
focus on aCDase, the fluorogenic coumarinic substrates RBM14 (Fig. 4) 
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were designed. After the enzymatic hydrolytic amide cleavage of the above 
substrates, oxidation of the resulting vicinal amino diol renders an 
intermediate aldehyde AL (Fig. 4), whose subsequent β-elimination under 
basic conditions liberates the fluorescent reporter (Fig. 4) [17,18]. 
Interestingly, the specificity of the substrates towards ceramidases could be 
modulated by choosing an appropriate acyl chain length. Thus, for aCDase, 
the highest rate of hydrolysis was observed for the probe with a dodecanoyl 
group (RBM14-12). The recombinant human neutral ceramidase preferred 
the hexadecanoyl derivative (RBM14-16), while the tetradecanoylamide 
(RBM14-14) was preferentially hydrolyzed by lysates of neutral 
ceramidase-null mouse embryonic fibroblasts at pH 8.5 in the presence of 
Ca
+2
. It is worth mentioning that this fluorogenic method is currently used 
for the diagnosis of Farber disease, a rare disease characterized by the 
deficiency of aCDase [18]. 
 The in situ generation of umbelliferone as a fluorescent reporter to 
monitor SL enzyme activity was also been applied for the development of a 
HTS protocol for sphingosine-1-phosphate lyase (SPL). This enzyme plays 
an important role in cellular functions linked to tumor progression and 
immunosuppression [19]. It catalyzes the retroaldol cleavage of long chain 
base phosphates into phosphoethanolamine and a fatty aldehyde (Fig. 5). 
Since both saturated and unsaturated, as well as truncated base phosphates 
are transformed by SPL and the reaction is highly stereoselective for the 
d-erythro isomer [20], we reasoned that compound RBM13 contained the 
required structural features to behave as a suitable SPL substrate. 
 
 
 
Figure 4. Fluorogenic coumarinic fluorogenic probes to determine CDase and SPL 
activities. 
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Figure 5. Retroaldol reaction catalyzed by SPL. 
 
 Upon enzymatic cleavage, aldehyde AL (Fig. 4) is first produced to 
render the fluorescent umbelliferone reporter after β-elimination under 
alkaline conditions [21]. In our optimized protocol, the assay can be 
performed in microtiter wells, and can be easily adapted to HTS formats. 
 The above substrates were inspired in the pioneering works by Reymond 
and co-workers for the development of a fluorogenic assay for hydrolytic 
enzymes [22]. 
 The synthesis of the above probes can be carried out starting from 
Garner’s aldehyde, following the approach indicated in Fig. 6. The common 
intermediate B, obtained from acidic hydrolysis of A, arising, in turn, from 
Garner’s aldehyde in five synthetic steps [17], was selectively 
phosphorylated at the primary hydroxyl group, to give C, and further 
deprotected in a one-pot two-step process to the required amino phosphate 
RBM13. Alternatively, Boc removal from intermediate B, followed by 
standard N-acylation afforded the required RBM14 probes. 
 
 
 
Figure 6. Synthesis of the fluorogenic coumarinic probes RBM13 and RBM14. 
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3. Azidosphingolipids as probes to study membrane 
organization 
 
 The use of synthetic lipid probes for biophysical applications is a 
well-recognized strategy in lipid research [23]. In particular, the use of 
fluorescent tags is useful for the visualization of the membrane architecture 
and the study of its dynamic properties. The suitability of the substrate is 
determined by its ability to afford a fast and sensitive detection and also to 
behave similarly as its untagged counterpart. These two requirements are 
somehow contradictory when large aromatic fluorescent moieties are used. 
Because natural membrane lipids do not have such bulky fluorescent tags, 
dramatic effects on the properties of the resulting probes can be expected, 
especially as far as trafficking, sorting and/or domain formation is concerned 
[24]. Ideally, a suitable probe should be structurally similar to its natural 
counterpart and allow an efficient in situ chemoselective functionalization 
with a suitable fluorescent reagent in a natural environment. These 
requirements can be envisaged by a judicious use of bioorthogonal chemical 
reporter strategies, a technique that has become common place for the 
labelling of biomolecules [25,26]. Based on these premises, and aiming to 
widen the scope of our research, we undertook the synthesis of the α- and 
ω-azido probes RBM2-79 and RBM 2-77 shown in Fig. 7. As sphingolipid 
analogs, these probes are amenable to incorporation into natural or artificial 
membranes. In addition, due to the presence of the terminal azido group, the 
possibility of a bioorthogonal alkyne-azide cycloaddition “click” reaction 
with the fluorogenic tag D [27] was considered. 
 
 
 
Figure 7. Design of bioorthogonal “click” reactions with azido sphingolipid probes 
RBM2-77 and RBM2-79. Doble enlace en triazol 
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 In this context, the recent advances in the development of bioorthogonal 
reactions have boosted their applications in chemical biology [28]. In 
particular, those involving the Cu(I)-catalyzed Huisgen [3+2] cycloadditions 
of terminal alkynes with azides [29] (CuAAC, the paradigm of “click 
chemistry” [30]) have become attractive to researchers due to their 
simplicity and high reactivity. In order to avoid the potential toxicity of 
Cu(I) salts, several modifications have been developed to reduce Cu(I) 
concentration, as the use of water-soluble Cu(I) ligands [31,32] or 
Cu(I)-chelating azides [33]. 
 In our case, the probes shown in Fig. 7 have been designed to mimic the 
behaviour of natural ceramides in artificial membranes [34]. Membrane 
ceramides are important metabolic signals [35,36] that are known to separate 
laterally to give rise to gel-like ceramide-enriched domains [37–39]. Because 
of their structural similarity, our probes RBM2-77 and RBM2-79 were able 
to orient in lipid bilayers in parallel with the phospholipids, and eventually to 
give rise to domains similarly to natural ceramides. Gratifyingly, our in situ 
synthetic method allowed the observation of ceramide domains in living 
cells.  
 Click reactions required the use of an in situ generated Cu
+
 catalyst by 
ascorbate promoted reduction of a Cu
2+
 salt. The photoactivation of the 
probes was checked by microscopy experiments using giant unilamellar 
vesicles (GUVs) of ePC:1 and ePC:2 (10 mol% of clickable probe in both 
cases). When GUVs were treated with the labeling solution, a clear 
fluorescence intensity was collected in both cases between 450-500 nm, 
which was attributed to the formation of the corresponding fluorescent click 
cycloadducts shown in Fig. 7. This fluorescence was not observed when 
GUVs were incubated under control conditions (in the absence of the Cu
2+
 
salt catalyst precursor) after 3h incubation. These results constitute a proof 
of principle that fluorescent ceramide derivatives may be formed within lipid 
membranes starting from minimally modified non-fluorescent azido 
sphingolipids. This technique can be extended to the study of 
ceramide-enriched domains by fluorescent confocal microscopy and also to 
the study of the so-called ceramide platforms [40]. Finally, despite Cu
2+
 may 
be toxic to cells, localization of ceramide-rich domains in cell membranes 
can be performed on fixed cell preparations. In any, case, the use of Cu-free 
click chemistry protocols [41] is also considered as a natural evolution of 
this technique.  
 The above probes were synthesized following standard protocols, as 
exemplified for RBM2-77 in Fig. 8. Thus, the cross methathesis [42,43] of 
11-bromo-1-undecene with vinyl alcohol E, obtained from Garner’s 
aldehyde following a reported protocol [44], afforded bromide F in moderate  
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Figure 8. Synthesis of probe RBM2-77; a: 11-bromo-1-undecene, Grubb’s 2nd 
generation, CH2Cl2, 45 ºC, 59%; b: NaN3, DMF, 80 ºC (93%); c: ClCOCH3, MeOH, 
rt, 1h (84%); d: C15H31COOH, EDC. HOBt, Et3N, CH2Cl2, 65%. 
 
yield and excellent E-selectivity. Reaction of F with excess NaN3 in DMF at 
80 ºC, followed by the simultaneous deprotection of the oxazolidine and 
N-Boc groups of intermediate azide G under acidic conditions, afforded 
RBM2-31 in excellent yield. Acylation with palmitic acid, using EDC/HOBt 
as coupling system, afforded probe RBM2-77. 
 
4. Conclusions 
 
 In this review we have tried to show the potential of the chemical 
modifications of sphingolipids by means of a selection of some of our recent 
results in this area. Thus, the biochemical functions of natural sphingolipids 
can be efficiently modulated by the judicious design of analogs addressed at 
interfering with specific enzymes of key sphingolipid metabolic pathways. 
In this account, this approach has been illustrated with the design of a new 
family of aCDase inhibitors, which have also allowed the identification of 
this enzyme as a therapeutic target in chemoresistant forms of prostate 
cancer. In a conceptually different approach, chemical modifications of 
sphingolipids have also been used to design chemical probes with specific 
applications in structural and cell biology. This is the case of the fluorogenic 
probes RBM13 and RBM14, designed to develop HTS protocols to monitor 
the activity profiles of SPL and CDases, respectively. In a related context, 
the azido sphingolipids RBM2-77 and RBM2-79 have found applications in 
structural biology for their ability to visualize the membrane organization of 
natural ceramides after a biorthogonal click reaction with a suitable 
fluorogenic reporter. 
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Abstract. Human health risk assessment is the basis for groundwater 
contamination and remediation goals definitions. Chlorinated solvents 
have a high toxicity for humans, even at low concentrations, and are 
important soil and groundwater pollutants.  The main objective of this 
work is to assess the human health risk derived of exposition to a 
contaminated groundwater using a commercial Risk Analysis model 
(RBCA) and taking into consideration different exposure factors. A 
case study was used. Some risk differences were observed using 
specific exposure factors in different countries, which were explained 
by differences in life style. 
 
Introduction 
 
 Chlorinated solvents are a type of DNAPLs (Denser-than-water                         
Non Aqueous-Phase Liquids) that include: Tetrachloroethene (PCE), 1,1,1 
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Tricloroethane (111TCA), 1,1,2 Tricloroethane (112TCA), 1,2 
Dichloroethane (DCA), Chloroethane (CA), Trichloroethene (TCE), cis-1,2- 
Dichloroethene (c-DCE), trans-1,2-Dichloroethene (t-DCE), Vinylchoride 
(VC), Carbon tetrachloride (CT), Chloroform (CF), Dichloromethane 
(DCM), and Chloromethane (CM).  
 They have been produced and utilised widely since the beginning of the 
20th century. The typical uses were: dry cleaning (mostly tetrachloroethene), 
metal degreasing, pharmaceutical production, and pesticide formulation [1]; 
they were also used in the rubber industry and as coating products [2]. Their 
importance as soil and groundwater contaminants was not recognised until 
the 1980s.  
 Thereby since 1970, chlorinated solvents have been less and less used in 
order to preserve the environment. They are now under control by REACH 
(European Regulation on Restriction, Evaluation, and Authorization of 
Chemicals) [3]. 
 These solvents have a high toxicity, even at low concentrations [1]. The 
major target organ of these compounds is central nervous system; other 
targets are skin and mucus membranes, heart, eyes, lung, liver, and kidneys. 
An acute toxicity can be observed on these organs that results in: ravage of 
the central nervous system (depression, reversible mood, and behavioural 
changes, impairment of coordination,…). PCE can cause irritation of the upper 
 
 
 
Figure 1. Fate of chlorinated solvents in the media. 
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respiratory tract and eyes, kidney dysfunction, headache, sleepiness  and 
unconsciousness. The liver toxicity is particularly due to carbon 
tetrachloride. Heart excitability or irritation of the nose and throat are 
consequences of TCE exposition. High concentrations of TCE have caused 
numbness and facial pain, unconsciousness, irregular heartbeat, and death. 
CF causes depression, rapid and irregular heartbeat, as well as liver and 
kidney damage [4]. A chronic toxicity has all been stated on all the targets 
organs, as well as a potential carcinogen effect [2]. VC is admitted to 
produce angiosarcoma [5]; indeed, IARC (International Agency for Research 
on Cancer) classifies: VC in the group 1, carcinogenic to humans, [6]; TCE, 
in group 2A, probably carcinogen to humans; PCE, CT, CF and DCM in 
group 2B, possibly carcinogen to humans, and TCA in group 3, 
unclassifiable by its carcinogenicity to humans [7,8].  
  There may be a natural attenuation of such a contaminants by physical 
(volatilization), chemical (dilution, absorption, dispersion) and biological 
processes (biodegradation). The above mentioned processes contribute to the 
diminution of risk for the human health [4].  
 Some microorganisms as Dehalococoides spp. are able to use 
chlorinated solvent as electron acceptors during the dehalorespiration and 
dechlorinate them. Sometimes, biotransformation of the initial compounds 
produces other compounds more toxic or more persistent at the media [4]. 
 The first exposed people are usually the workers in the industries but, 
due to the dispersion in groundwaters, the population can be also exposed 
during long time through the consumption of drinking water, representing an 
important public health issue locally.  
 
 
 
(Source: Danish Environmental Project No. 1295, 2009) [9] 
Figure 2. Natural attenuation of chlorinated solvents at the media. 
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 RBCA (Risk Based Corrective Action) is a tool developed by the 
American Society of Testing and Materials (ASTM) for determining the 
amount and urgency of necessary actions for a polluted site regarding human 
health [10]. This model is used to identify exposure pathways and receptors 
at a site, determine the level and urgency of response required, determine the 
level of surveillance appropriate for a site, and incorporate risk analysis into 
all phases of the corrective action process [11]. RBCA combines 
contaminant transport models and risk assessment tools to calculate baseline 
risk levels and derive risk-based clean-up standards for a full array of soil, 
groundwater, surface water, and air exposure pathways. Environmental site 
managers, regulatory authorities, and consultants around the world have 
increasingly turned to Risk-Based Corrective Action (RBCA) for the 
management of contaminated soil and groundwater [12]. 
 
Table 1. Main exposure related parameters. 
 
 
 
 The main objective of this work is to assess the human risk of 
contaminated groundwater by chlorinated hydrocarbons using the RBCA 
model that is widely regarded as a useful one for specific scenarios. Site-
specific consideration allows for attenuation process to be taken into account 
along the pathway from the source of groundwater pollution. Secondary 
objectives are: to verify the correct toxicological and exposure values to be 
used to fit the model, to establish different exposure scenarios, and to 
identify data gaps. 
 
1. Study area 
 
 The pollution episode studied was detected in 1996 at an industrial plant 
inside a chemical complex, but it is not well known when the episode started. 
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Two chlorinated methanes were associated with the episode: carbon 
tetrachloride (CT) and chloroform (CF), stored independently at the site. 
Repeated leaks and spills are responsible for the current situation. The area is 
located at a small sedimentary basin. Characterization studies, monitoring, and 
control of groundwater’s quality began in 1996. 196 m2 of the soil were then 
affected by contamination of CT, CF, DCM, 1,1,1,2 PCA, 1,1,2,2 PCA, 1,1,1 
TCA 1,1,2 TCA, PCE, TCE, 1,1 DCE, tDCE, and cDCE, from 0.5 to 6 m of 
depth.  
 Concerning the water, the polluted plume is supposed to be 4 m thick 
and big of 2 m. Concentrations recorded at the groundwater, ranged between 
15 and 22,600 μg/L for CF, and between the detection limit and 86 μg/L for 
CT [13]. Six samples were taken from a well for analysis; every sample was 
analysed by triplicate. The methodology used for chlorinated solvent 
characterization has been gas chromatography because, being sensible, 
specific and applicable, it is the most performing method, with a detection 
limit of 0,01-0,1 μg L-1[14,15]. 
 
2. Exposure assessment  
 
 The following equation has been used to model the exposure rate (E):  
 
E = (CR x EF x ED) / (BW x AT)          [1] 
 
 Which depends on the entrance via (ingestion, inhalation, dermal 
contact) rate (CR), the exposure frequency (EF), the exposure duration (ED), 
the body weight (BW), and the average time of exposure (AT).  
 Due to the presence of an operating industrial plant at the polluted area, 
the first receptors are regular and temporary workers. Exposure point primarily 
for on-site workers involved in excavation, digging, and other activities that 
turn over the soil or that are in touch with groundwater. Workers can be 
exposed principally by inhalation of the compounds in the outdoor air, but 
national legislations use to oblige also to take into account: accidental 
ingestion of contaminants in soil, and inhalation of contaminated dust in air.  
 No residents are present at the affected area, but to take into 
consideration population that could be exposed outside the area (residents 
and visitors who dig holes for planting trees, installing swimming pools, or 
other uses) it has been considered that the residential population can be 
exposed 500 m far from the area (Point of Exposure 1, POE1) and 1,000 m 
far from the characterised area (POE 2); if contaminated groundwater is 
being supplied as drinking water, then the residents may be exposed via 
ingestion, inhalation (from volatilization during shower), and dermal contact 
(when taking a shower/bath). 
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Figure 3. Points of exposure (POE) considered at the modelisation. 
 
3. Toxicity assessment 
 
 For non-carcinogenic compounds, the RfD is the used reference, which 
is an estimate (with uncertainty spanning perhaps an order of magnitude) of 
the daily exposure to the human population, including sensitive subgroups, 
that is likely to be without an appreciable risk of deleterious effects during 
the lifetime. The RfD is generally expressed in units of milligrams per 
kilogram of body weight per day (mg/kg/day). The RfD is determined for all 
routes of exposure by using the following equation:  
 
RfD = NOAEL / (UF x MF)         [2] 
 
 RfD is usually derived from an experimentally determined "no-
observed-adverse-effect level (NOAEL) which is the experimentally 
determined dose at which there was no statistically or biologically 
significant indication of toxic effects of concern. Uncertainty Factors (UF) 
and Modifying Factors (MF) are used, based on a professional judgment 
[16].  
 For the carcinogenic exposure this is done by quantifying how the 
number of cancers observed in exposed animals or humans increases with 
the dose. Typically, it is assumed that the dose-response curve for cancer has 
no threshold (i.e., there is no dose other than zero that does not increase the 
risk of cancer), arising from the origin and increasing linearly until high 
doses are reached. Thus, the most convenient descriptor of cancer potency is 
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the slope of the dose-response curve at low doses (where the slope is still 
linear). This is referred as the Slope Factor (SF), which is expressed as risk 
of cancer per unit dose. 
 
4. Individual risk analysis 
 
 For the non-carcinogenic compounds it’s represented by the Hazard 
Ratio (HR): 
 
HR = E / RDf            [3] 
 
 If HR is higher than 1, they is a risk because the exposure dose is higher 
than the exposure dose without significant effect. 
 For the carcinogenic compounds which don’t have threshold, the 
following equation is used: 
 
R = E x SF           [4] 
 
Where: 
R = Risk, a unitless probability (e.g., 2 x 10-5) of an individual developing cancer; 
E = chronic daily intake averaged over 70 years (mg/kg-day); 
SF = slope factor, expressed in (mg/kg-day). 
 The most widely used value of acceptable risk is 10
-5
, what means that 
one new case of cancer due to this compounds exposure every 100,000 
people is accepted. 
 
5. Cumulative risk analysis  
 
 The risk commonly used for the case by case risk assessment is the 
cumulative risk, which takes into account all the compounds together. The 
cumulative risk for carcinogens (sum of risk for all chemicals and all 
complete exposure pathways) must not exceed 1x10
-4
 or 1x10
-5
, according 
different legislations.  
 For non-carcinogenic compounds, the site-wide hazard index, which is 
the sum of hazard quotients for all chemicals and all complete exposure 
pathways, must not exceed 1.0.  
 
6. Pollutant transfer and degradation  
 
 Pollutant transfer and degradation contribute to contaminants depletion, 
which results in less risk. Risk analysis considers a constant concentration 
value for the contaminant/s throughout the entire exposure period, which is a 
very conservative assumption.  
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 Cross media transfer factors: To take in account the transfer of pollution 
between media, as for example, volatilisation of chlorinated solvent from the 
groundwater to the outside air, the used model applies the following 
equations: 
 
Groundwater Volatilization Equation 
 
 
 
 
 
 
    (Source: GSI, 1996) [17] 
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Lateral Groundwater transport equation 
 
 To account for attenuation of affected groundwater concentrations 
between the source and the receptors, this model considers a partially or 
completely penetrating vertical plane source, perpendicular to groundwater 
flow, to simulate the release of organics from the mixing zone to the moving 
groundwater. 
 
 
 
Lateral Groundwater Dilution Attenuation Factor 
 
 
 
Source: GSI, 1996 [17]. 
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 The general experience is that these substances may be, under different 
environmental conditions, adaptively degraded.  
 The estimated half-lives for chlorinated solvents should therefore be 
considered, being in accordance with “the realistic worst-case concept”, in 
order to establish the realistic exposition level. 
 
Table 2. Half life of chlorinated solvents in groundwaters. 
 
COMPOUNDS 
  Half time life (days)   
CAS Model value Min Max 
CT 56-23-5 360 a 7 b 360b 
CF 67-66-3 1800 a 1825 b 
CM 74-87-3 546 c 14 b 56 b 
DCM 75-09-2 56 a 14 b 56 b 
PCE 127-18-4 720 a 360 b 720 b 
TCE 79-01-6 1653 a 321 b 1653 b 
tDCE 156-60-5 2880 a 
 2880 a 
  
cDCE 156-59-2 2875 c 
2880 a  
  
VC 75-01-4 2880 a 56 b 2850 b 
1,1,1 TCA 71-55-6 730 a 140 b 546 b 
1,1,2 TCA 79-00-5 730 c 136 b 730 b 
1,2DCA 107-06-2 360 a 100 b 360 b 
CA 75-00-3 56 a 14 b 56 b 
        a: Data from the RBCA model 
        b: Data bank of environmental properties of chemicals (EnviChem), 2013 [18]. 
 
7. Data used to fit the model 
 
Physicochemical parameters and toxicological data of contaminants 
 
 The verification of the properties’ data in the model is important for the 
validity of the results. The variability in parameter values may have a 
significant effect on the predicted contaminant’s behavior and ultimately on 
the estimated human exposure. So, it has been decided to take into account 
the maximum and the minimum values, and to make the average of the 
different values found in bibliography to have a complete extent. 
 From different data bases, such as Reaxys, and IRIS [16,19], or 
toxicological reviews of the EPA [20,21], we built a data base with 
maximum, minimum and average values for: Solubility, Vapor pressure, 
Henry’s constant, Partition Coefficient octanol/water, Coefficient Koc, and 
Coefficient of diffusion in air and in water (see Table 3). 
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The same process has been accomplished to collect the toxicological 
data from IRIS [16] and other reviews or articles [22]. Concerning the 
toxicological properties, Reference Dose (RfD) and Reference 
Concentration (RfC) for different routes of entry has been used to 
determine the potential of a toxic effect. Slope factors (SF) and Unit risks 
level (URL) have been used to determine the development of excess 
number of cancers in receptors [23]. 
 
Exposure parameters 
 
 The exposure factors change according to the social behavior, which 
is different from one place to another, from one gender to the other, or 
according to the age. For example, children have usually hand-to-mouth 
activities; at the adolescence, they stop this behavior but they are                       
still in contact with higher amounts of soils (through playing                     
football or other games) than adults [24]. So it is interesting to 
differentiate the risk evaluation for each subpopulation group. Indeed, 
males and females (as children/adults) do not have the same food needs 
or body weights.  
 Exposure parameters for different countries have been checked. 
Concerning quantity of food ingested, exposure time, the maximum 
available values or the 95th percentile have been chosen, in order to have 
the worst scenarios. If the specific exposure parameter was not available, 
the default value of the RBCA model has been used. 
 
Groundwater parameters 
 
 A minimum of three wells in the aquifer have been necessary for 
triangulation of water levels and to indicate groundwater flow direction. 
Other parameters are shown in Table 5.1. 
 
Air parameters 
 
 It has been also needed to characterize air parameters, the dimension of 
the zone, and also the dispersion taxes (see Table 5.2). 
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Table 5.1. Water parameters to fit the RBCA model. 
 
 
 
Table 5.2. Air parameters  to fit the RBCA model. 
 
 
 
8. Results 
 
 Thanks to the risk analyses applied according exposure parameters 
considerations made in different countries, we have had a large view of different 
scenarios, with different exposure parameters for the potential on site receptors.  
Chlorinated solvents at groundwaters risk assessment 27 
 
 
 
Figure 4. Hazard Ratio from the exposition of males and females working at the 
polluted area and exposed to polluted groundwater according to exposition default 
values applied at each country. 
 
 
 
 
Figure 5. Excess risk of cancer from the exposition of males and females working at 
the polluted area and exposed to polluted groundwater according to exposition 
default values applied at each country. 
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Figure 6. Hazard risk from the exposition of males and females living at the polluted 
areas and exposed to the polluted groundwater according the exposition default 
values applied at each country.  
 
 
 
 
Figure 7. Excess risk of cancer from the exposition of males and females living at 
the polluted areas and exposed to the polluted groundwater according the exposition 
default values applied at each country.                  
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 The variation of the calculated risk between female and male depends on 
the exposure parameters which can differ from one gender to another, when 
considering specific exposure parameters (body weight, dairy products 
ingestion,…). The parameter which changes the most is the body weight. For 
example, for Catalonian female body weight is statistically 55 kg, whereas for 
male is 70 kg; or, 70 and 83.2 kg respectively in UK. Indeed, as female have a 
lower body weight than male and that body weight is on the denominator of 
the excess risk equation, a lower body weight increase the risk. Vegetable 
uptake or skin surface are also changing between male and female. Indeed, the 
UK exposure factors, for the consummation of water polluted for the receptor 
residential the risk is higher for men than for women. This can be explained by 
differences in the water uptake for man (3.17 L) and woman (2.27 L), so male 
is more exposed and that means a higher risk. 
 
Conclusion 
 
 This work was focused on the value of the real exposure time and 
exposure parameters in a particular industrial region and on contamination of 
chlorinated solvent DNAPL’s, but it can be extrapolated to different 
scenarios. Differences in human exposure factors data, including 
anthropometric and sociocultural data (e.g., body weights, skin-surface 
areas, and life expectancy), behavioural data (e.g., non-dietary ingestion 
rates, activity/time use patterns, and consumer product use), factors that may 
be influenced by the physiological needs of the body, metabolic activity, and 
health and weight status (e.g., water and food intake, and inhalation rates), 
and other factors (e.g., building characteristics) can lead to variations in 
calculated risk. 
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Abstract. Plant cell and organ cultures constitute a promising 
platform for the production of numerous valuable secondary 
compounds. Currently, in vitro culture techniques involve both 
empirical and rational approaches as suitable strategies to condition 
high metabolite production and establish competitive plant cell-based 
bioprocesses. In this context, we have developed hairy root cultures of 
Panax ginseng, and engineered hairy root cultures of Duboisia, 
Datura metel and Hyoscyamus spp and plant cell cultures of Centella 
asiatica and Taxus spp. This chapter describes our work on the 
development of two different biotechnological systems to improve 
taxol production in cell suspension cultures of Taxus spp and 
ginsenoside production in hairy root cultures of Panax ginseng. 
 
Introduction 
 
 Plant secondary metabolites play an important role in plant defense and 
constitute a source of phytochemicals for human health and nutrition. The 
three main groups of plant secondary metabolites (alkaloids, polyphenols 
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and terpenes) include a wide range of compounds with high added value. 
Some of them can be synthesized chemically, but due to their highly 
complex structures most are extracted from the plant. However, sometimes 
even extraction from the plant is not feasible, due to low production levels, 
and the risk of endangering the species. 
 In vitro culture techniques using plant cell and organ cultures are 
promising tools for the production of numerous valuable secondary 
compounds. Empirical approaches have long been employed for the 
development and optimization of plant cell-based bioprocesses, focusing on 
input (cell line, medium, culture parameters, bioreactors, process operations, 
etc.) and output factors (cell growth, nutrient uptake, productivity, yield, 
etc.). In addition, a rational approach, taking into account the molecular and 
cellular basis of metabolic pathways and their regulation, is currently being 
used. The successful biotechnological production of phytochemicals with 
high added value, such as the anticancer compound taxol, shows that plant 
cell and organ cultures can constitute an alternative to the culture of the 
whole plant for the production of secondary metabolites with biological 
activity [1].  
 The biotechnological production of plant secondary metabolites has 
several advantages over the culture of the whole plant in the field, including:  
 
• The desired product can be harvested anywhere in the world, maintaining 
strict control of production and quality. 
• It is not necessary to use herbicides and pesticides. 
• Climate or ecological problems are avoided. 
• Growth cycles are of weeks rather than years.  
 
 Our research is based on plant in vitro culture and genetic and metabolic 
engineering techniques with the aim of increasing the production of high-
value phytochemicals and obtaining plant stem cells for cosmetic uses             
(Fig. 1). Working with plant in vitro cultures, we are interested in the 
selection of highly productive genotypes and the micropropagation of 
aromatic and medicinal plants in order to maintain the most productive ones 
and, in cases of endangered plants, to help preserve the species. Plant 
micropropagation also represents the best way to obtain virus-free plants to 
meet phytosanitary requirements for plant import-export. Another goal is 
using plant cells and hairy root cultures for the production of 
phytochemicals. 
 Another field of our research involves the application of genetic and 
metabolic engineering techniques to improve the production of target 
secondary metabolites. In this case, it is necessary to understand the relevant 
biosynthetic pathways and to know which enzymes catalyze the sequence of  
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Figure 1. Plant in vitro culture and genetic and metabolic engineering techniques as 
the basis of Plant Biotechnology. 
 
reactions, especially the slow steps, and the genes encoding these enzymes. 
Using the aforementioned techniques, the plant secondary pathways are 
studied to detect the flux-limiting steps and improve production. 
 In this chapter, we will describe the different in vitro techniques being 
used in our laboratory, with relevant examples of the plant species we have 
studied. Finally, we will describe our work on the development of a 
biotechnological system to increase taxol and taxane production using Taxus 
baccata and T. media cell suspension cultures and ginsenoside production in 
hairy root cultures of Panax ginseng. 
 
1. Plant in vitro cultures 
 
Micropropagation of aromatic and medicinal plants 
 
 Micropropagation is a way of obtaining a large number of plants in vitro 
in an asexual manner, ensuring that they are genetically and phenotypically 
identical to the original plant. It consists of the culture of variably sized plant 
pieces using a suitable culture medium. In this field, our group has 
developed specific protocols to micropropagate Lavandula dentata [2], 
Ruscus aculeatus [3], etc. Recently our work has focused on the 
micropropagation of Centella asiatica using synthetic seeds and obtaining 
several virus-free varieties of Vitis vinifera plants for exportation (Fig. 2). 
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Figure 2. Our Background in Micropropagation. 
 
Plant cell factories and stem cells 
 
 Plant cell factories constitute a biotechnological platform for the 
production of phytochemicals. In this way, cell cultures, also known as 
plant stem cells, can be utilized as cell suspensions or immobilized cells. 
Plant stem cells have an unlimited capacity for growth and an ability to 
produce identical new plants. By means of in vitro culture techniques, we 
are able to obtain plant stem cells with the same biosynthetic capacity as 
the whole plant. To establish a cell suspension culture that can act as a 
plant cell factory, it is first necessary to obtain a high callus biomass.  
 The methodology employed (Fig. 3) involves the following steps: 
selection of highly productive genotypes of the target plant; induction of 
calli from the best explant to obtain callus biomass; disintegration of calli 
by shaking in a liquid medium to obtain cell suspension cultures; 
optimization of the culture conditions by assaying several basic media, 
plant growth regulators (PGRs), sugar supplements, addition of elicitors, 
precursors, etc. to improve the production; and finally, scale-up to 
bioreactor level. Sometimes immobilization in alginate beads may be 
necessary to improve the biotechnological production [4]. 
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Figure 3. Plant cell factories: methodology 
 
 Regarding the development of plant biofactories, our group is working 
on centelloside production in cell suspension cultures of Centella asiatica 
[5]. We are also working on ruscogenin production in Ruscus aculeatus and 
podophyllotoxin production in Linum album, but our main research line is 
focused on the biotechnological production of taxol and taxanes in cell 
suspension cultures of Taxus baccata and T.media [6, 7]. We have 
previously developed cell cultures for the production of digoxin, digitoxin, 
tobacco alkaloids and galphimines. 
 We have also recently obtained plant stem cells of Vitis vinifera and 
Centella asiatica for cosmetic uses. C.asiatica was traditionally used in 
Ayurveda medicine and due to its dermatological applications, its stem cells 
are currently an important target for cosmetic purposes in Europe. 
 
Plant biotransformations 
 
 Another cell culture application is biotransformation. In this context, 
we have established a single protocol for extracting -amyrin from copal 
resin, which is then added as a substrate to cell suspension cultures of                
C. asiatica for its bioconversion into compounds with high added value, 
such as centellosides [8]. The results have demonstrated that cell lines are 
capable of biotransforming a compound with low biological activity but 
that is abundant in nature, such as amyrin, into other compounds widely 
used for their pharmacological properties, such as the centellosides            
(Fig. 4). 
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Figure 4. Biotransformation of the substrate -amyrin into centellosides. 
 
Hairy root cultures 
  
 Sometimes the production of plant secondary metabolites requires 
organized cultures such as roots or aerial shoots. In this context, our group 
uses the Agrobacterium rhizogenes system to genetically transform plant 
cells and develop hairy root cultures. A.rhizogenes is a bacterium that infects 
plants in nature, transferring a part of its plasmidic DNA, the Transfer-DNA 
or T-DNA, to the plant cell. The infected plant then develops large roots 
called hairy roots. Biotechnological processes based on hairy root cultures 
show a very high biomass production and a metabolic profile similar to the 
root of the whole plant. 
 This methodology (Fig. 5) is based on obtaining hairy root lines after 
infection with A.rhizogenes, the isolation and selection of the most 
productive root lines, optimization of culture conditions for maximum 
production and eventual scale-up to bioreactors. The scaling up of these 
cultures is very difficult because bioreactors are generally designed for the 
culture of microorganisms and need to be specially adapted for the culture of 
transformed roots. 
 Our group has worked with hairy root cultures for the production of 
ajmalicine in Catharanthus roseus [9], ginsenosides in Panax ginseng [10], 
tropane alkaloids in Datura metel, Duboisia sp and Hyoscyamus sp. [11,12], 
withanolides in Withania coagulans [13] and lately we have also been 
working on transformed root cultures of Linum album for the production of 
podophyllotoxin and methoxypodophyllotoxin [14]. 
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Figure 5. Hairy root cultures of Catharanthus roseus scaled up to airlift bioreactor 
level. 
  
2. Genetic and metabolic engineering techniques 
 
 To improve the biotechnological production of a secondary metabolite, 
it is necessary to understand the relevant biosynthetic pathways. It is also 
necessary to know which enzymes catalyze the sequence of reactions, 
especially the slow steps, and the genes encoding these enzymes. Using 
genetic and metabolic engineering techniques, we can study the plant 
secondary pathways to detect the flux-limiting steps in the biosynthesis of 
phytochemicals and use engineering techniques to design plants and cell 
cultures with improved production. 
 We have used metabolic engineering techniques to improve the 
production of scopolamine in the species Datura metel, Hyoscyamus muticus 
and a Duboisia hybrid. The first step was to obtain hairy root cultures of the 
aforementioned species and then select the most productive ones to be scaled 
up to bioreactor level (Fig. 6). 
 The second step was the overexpression, both separately and together, of 
the genes encoding the enzymes putrescine methyltransferase (PMT), which 
constitutes the first committed step in the scopolamine biosynthesis, and 
hyoscyamine 6- -hydroxylase (H6H), which transforms hyoscyamine into 
scopolamine [15]. The best results were obtained by overexpressing both 
genes together in transformed roots of H. muticus (Fig. 7). 
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Figure 6. 1st step: Obtaining hairy root cultures of a Duboisia hybrid and scaling up 
to wave bioreactor level. 
 
 
 
Figure 7. 2nd step: Overexpression of putrescine methyltransferase and hyoscyamine 
6- -hydroxylase. 
 
 Thirdly, since scopolamine is an alkaloid of greater commercial interest 
than the more naturally abundant hyoscyamine, we developed a 
biotechnological system to biotransform exogenous hyoscyamine into 
scopolamine based on tobacco transformed roots carrying the hyoscyamine 
6- -hydroxylase gene of H. muticus (Fig. 8). 
 In addition, with the aim of scaling up the system and avoiding the 
problems of root cultures in bioreactors, we dedifferentiated the roots and 
established cell suspensions that were also able to biotransform hyoscyamine 
into scopolamine at a bioreactor level [16]. 
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Figure 8. 3rd step: Biotransformation of hyoscyamine into scopolamine in tobacco 
hairy root cultures. 
 
 
 
Figure 9. Improving secondary metabolite production using empirical and rational 
approaches.  
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 To sum up, to improve secondary metabolite production using in vitro 
cultures one can consider two principal approaches (Fig. 9).  An empirical 
strategy involves the modification of input factors, such as the selection of 
more productive cell lines, optimizing culture media, the use of elicitor 
treatments, bioreactor design, etc. However, this does not provide 
information about what is happening in the producer cells at the molecular 
level. By taking a rational approach based on genetic and metabolic 
engineering techniques, we can study how the input factors change the 
metabolic and transcriptomic profile of the target cell cultures. 
 
3. Improving taxol and taxane production in cell suspension 
cultures of Taxus sp. 
 
 For some time now, one aspect of our research work has been focused 
on taxol production using cell cultures of different Taxus species. Taxol, a 
diterpene alkaloid with a very complex chemical structure, is one of the most 
effective anticancer drugs ever developed. It presents a unique mode of 
action on the microtubular cell system by inhibiting cell proliferation at the 
G2 phase of the cell cycle, thus blocking mitosis. 
 The natural source of taxol is the inner bark of several Taxus species. 
The disadvantages of this source are that taxol accumulates at a very low 
concentration (0.02% of dry weight), its extraction involves the destruction 
of yew trees and is very expensive. Moreover, the endangered status of 
several Taxus species excludes this method of obtaining taxol. For these 
reasons, alternative sources of taxol have been assayed, including its 
preparation by total synthesis, but this process is not commercially viable. 
Another possibility is producing taxol semisynthetically from more abundant 
taxanes, for example, via the conversion of baccatin III found in Taxus 
needles, but the cost and difficulty of the extraction and purification process 
of these precursors are also very high. An alternative consists of cultivating 
Taxus trees in the field. In fact, in Yunnan province in China, there are 
conventional Taxus crops for the production of taxol, but a harvest can only 
be obtained after several years and the extraction remains very expensive 
[17]. Therefore, the most promising approach to a sustainable commercial 
production of taxol, or other compounds synthesized by plants in similarly 
small quantities, is provided by plant cell cultures.  
 In order to obtain cell suspensions, first on a small scale and then at 
bioreactor level, it is necessary to establish fast-growing callus cultures from 
which the cell suspensions are derived. Taxus callus cultures were obtained 
from young stems of 3-4-year-old yew trees cultured in optimum conditions. 
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Figure 10 shows the whole process until the establishment of a small-scale 
cell suspension culture. 
 To develop a biotechnological system for a high taxol production, it is 
necessary to optimize the culture conditions by assaying several basic media, 
plant growth regulators, sugar supplements etc., which requires knowledge 
of the growth curves of the system. A growth curve represents the biomass 
production (growth) in relation to the time of culture, and appears as a 
sigmoid curve with 3 characteristic phases: 1) A lag phase in which the 
biomass does not increase, when cells are preparing all the machinery for the 
cell division that will start in the exponential phase. 2) An exponential phase 
in which cells are dividing continuously by mitosis. All the processes related 
with mitosis, which are part of the plant’s primary metabolism, are now 
taking place inside the cells, including DNA duplication, and RNA and 
protein synthesis. In these conditions secondary metabolism is inhibited. 3) 
A stationary phase in which the biomass of the system remains constant and 
the number of cells that divide by mitosis is almost equal to the number of 
dying cells. In these conditions, the cells can accumulate precursors for the 
biosynthesis of phytochemicals and the machinery of plant secondary 
metabolism begins to work. 
 
 
 
Figure 10. Establishment of Taxus cell suspension cultures. 
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 Once the growth curve of a culture is established, we know how long 
each phase is and when the stationary phase begins, which is the moment 
for adding precursors, elicitors, permeabilizing agents etc. to improve the 
production. Knowledge of the growth curve is particularly useful in a two-
stage culture, that is, when a separate medium is required to enhance 
growth and another to increase production. In this case, during                             
the exponential phase the cells are cultured in the growth medium and      
then transferred to the production medium at the start of the stationary 
phase. 
 A two-stage culture system was established for taxol production. Plant 
cells were first cultured in a medium optimised for their growth, which 
was then replaced by a production medium that mainly stimulates the 
biosynthesis of secondary metabolites. This system has an added 
advantage of permitting the addition of biosynthetic precursors and 
elicitors in the production medium.  
 In summary, taxol and baccatin III production was clearly enhanced by 
the transfer of cells from the growth to the production medium containing 
the elicitor methyl jasmonate (MeJA) [18]. After optimizing the culture 
conditions, we scaled up the culture in a stirred bioreactor where the 
production improved 2.4-fold for taxol and 9-fold for baccatin III.  
  
 
 
Figure 11. Taxol production in immobilized cell cultures of Taxus baccata in a 
stirred bioreactor. 
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 We continued our study on the improvement of taxol and related taxane 
production by establishing immobilized cell cultures, first on a small scale 
and then at bioreactor level. Numerous studies have reported that 
immobilization of plant cell suspensions enhances the production of valuable 
plant metabolites. Taxol production clearly improved when cell suspensions 
were immobilised in 2% alginate beads and cultured in a stirred bioreactor, 
using the optimum medium for the biosynthesis of taxol. When the taxol 
production was at its highest, on day 16, its levels were more than 5-fold 
higher than those obtained by the same cell line growing freely in the same 
conditions (Fig. 11). The novelty of this work was to demonstrate that 
immobilization strongly constrains the physiology of T.  baccata cells and 
substantially enhances taxane production in bioreactor cultures [4]. 
 
4. Ginsenoside production in hairy root cultures of Panax 
ginseng 
 
 Ginsenosides are triterpenes with a great variety of properties, being 
used as tonics, analgesics, antipyretics, stress-beaters, etc. 
   
 
 
Figure 12. Improving ginsenoside production in hairy root cultures of Panax 
ginseng. 
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 Hairy root cultures were obtained using the following protocol. After 
infection of the rhizome with A. rhizogenes, we obtained hairy roots that 
were cultured in a solid growth medium and their transformed nature was 
confirmed. The transformed roots were then transferred to a liquid medium 
to optimize growth and production, using elicitors, precursors and beta-
sitosterol. Finally, we scaled up the culture by assaying different types of 
bioreactors, optimizing the culture conditions. A two-stage system was not 
used in this case. Figure 12 summarizes the whole process. 
 After the infection of the rizome with A. rhizogenes we obtained roots 
with 3 types of morphology: 50% had a typical hairy root morphology (HR-
M), 35% a callus morphology (C-M) and 15% a thin morphology (T-M) 
[19]. The transformed nature of each type of root was confirmed by 
amplifying the rol C gene. The highest growth in solid medium was 
displayed by C-M roots, although the total ginsenoside content was higher in 
T-M roots, albeit lower than in the plant rhizome. 
 After transferring the roots from the solid to the liquid medium to 
optimize the growth and production, the best growth was achieved by the             
C-M roots, followed by the HR-M roots, as occurred in the solid medium. It 
should be emphasized that all the roots grew better in liquid medium. 
 Regarding the ginsenoside production, the best results were obtained 
with HR-M roots in liquid medium, in contrast with the solid medium where 
the best production was obtained with T-M roots. 
  We then optimized the culture conditions by assaying several elicitors 
(chitosan, methyl jasmonate, vanadyl sulfate), precursors (mevalonic acid, 
squalene, farnesol) and beta-sitosterol (which bioregulates the synthesis of 
ginsenosides). The best result was obtained with MeJA, which increased the 
production of ginsenosides in all the root types [20]. The precursors and 
beta-sitosterol did not yield any significant results. Compared with a 4-year-
old Panax ginseng plant rhizome, the ginsenoside production of a 
transformed HR-M root grown in liquid medium with MeJA for 4 weeks 
was almost 2-fold higher. 
  Finally, we optimized the process at a bioreactor level. We first selected 
the most productive hairy root line (HR-M), which was cultured in the liquid 
medium optimized on a small scale in 3 types of bioreactors: airlift, spray 
and wave. After 28 days of culture without changing the medium, the best 
growth was obtained in the wave bioreactor, but the best ginsenoside 
production was achieved in the spray bioreactor. However, if we determine 
the productivity, that is, the ginsenoside production per liter and per day, the 
best results were obtained with the wave bioreactor in the same culture 
conditions: after 28 days without changing the media. This confirms that the 
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productivity of a culture does not only depend on the accumulation of the 
target compound but also on its growth capacity. 
 In summary, after 28 days of culture without changing the media, we 
obtained the best production in a spray bioreactor but the best productivity in 
a wave bioreactor. Optimum growth was also obtained in the wave 
bioreactor. 
 We next determined the biomass and ginsenoside production in 2 
bioreactors (spray and wave) after 28 days of culture but this time changing 
the culture medium at day 15. In these conditions, the biomass production 
increased in both bioreactors, and was therefore higher in the wave 
bioreactor. Regarding the ginsenoside production, the results again showed 
more production in the spray bioreactor, but when we determined the 
productivity, the roots in the wave bioreactor were the most productive, as 
before.  
 Finally, we cultured the roots (HR-M) in the two bioreactors (spray 
and wave) but now for 56 days and changing the medium every 15 days 
[21]. The highest productivity of the roots was again achieved in the                  
wave bioreactor, being almost 2-fold higher than in the small flasks              
(Fig. 13). 
  
 
  
Figure 13. Ginsenoside productivity of typical hairy roots (HR-M) grown in small 
flasks, spray and wave bioreactors on a 56-day culture with change of media every 15 
days. 
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5. Conclusion 
 
 We have established two biotechnological systems (cell suspension cultures 
of Taxus sp. and hairy roots of Panax ginseng) to improve the production of two 
high-value target compounds (taxol and ginsenosides) using an empirical 
approach that considers input and output factors (Fig. 9). Taxol production was 
improved employing a two-stage culture system, elicitation with MeJA, 
immobilization in alginate beds and scaling up in a stirred bioreactor. 
Ginsenoside production was improved using selected hairy root lines of three 
different morphologies, elicitation with MeJA, changing the medium during the 
culture, assaying three bioreactor designs and taking into account production and 
productivity. These results can be improved in future studies taking a rational 
approach. 
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Abstract. ADHD (Attention Deficit and Hyperactive Disorder) is the 
most common neurobehavioral disorder of childhood, presenting with 
pervasive and impairing symptoms of inattention, hyperactivity, 
impulsivity, or a combination. There is scientific evidence that some 
dietary and physical activity strategies may be useful to improve the 
symptoms of ADHD and benefit the social, cognitive and academic 
performance of children and adolescents with ADHD. The purpose of 
our study was to review the scientific literature on the role of diet and 
physical activity in ADHD symptomatology up to date. 
 
Introduction 
 
 Attention deficit and hyperactivity disorder (ADHD) is one of the                  
most common psychiatric disorders in early childhood and adolescence with 
a prevalence rate exceeding 5% [1]. Some of the most common symptoms 
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associated with ADHD are hyperactivity, attention deficit, cognitive deficit 
and poor impulse control [2]. The etiology of ADHD is still unknown, 
although there are several factors which may have a certain influence in the 
symptomatology, including diet and physical activity [2].  
 The research aimed to study the association between diet and ADHD has 
been growing in the last decades. Thus, children and adolescents with 
ADHD seem to have lower levels of certain nutrients such as: iron [3], zinc 
[4,5], and omega 3 [6,7], among others. In some cases, the supplementation 
with these nutrients, especially with omega 3 [6], has showed to improve the 
ADHD symptomatology. The most significant research done in this field is 
summarized in Table 1.  
 
Table 1. Relevant scientific evidence of deficiency or supplementation in essential 
nutrients observed in ADHD children and adolescents.  
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 Other studies suggest that diets rich in sugars and artificial colorings 
increase the hyperactivity of children [18–22]; however, those findings are 
still inconsistent and more data are needed. Research about the associations 
of different dietary patterns and ADHD has also been conducted [22–25]. 
This approach is really interesting since it assesses the influence of the 
whole diet.  
 Besides the potential benefits that a healthy dietary pattern may have on 
neurocognitive, behavioral and physical growth, it has also been suggested 
that physical activity might have a positive impact in behavior, 
neurocognitive function, motor skills, and school performance of children 
and adolescents with ADHD [26–29], as it will be discussed further. 
 Although the pathophysiology of ADHD has been not fully 
demonstrated, there is an important hypothesized mechanism of deregulated 
dopamine in the prefrontal cortex (PFC). The PFC has the function to 
regulate behavior, inhibit inappropriate emotions, impulses and habits [30]. 
Several studies indicate that patients with ADHD present anatomic 
abnormalities or neurochemical brain dysfunction [31]. Stimulant 
medications (such as methylphenidate and amphetamines) are used to treat 
the majority of the symptoms of children with ADHD, but not all the 
patients have a good response to them and some parents have the concern 
about the side effects of these drugs in the growth, nervous and 
cardiovascular system of their children [32]. There is an important need to 
develop other interventions that do not have repercussion in the health and 
wellness of the children. Thus, it has been proposed that the combination of 
diet and physical activity could help children and adolescents with ADHD to 
improve the symptomatology and their whole quality of life.  The aim of this 
chapter is to review the scientific literature regarding the possible benefits of 
different dietary approaches and physical activity for symptom management 
for children and adolescents with ADHD. 
 
1. Role of the whole diet on ADHD: healthy patterns versus 
restrictive elimination diets? 
 
1.1. Dietary patterns and ADHD 
 
 As mentioned above, several studies have analyzed the beneficial or 
detrimental effects of specific single nutrients on ADHD symptomology 
[33]. Moreover, associations between dietary patterns and ADHD have been 
recently examined in several cross-sectional studies (Table 2). This new 
approach is of great interest since nutrients are nearly always consumed 
together, and they are highly interrelated in the food matrix. Therefore, the 
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study of dietary patterns is really useful for understanding much better the 
role of diet in ADHD. Assessing the whole diet instead of the effects of a 
single nutrient on the relation between diet and ADHD may contribute even 
more to understand this complex relationship. 
 The majority of studies on diet and ADHD conclude that ADHD 
patients have a tendency to have a poor quality diet, which could cause 
certain nutrient deficiencies. Those deficiencies might affect the 
neurocognitive, behavioral and physical development at this important stage 
of life. Indeed, Park et al. [35] found that higher intakes of sweetened 
desserts, fried food, and salt were associated with more learning, attention, 
and behavioral problems. On the other side, a balanced diet, regular meals, 
and a high intake of dairy products and vegetables were associated with less 
learning, attention, and behavioral problems.  
 
Table 2.  Summary of the main studies on the influence of the diet on children and 
adolescents with attention-deficit and hyperactive disorder (ADHD). 
 
 
Diet and physical activity in children and adolescents with ADHD 55 
 The “unhealthy” dietary patterns identified in the different studies (such 
as “Western”, “fast food” or “sweet” patterns) were generally high in total 
fat, saturated fat, refined sugars, and sodium. The relationship observed 
between higher scores for the “unhealthy” dietary pattern and an increased 
odds for ADHD supports the hypothesis that highly processed and energy-
dense foods are linked with ADHD symptomatology [24,34,35]. 
 Howard et al. [24] suggested that children eating a “Western” diet, high 
in fried food, sweetened desserts and unbalanced, are also likely to have 
micronutrient and/or PUFA deficiencies. Iron, zinc or magnesium 
deficiencies and lower circulating levels of omega-3, higher levels of  
omega-6, and a lower omega-3 versus omega-6 ratio has been reported in 
children and adolescents with ADHD [8]. An inadequate micronutrient 
intake, coming from an unbalanced dietary pattern, could result in 
suboptimal brain function in children and adolescents [23]. Futhermore, Van 
Egmond-Fröhlich et al. [34] pointed out that ADHD symptoms might be 
associated with poor food selection rather than overeating in terms of 
volume. 
 “Unhealthy” or “junk foods” besides being usually high in fat and sugars 
may be rich also in artificial food colorings and preservatives, which could 
negatively affect ADHD symptoms [38]. It has been suggested, as it will be 
discussed below, that certain food additives may lead to hyperactivity or 
changes in neurotransmitter function [21]. An interesting point is that the 
relationship observed between poor dietary choices and ADHD may be 
bidirectional [24]. The results observed could be explained, especially for 
adolescents, by the tendency of them to experience emotional distress to 
crave fat-rich snack foods as a self-soothing strategy. Therefore, the results 
found could be more reflective of adolescent dietary preferences and 
cravings rather than nutritional factors alone.  Also, it has been observed that 
a healthy diet is related to better family functioning [39] and given that 
families of children and adolescents with ADHD are more likely to face 
parenting challenges, it is possible that the relationship between a 
“unhealthy” dietary pattern and ADHD diagnosis is mediated by poor family 
functioning [24]. 
 Despite the fact that conclusions of these studies are challenging, we 
cannot justify that a poor dietary choice is the responsible for ADHD. The 
idea that dietary factors are the exclusive and sufficient explanation for 
childhood behavioral problems may place a barrier in the way of access to 
appropriate evidence-based assessment and treatment – so placing the child 
at unnecessary risk [40]. Further studies are necessary to understand the role 
that the dietary pattern has in this disorder and to know which dietary 
approaches can benefit the ADHD symptomatology. 
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1.2. Restrictive dietary treatments for ADHD 
 
 There are mainly two dietary treatments for ADHD, which have been 
tested in repeated, randomized controlled trials: the artificial food colors 
elimination (AFCE) and the restricted elimination diets (RED). 
 
1.2.1. Artificial food colorants elimination (AFCE) 
 
 The research within artificial food colorants and other additives began in 
the 1970s. Dr. Benjamin Feingold proposed a new diet called the “Kaiser 
Permanente diet” also known as the “K-P diet” or the Feingold diet. It was 
hypothesized that the hyperactivity and learning problems observed in 
certain schoolchildren were due to the ingestion of certain foods and food 
additives [41].  
 The K-P diet removed all foods containing artificial food colors and 
flavorings and certain preservatives and also food which naturally contain 
salicylates (Table 3). It was very popular during the 70s and 80s, although 
it received repeated criticism because solid scientific studies demonstrating 
its efficacy were very scarce [41] and subsequently support from 
professionals waned. The “K-P diet” is not longer used, but some of the 
recommendations, including the elimination of artificial colors, are still 
being applied. Indeed, two recent meta-analyses carried out concluded that 
artificial food colorants have small, but statistically significant adverse 
effect on ADHD symptoms in some children [38,42], even though the 
conclusions were based on studies of limited quality, as the authors 
themselves pointed out. 
 
Table 3. Dietary guidelines of the “Kaiser Permanente diet”. 
 
- To avoid all food, medications, and cosmetic which may 
contain artificial colors and flavors. 
- To avoid all food that may contain preservatives such BHA, BHT,  
TBHQ and sodium benzoatea 
- To avoid foods that naturally contain salicylates: almonds, apples,  
peaches, apricots, nectarines, cherries, grapes, raisins, oranges, 
plums, tomatoes, cucumber, coffee and tea. 
 
a Those preservatives were later added to the list. Abbreviations: BHA, buttylated 
hydroxyanisole; BHT, butylated hydroxytoluene; TBHQ, tertiary butylhydroquinone. 
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 In the same direction, Stevenson et al. [43] concluded that the artificial 
food color elimination is a potentially valuable treatment for ADHD but its 
effect size remains uncertain, as does the type of child for whom it is likely 
to be efficacious. The authors added the urgent need for studies using more 
redefined methodologies with blind evaluation to unselected samples of 
children with ADHD and also the concern that some studies of food 
colorings and additives were undertaken some time ago, so the findings 
could be no clear as diet and food products have changed markedly. 
 The possible mechanisms by which the food colorants and other 
additives may trigger symptoms are not well understood [44]. Therefore, the 
controversy about the hypothesis that certain food colorants and additives 
mainly may cause hyperactivity and inattention in children both ADHD 
diagnosed or without this disorder is still open. Some authors strongly affirm 
that these additives do not cause ADHD [2,45], relaying in the fact that the 
symptomatology of ADHD is different from those induced by artificial 
coloring [21,44]. The last ones have been associated with more irritability 
and insomnia than restlessness and inattention.  
 In 2007, a study funded by the Food Safety Agency (FSA) from UK 
and conducted by McCann et al. [21] had a high impact on the public 
opinion. The authors provided statistically evidence on the relationship 
between the consumption of certain mixtures of artificial food colorings 
(tartrazine, quinoline yellow, sunset yellow, azorubine, cochineal red and 
allura red) and an artificial preservative (sodium benzoate) and the increase 
of the hyperactivity in children of 3 years and also in children from 8 to 9 
years. In view of these results, the FSA recommended to parents with 
hyperactive children to consider limiting the intake of these colorants and 
preservatives. The study, however, has certain methodology weaknesses, 
as the authors themselves recognized in their publication. The changes 
observed in the hyperactivity children were very small relative to the inter-
individual variation, while the changes in behavior were not evident in all 
the studied children. Furthermore, it was not possible to extrapolate the 
study findings to each single additive, which was in the mixture assayed. 
Moreover, information about the possible biological mechanisms was not 
provided. 
 While neither the EFSA (European Food Safety Agency) nor the 
European Commission have issued any cautious recommendation, 
nowadays, in the European Union, is required on the food packaging the 
following warning “This product may have adverse effect on activity and 
attention in children” when sunset yellow (E110), quinoline yellow (E104), 
azorubine/carmoisine (E122), allura red AC (E129), tartrazine (E102) and 
cochineal natural red (E124) are employed in foods and beverages. 
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 There is a consensus in the scientific community about the need for 
more studies on the association between artificial colorings and hyperactivity 
and ADHD. It is required some caution before advising a complete 
restriction of foods containing these colorings. The imposition of a diet 
completely free of artificial colorings should not be done until a reliable 
methodology is developed to identify which colorant or colorants may be 
responsible, and who is really sensitive to these compounds, given the inter-
individual variation observed. 
  
1.2.2. Restricted elimination diets (RED) or few foods diets 
 
 A restricted elimination diet (also called oligoantigenic) removes most 
foods that may have antigenic or allergenic potential, such as milk and dairy 
products, eggs, nuts and some fruits, among others. It is thought that ADHD 
may be, in some children, a hypersensitivity reaction to certain foods 
[41,45,46]. Therefore, according to this allergic hypothesis, there would be 
foods that induce high levels of IgG, leading to a relapse in ADHD child 
behavior, while the intake of those that does not induce IgG or very low 
levels of them, would not cause a recurrence in ADHD symptoms [32,47]. 
While interesting the hypothesis, it has not yet been fully demonstrated. 
Pelsser et al. [45] carried out a study about restricted elimination diets with 
uncertain results. They did conclude that the children who responded to the 
dietary intervention, independently of whether IgG levels were high or low, 
showed a decrease of 20.8 points on the ADHD rating scale (ADHD Rating 
Scale) and 11.6 points on the Conners Scale (Conner's Score). However, the 
determination of IgG levels was not useful, since the levels of IgG and 
symptoms of ADHD were totally independent.  
 More recently a meta-analysis on ADHD, restriction diet and food color 
additives has been published [42], concluding that a restriction diet benefits 
some children with ADHD since it reduces ADHD symptoms; however, the 
authors themselves strongly recommended a renewed investigation of diet 
and ADHD. From a practical point of view, the restricted elimination diets 
are very difficult to follow, both for ADHD patients and for the families. 
Moreover, children and adolescents who are prescribed to follow a different 
diet than their friends may influence in their behavior, creating unnecessary 
stress situations [19,20]. 
 To summarize, restricted elimination diets may be beneficial, but large-
scale studies are needed, using blind assessment, and including assessment 
of long-term outcome. On the other hand, artificial food color elimination is 
a potentially valuable treatment but its effect size remains uncertain, as does 
the type of child for whom it is likely to be efficacious. Three 
recommendations have been suggested for the design of future studies: 1) To 
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have a sample of children with ADHD who have not been selected on the 
basis of previous responses to food constituents, 2) To include observations 
of the children´s behavior by a reporter who is truly blind as to dietary 
treatment, and 3) to control for nonspecific treatment effects [38,43]. 
 
2. The role of physical activity on ADHD  
 
 It is well established that physical activity (PA) has positive effects on 
mental health in both clinical and nonclinical populations. In the last decade, 
several studies have been addressed to study the potential benefits of 
exercise in children diagnosed with ADHD. The evidence suggests that 
physical exercise may have benefits in behavioral, neurocognitive, and 
scholastic performance [27,47,48] and in inhibitory control [47,49]. The 
etiology of ADHD and the putative mechanisms by which PA impacts 
cognitive performance suggest that PA might be particularly beneficial for 
ADHD individuals [27].  
 Pontifex et al. [48] concluded that moderately intense aerobic exercise 
might have positive implications for aspects of neurocognitive function and 
inhibitory control in children with ADHD, improving their school 
performance (Fig. 1). The children could better focus and were less 
distracted after a quick workout. Moreover, it seems that this type of 
exercise produces enhancements in reading and in mathematics [49]. This is 
interesting because children with ADHD have usually more learning 
problems in these two areas. On the other hand, moderate exercise sessions 
in ADHD’s children have led to improvements in behavior and attention, but 
no relationship with academic performance has been found [50]. 
 
 
 
Figure 1. Mean (+SE) standard score for each session on each of the three academic 
performance tests done. Bars with * are statistically different (adapted from [48]). 
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 Other authors have investigated if the beneficial effects of short 
moderate PA are also helpful when exercise is carried out for longer periods 
of time. Thus, Verret et al. [50] demonstrated that, in addition to producing 
improvements in strength and motor skills, exercise showed a positive 
influence on the behavior and attention of ADHD’s children. Also, the work 
done by Smith et al. [47] suggested that after 26 min of continuous 
moderate-to-vigorous physical activity daily over eight school weeks offered 
benefits to motor, cognitive, social, and behavioral functioning in young 
people exhibiting ADHD symptoms. Both authors [47,48] pointed out that 
the benefits of PA would act on the inhibitory control and the executive 
function. ADHD appears to have a strong impact on executive function, 
where processes related to learning and behavior are altered. Although it is 
not clear which elements are regulated by the executive function, it is 
believed to be related to cognitive processes such as memory, emotional 
control, activation, arousal, effort, organization and planning tasks [51]. 
 On the other hand, the majority of exercise and cognition research has 
primarily focused on aerobic exercise but it is also important to consider 
forms of coordinative exercise, which includes exercises involving motor 
coordination and cognitive training. Yu-Kai Chang et al. [52] demonstrated 
that an aquatic exercise intervention, which involves both aerobic and 
coordinative exercises, influences positively on the restraint inhibition 
component of behavioral inhibition in children with ADHD.  
 Research aimed to investigate the influence of PA in children with 
ADHD under drug therapy, such as methylphenidate, has also been carried 
out [53], demonstrating that the PA had a positive impact in ADHD 
symptomatology when medication was present, too. It was found that 
besides improving strength and motor skills, PA positively influences 
behavior and cognitive function such as attention in children under 
medication. Although there is limited research about how drugs affect the 
motor skills and physical lifestyle of children with ADHD, most of the 
studies agree that motor skills are improved as a result of PA [50]. In order 
to add support to those outcomes, future research should include greater 
executive functions assessment. Moreover, follow-up and additive effects of 
others therapies should be explored. 
 Children with ADHD might have lower participation in sport activities, 
because of their mood liability, disciplinary problems, poor self-esteem, 
anxiety and inattention. However, research evidence has showed that ADHD 
children who participated in three or more sports present fewer anxiety or 
depression symptoms than did those who participated in fewer than three 
sports. Another aspect worth to comment is the positive influence that PA 
has showed also in aerobic function, flexibility and cardiovascular fitness, 
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since children with ADHD have lower levels of them compared with 
typically developed children. Thus, when compared only between ADHD 
children the ADHD training group demonstrated more favorable levels of 
aerobic function and flexibility than the ADHD no training group after the 
PA intervention [54]. 
 All these findings related to PA and improvement in ADHD 
symptomatology would support the hypothesis that the pathophysiology of 
ADHD is related with inadequate levels of certain neurotransmitters [55] 
such as serotonin, dopamine, and noradrenaline. PA increased the levels of 
these three neurotransmitters in the prefrontal cortex, which seems to be 
crucial for the attention and inhibitory control [51]. Individuals with ADHD 
might have neurochemical and neuroanatomical anomalies in this brain 
region, which could lead to neurotransmitter deficits and originating some of 
the cognitive problems related to the ADHD. 
 As a summary, the research done up to now seems to support the fact 
that physical exercise could establish itself as an adjunct treatment for people 
with ADHD [28,47,48,50]. It is recommended that clinicians, parents and 
teachers work together monitoring the participation of these children in 
physical and sports activities to help them improve their motor skills 
performance (Fig. 2).  
 
 
 
Figure 2. Effects of exercise on ADHD children behavior. 
 
3. Conclusions 
 
 The cause of ADHD is multifactorial, with a certain influence of the 
environmental factors, such as diet and physical activity. The multimodal 
treatment is recommended by principal clinical practice guidelines for 
ADHD and includes psychological, psycoeducational and pharmacologic 
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treatment. Nevertheless, the review of the published scientific evidence 
indicated that several dietary strategies and physical activity might also help 
to improve the quality of life of children and adolescents with ADHD. The 
main recommendation is to educate families and children: 1) to have healthy 
eating habits with a balanced diet, avoiding excessive consumption of 
saturated fats and simple sugars, foods with artificial colorants, a good 
consumption of fish, nuts and seeds, all of them rich in omega 3 and 2) to 
introduce into the routine of children and adolescents daily physical activity, 
adapted to their preferences and needs.  
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Abstract. The zebrafish embryo has emerged as promising 
alternative model for traditional in vivo developmental toxicological 
screening due to their advantageous characteristics as their small size 
and transparency. In this paper, we reviewed the applicability of the 
zebrafish embryo model in some relevant areas to human toxicology 
as developmental toxicity, cardiovascular toxicity and neurotoxicity 
(behavioral assessment). Despite the promising results, further 
optimization and testing of more substances as well as a harmonized 
methodology is needed to streamline the methods and make the assay 
conducive to medium-throughput. 
 
Introduction 
 
 The potential toxicity of a chemical has traditionally been carried out 
through in vivo mammalian screening approaches. Traditional guideline 
methods are laborious, costly, require large number of animals and attract 
increasingly ethical concerns [1]. Moreover, animal testing will increase  
 
Correspondence/Reprint request: Dr. Elisabet Teixidó, Toxicology Unit, Faculty of Pharmacy, University of 
Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain E-mail: elisabet.teixido@gmail.com 
Elisabet Teixidó et al. 66 
dramatically over next decade as a consequence of implementation of EU 
initiative for the Registration, Evaluation and Authorization of Chemicals, 
REACH [2]. Reproductive and developmental toxicity studies will use by far 
the most animals and resources within REACH (61% of animals and 54% of 
resources). Thus, the use of alternative methods in hazard assessment is 
encouraged and animal experiments should only be used as a last resort [3]. 
In addition to the REACH initiatives, it has been estimated that out of 10,000 
new drug entities that a pharmaceutical may start with, only one or two are 
finally approved by the European Medicines Agency (EMA) at an estimated 
cost of €1,172 million [4]. A large proportion of this cost is due to animal 
testing. The use of alternative methods at multiple stages in the drug 
discovery process would potentially reduce the attrition rate and costs by 
reducing the use of mammals and unnecessary clinical trials. The use of 
screening assays before clinical phases to select the best candidates is also 
one strategy to identify potential new active pharmaceuticals ingredients.  
 Fish have been used for years to assess the ecotoxicity of xenobiotics, 
but during the last years assays using embryonic stages of the zebrafish 
(Danio rerio) have attracted the attention of toxicologists due to their several 
advantages. In particular, in compliance with international animal welfare 
regulations, the fish embryo provides an ethically acceptable small-scale 
analysis system with complexity of a complete organism [5-7]  
 Most advanced and promising in the field of human hazard prediction is 
the use of the zebrafish embryo test (ZFET) to screen for developmental 
disorders as an indicator of teratogenic effects. Modifications of the ZFET 
protocol allow the use of this model also for the detection of specific organ 
toxicity such as cardiotoxicity, neurotoxicity, hepatotoxicity or 
nephrotoxicity [8].  
 In the following sections, the applications of the zebrafish embryo test in 
toxicology are reviewed as a screening level tool and as a system to predict 
mammalian developmental toxicity. Considering the current research activity 
on this topic, and based in our own research experience, we have selected 
some examples of the use of the zebrafish embryo model in toxicology. 
Additionally, we have included some of our last results in the field.  
 
1. The zebrafish embryo as a model organism 
 
 Zebrafish is a tropical freshwater teleost fish native to the rivers of India 
and South Asia [9]. Adult fishes are simple and inexpensive to raise and 
maintain. One pair of adults routinely lays hundreds of fertilized eggs in a 
single cross. Large-scale breeding chambers allow the efficient and reliable 
generation of thousands of embryos each day (Fig. 1). 
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Figure 1. Custom made breeding chamber. A grid is located in the bottom in order to 
avoid predation of the eggs by the parent fishes. Plastic plants and marbles can be 
placed in the tank in order to stimulate the spawning. The shape of the tank, as a 
funnel on the bottom, allows simple release of the newly spawned eggs. 
 
 The development of zebrafish is very similar to the embryogenesis in 
higher vertebrates, but, unlike mammals, the zebrafish egg develops outside 
the mother. Moreover, the embryos themselves are transparent during the 
first few days of their lives allowing an easy visualization of internal organ-
tissues that facilitates developmental and organ toxicity studies. Also its 
development is very fast and has been well characterized, including 
morphological, biochemical and physiological information at all stages of 
early development [10]. 
 During the first 24 hours after fertilization, all major organs are formed 
and within 3 days the fish hatches. After 3-4 months zebrafish are sexually 
mature and can generate new offspring.  
 Besides this, the small size of the embryo allows the ability of culture 
large number of zebrafish embryos in small volumes of media facilitating 
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rapid toxicity testing of compounds, while using a minimal amount of 
compound [11]. All the above mentioned properties of the zebrafish model 
represent a reduction on the experimental time and cost.  
 Zebrafish has been used predominantly in fundamental research 
(developmental biology and molecular genetics), so a lot of resources are 
available (genetic tools, mutant lines…) which the community can get the 
most benefit. In addition, zebrafish shares a high degree of homology with the 
human genome (about a 70%) [12], as well as structural similarities (about 
86% of orthologs of human drug targets) [13]. All these unique advantages 
make using zebrafish an attractive alternative that also represents an advance 
towards the aim of reducing and refining animal use in research [14]. 
 
2. Zebrafish embryo assays in toxicology 
 
Teratogenesis  
 
 The assessment of potential developmental toxicity is an integral part 
of European (and international) regulation for the risk assessment of 
pharmaceuticals, industrial chemicals, food additives, biocides and plant 
protection products. The assessment is performed based on OECD 
guidelines to allow international harmonization. Particularly, in 
teratogenesis tests, pregnant laboratories animals of two species, typically 
rats and rabbits, are exposed to the investigated chemical during the period 
of major organogenesis and offspring is monitored for endpoints such as 
death, growth changes, and morphological abnormalities. The use of 
mammalian models is laborious, time-consuming and results in the 
suffering of animals.  
 Ever since the thalidomide tragedy, there has been a presumed need to 
routinely use two species for developmental toxicity testing. Next to ethical 
concerns, animal experiments have been also criticized because of the 
partially weak reliability for the prediction of human teratogenicity [15]. 
Further problems have arisen due to the new EU cosmetics directive, which 
excludes any animal testing for cosmetic ingredients. Therefore, there is an 
increasing demand to develop alternative in vitro methods.  
 Up to date a few alternative approaches have been proposed for 
teratogenicity testing of chemicals and drugs. These approaches require 
either cultured cell lines [16], dissociated cells of embryonic buds or the 
midbrain of rat embryos [17], or the culture of whole embryo rodents [18] 
and lower vertebrates (e.g. Xenopus and zebrafish)[19].  
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 Results from numerous small-scale pilot studies with zebrafish 
embryos have been shown to correctly classify mammalian teratogens and 
non-teratogens with an overall concordance of 72-92% (Table 1). These 
assays are focused on three manifestations of deviant development: death, 
malformation and growth retardation [20]. However, they applied different 
experimental protocols and the number and the variety of assayed 
substances were limited. Currently there is no consensus about the optimal 
procedure in some basic features as the specific endpoints and scoring 
systems to use, the time of exposure and the stage of embryonic/larval 
development to do the observations. There is an increasing common 
interest to harmonize zebrafish developmental toxicity assays in order to 
ensure high concordance with mammalian data and increase cross-
laboratory reliability [21].  
  
Table 1. List of the published zebrafish teratogenicity assays with its overall 
concordance with mammalian data. Exposure was done during different windows of 
development and the teratogenic potential of chemicals was based on different 
criteria.  
 
 
 
Note: a, collaborative pilot study of Phylonix, Inc. with Bristol-Myers Squibb. b, developed by 
DanioLabs Ltd and evaluated in a pilot study run by Pfizer, Inc. and ECVAM. c, results from Bristol-
Myers Squibb group. d, compounds tested in the ring test-2. n/d, not defined. Hours post-fertilization 
(hpf).     
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 In this regard, our group focused on achieving a better characterization 
of growth retardation in the zebrafish embryo test [28]. In this study the 
suitability of a biochemical endpoint, the measurement of 
acetylcholinesterase activity (AChE), as a marker of developmental delay in 
zebrafish embryos was explored. The expression of AChE starts early and 
increases with age along the embryo development. It is an easy, robust and 
sensitive endpoint that could be liable to automation and higher throughput 
than morphological endpoints like the measurement of head-trunk angle. 
Evidently, any substance with some specific action on AChE expression or 
activity, as AChE inhibitors, could produce results unrelated to 
developmental age. These substances can be easily discarded by means of an 
in vitro AChE activity assay. 
 The measurement of AChE activity allowed us to detect substances with 
a clear effect on developmental delay (valproic acid, methoxyacetic acid and 
boric acid) at non-teratogenic concentrations, thus increasing the sensitivity 
of the assay. As figure 2 shows, these substances presented a strong 
correlation between AChE activity and head-trunk angle with a slope similar 
to that obtained in normally developmental embryos at different 
developmental stages. However, our results do not allow concluding about  
 
 
 
Figure 2. Correlation analysis between AChE activity values versus normalized 
head-trunk angle values [(180°- head-trunk angle)*100/(180°- control head-trunk 
angle)] in each compound that produced a significant change in AChE activity. Slope 
and coefficient of correlation of each simple linear regression. The correlation 
analysis of the values of normally developed embryos was obtained from the 
evaluation of the age-dependent AChE activity and head-trunk angle. 
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the discriminating efficiency of developmental retardation endpoints in the 
zebrafish assay to predict teratogenic potential in mammals. Probably, for a 
major part of substance, developmental delay is an unspecific effect 
unrelated or secondary to teratogenic activity.     
 
Cardiovascular toxicity 
 
 Cardiotoxicity is a highly relevant area of toxicity assessment as drug 
candidates were frequently found to have cardiac adverse effects being a 
leading cause of drug withdraws [29]. Current available in vivo assays such 
as the Langendott-perfused rabbit heart model are laborious, costly and      
time-consuming [30]. Moreover, in vitro cardiotoxicity screenings such as 
the patch clam assay focusing on assessing the effects of compounds on 
potassium, sodium and calcium ion channels are limited by biological 
simplicity and an inability to detect drug–drug interactions [31]. Due to the 
limitations of both traditional mammalian models and in vitro approaches, 
researchers are showing increasing interest in zebrafish-based assays to 
assess cardiovascular safety and toxicity.  
 The cardiovascular system is the first major system to function within 
the embryo. Unlike the double circulation in mammals, the fish heart is         
two-chambered, consisting of an atrium and a ventricle separated by an 
atrioventricular valve. Zebrafish and mammalian heart exhibit a closed 
cardiovascular system, but organs and tissues of zebrafish embryos do not 
depend on the cardiac output for oxygen delivery. Embryos rely on oxygen 
diffusion through the skin from the swimming medium up to 14 days             
post-fertilization (dpf) [32]. Therefore, this feature permits embryos with 
severe cardiovascular defects to survive during the initial phase of 
embryonic development. By contrast, avian and mammalian embryos would 
die rapidly in the absence of a functional cardiovascular system.  
 Effects on cardiovascular system can be visually assessed in living 
zebrafish using a stereomicroscope and a microscope. Different cardiac and 
vascular abnormalities from developmental exposure to zebrafish have been 
reported (Table 2) being edema and heart rate change the most commonly 
assessed [33].  
 Several methods have been employed successfully in the larval fish to 
study heart function, for example, electrocardiogram [34], laser Doppler 
microscope technique [35] and laser confocal scanning microscopy [36]. 
However, these tools are labor-intensive, require special instrumentation and 
are not scalable for high-throughput screening. Therefore, we propose the 
use of a non-invasive method using simple light microscopy and a                   
fast  digital camera. Recent development in digital image analysis tools makes  
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Table 2. Cardiac and vascular abnormalities reported from developmental exposure 
to zebrafish (Reviewed by [33]). 
 
 
 
analysis of cardiovascular function, such as cardiac output, traveling speed 
of the blood cells, blood cell count, visualization and analysis of blood 
cells distribution in transparent zebrafish larvae easier [37].  
 The zebrafish is also used as a preclinical model in order to study 
drug-induced cardiac arrhythmias such as QT prolongation [38]. Drug-
induced prolongation of the QT interval in the electrocardiogram usually 
results from concentration dependent inhibition of the hERG (the human 
Ether-à-go-go-Related Gene) potassium channel. Moreover, drugs 
blocking this potassium current either as an intended pharmacologic effect 
(eg. antiarrhythmics dofetilide and almokalant) or as an unwanted side-
effect (eg. antihistamine drugs, antidepressive drugs and macrolide 
antibiotics) are potential human teratogens [39]. 
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 Numerous groups have screened pharmacologically relevant collections 
of compounds in zebrafish using bradycardia or/and atrioventricular 
dissociation as indicators of QT prolongation [30, 40, 41]. These assays were 
able to detect known QT prolonging drugs that block hERG such as 
terfenadine or cisapride, as well as compounds that block L-type calcium 
channels, not affecting the hERG channel. 
 In our case, we established the methodology for screening 
cardiovascular drugs using two reference compounds, terfenadine and 
isoprenaline (Fig. 3 and Fig. 4). Embryos exposed to terfenadine (10 µM) 
displayed a 2:1 atrioventricular block and bradychardia with a reduced 
cardiac output. In contrast, isoprenaline exposure increased the heart rate and 
cardiac output without causing an atrioventricular block. 
 Cardiovascular performance can also be assessed by recording the blood 
flow through the dorsal aorta. Scan lines obtained parallel to the flow of 
blood within the dorsal aorta were used to measure the cellular velocity and 
other cardiac indices. Figure 5 shows as an example the measured changes in 
blood flow velocity and diameter of the blood vessel in zebrafish embryos 
exposed to terfenadine and isoprenaline. 
 
 
 
Figure 3. Atrial and ventricular rates of embryos exposed to terfenadine and 
isoprenaline for 3 h at 72 hpf. Values are mean ± SEM of two independent test                 
(n= 6). Asterisks indicate significant difference at ***p<0.001, t-student test. 
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Figure 4. Representative end-diastolic (A) and end-systolic (B) images of a heart 
ventricle of zebrafish larva at 3 dpf. Calculation of ventricle volume during systole 
and diastole was based on the formula for the volume of a prolate spheroid: 4/3πab2 
where a represents the major axe radius and b of the minor axe radius of the ventricle 
image. Cardiac output (nl/min) = Stroke volume (end-diastolic volume – end-systolic 
volume) x heart rate. (Scale bar= 20µm).Table at the right shows the cardiac output 
of zebrafish embryos exposed to terfenadine and isoprenaline (n= 6). Asterisks 
indicate significant difference respect the control group at ***p<0.001, t-student test. 
 
 
 
Figure 5. (A) Maximum and minimum blood cell velocity, measured from embryos 
treated with terfenadine and isoprenaline. Data are presented as mean ± SEM (n=6). 
(B) Mean vessel cross section represented as a black outline, while the surrounding 
color shading indicates the standard deviation of the mean. Numerical values indicate 
the corresponding vessel cross-sectional area (μm2). Asterisks indicate significant 
difference at *p<0.05 and ***p<0.001, t-student test. 
 
 In addition, several transgenic lines with heart tissue and vascular 
fluorescent reporters have been generated [42, 43] and can be really useful 
for detecting changes in specific tissues, to visualize cardiomyocytes and 
vascular endothelium as well as precursor cells.  
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 These tools can contribute to a better understanding of the key 
cardiotoxic mechanisms in a whole-organism, cost-effective and medium 
high-throughput manner.   
 
Behavioral assessment of neurotoxic effects 
 
 Current in vivo methods for the assessment of developmental neurotoxic 
compounds [44] are designed to screen for adverse effects of pre and 
postnatal exposures on the development and function of the nervous system. 
However, these guidelines are unsuitable for screening large number of 
chemicals for many reasons including low throughput, high cost, and 
questions regarding reliability [45]. Therefore, new, reliable, and efficient 
screening and assessment tools are needed for better identification, 
prioritization, and evaluation of chemicals with the potential to induce 
developmental neurotoxicity. 
 Larval zebrafish nervous system exhibits developmental, structural and 
pharmacological conservation with the mammalian nervous system [46]. 
Locomotor patterns that develop early in the larva [47] (see Fig. 6) can be 
monitored for systematic screening of the genes, pharmaceuticals and 
environmental toxicants that can influence behavior [48, 49]. Moreover,  
 
 
 
Figure 6. Chronological sequence of appearance of motility patterns during 
development of the zebrafish. 
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several studies suggest that zebrafish larvae are sensitive to neuroactive 
drugs and that their locomotor response is similar to that of mammals               
[50, 51]. 
 Many assays have been developed in zebrafish larvae by taking 
advantage of its locomotor repertoire and inherent visual reflexes (Table 3). 
Among these is the visual motor response test that consists in brief (10-30 
min) alternating periods of light and dark and is characterized by low (basal) 
locomotor activity under light exposure and transient but robust behavioral 
hyperactivity on sudden transition to dark [52].  
 
Table 3. Different types of behavioral patterns exhibited by zebrafish larvae that can 
be measured as indicators of toxicant exposure (modified from [53]). 
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 Locomotor activity endpoints included swimming speed, distances 
swum, time spent in the different sections of the tank, time spent immobile, 
erratic movements, turning rate, etc. For an accurate, objective, and efficient 
measurement of these parameters, the use of automated video tracking 
systems is recommended [53]. In these systems, movement in the vertical 
plane is usually ignored or minimized by reducing water depth of the vessels 
[54] and currently, several commercial setups are available on the market 
(e.g. Viewpoint ZebraLab videotrack system).  
 Figure 7 shows as example the assessment of locomotor activity of 
zebrafish after being exposed to increasing concentrations of                                
d-amphetamine. The experimental conditions and data processing 
implemented in our laboratory permitted to reproduce the effects of                       
d-amphetamine being the results similar to those reported by Irons et al. [50]. 
Our results demonstrated that d-amphetamine produced an evident biphasic 
“inverted U” concentration-response pattern with a highly consistent 
behavioral pattern between light and dark periods. The lowest concentration  
 
 
 
Figure 7. Effects of d-amphetamine on larval locomotion. Values are mean + SEM 
of the total distance moved in 4 min interval Asterisks indicate significant difference 
at *p<0.05, **p<0.01 respect control. Black and white bars at the bottom signify dark 
and light conditions, respectively. 
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of d-amphetamine produced hyperactivity and the highest concentration 
tested caused hypoactivity, mainly in dark periods. The effects reflect those 
found in mammalian models, proving the usefulness of the zebrafish embryo 
model for neurobehavioral studies. In addition, it is likely that can be used to 
unveil abnormal nervous system developmental/maturation due to 
developmental neurotoxicity [50].   
 There are several conditions which need to be controlled in order to get 
consistent and reproducible outcomes especially involving locomotor 
activity (Table 4). For example, MacPhail et al. [60] found that zebrafish 
larvae are more active in the morning than in the afternoon, so locomotor 
activity depends on the time of day. It must be noted that, although behavior 
is the ultimate result of neuronal development and signaling, not all 
behavioral modifications are of neurological origin. Malformed limbs or 
other morphological based conditions may be associated with behaviors not 
apparent in normal individuals. For instance, a reduced visual sensitivity or 
higher visual threshold could delay the transition in activity when darkness is 
switched to light [60]. Therefore, if our final objective is to detect neurotoxic 
effects, embryos with malformations should be not used in the locomotor 
activity assay [61].  
 
Table 4. Variables that influence larval zebrafish behavior. 
 
 
. 
Hurdles to the acceptance of zebrafish assays 
 
 Despite the promising zebrafish studies described above, there are still 
significant issues to be addressed before the zebrafish is accepted as a 
toxicological model.  
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 Absorption, distribution, metabolism and excretion are crucial factors 
affecting the toxicity of chemicals. Most of the zebrafish assays relay on 
aqueous exposure and compound uptake predominantly by diffusion through 
the skin. Compound uptake may be not linear and it is dependent upon a 
number of physicochemical variables [65]. Internal concentration analysis is 
therefore needed in order to correlate the toxic phenotype observed with the 
actual concentration of the compound within the larvae. It is also necessary 
in order to identify false-negative results attributable to poor compound 
absorption and to link effect concentrations between mammals and fish 
embryos [66]. 
 One of the alleged weaknesses of the zebrafish embryo as a model for 
teratogenicity in mammals is the difference in metabolic activity towards 
exogenous substances. This is especially relevant in the case of xenobiotics 
that need bioactivation. Zebrafish embryos and larvae have the ability to 
perform both phase I (oxidation, n-demethylation, o-demethylation and                
n-dealkylation) and phase II (sulfation and glucuronidation) metabolism 
reactions [65]. In particular, zebrafish have a total of 94 CYP genes, 
distributed among 18 gene families, most of which are direct orthologs of 
human CYPs. Most of these CYPs are expressed in embryos during various 
time courses along the first 48 hours after fertilization. Indeed, some 
maternally-derived CYPs RNA transcripts are present in the unfertilized egg 
[67]. Some studies have been shown the capacity of zebrafish embryos to 
metabolize different drugs, some of that known human proteratogenic 
substances [68-70]. However, differences to mammalian metabolic pathways 
have been identified. Cisapride, for example, was mainly metabolized to 
cisapride N-sulfate in zebrafish larvae, which is only a minor metabolite in 
mammals. Therefore, more extensive studies are required to evaluate the 
similarities and differences in metabolic pathways between human and 
zebrafish.  
 
Conclusions 
 
 We have shown various examples of the applicability of the zebrafish 
embryo model in toxicology, focusing on the developmental toxicity 
evaluation of chemicals. The zebrafish embryo model is still struggling for 
recognition by regulators and industry as a screening tool in drug 
development and toxicological testing of chemicals other than water quality 
assessment. The first steps are promising [13, 71] and demonstrate the 
reliability of the zebrafish embryo model in human risk assessment. Further 
systematic testing of toxicologically concerning substances in all applicable 
areas relevant to humans will definitely provide a significant picture of the 
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predictive power of the zebrafish embryo assay. However, embryonic 
development is a very complex biological process so a single in vitro test 
capable of covering this whole process with satisfactory predictivity cannot 
be expected. An integrated testing approach with different test species 
should help minimize risk in the animal-human extrapolation [72].  
 In order to accurately predict and relate chemical impacts across species, 
it is necessary to have a mechanistic understanding of the effects of pathway 
perturbation. Recently, the use of the concept of Adverse Outcome pathways 
(AOPs) provides a framework in which data and knowledge are collected at 
many levels of biological organization and can be synthesized in a way that 
is useful to risk assessors and toxicologists that support this activity [73]. All 
this new developments in hazard assessment will contribute to have a more 
human-relevant and more predictive alternatives to traditional testing.  
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Abstract. The diversification of Cheirolophus in Macaronesian 
archipelagos constitutes a paradigmatic example of radiation on 
oceanic islands. Phylogenetic and molecular dating analyses indicate 
an extraordinarily fast process, showing one of the highest speciation 
rates ever found on plants from oceanic islands. Such radiation has 
been recently studied employing phylogeographic, population genetic 
and molecular cytogenetic approaches. Here, the main potential 
patterns and processes involved in the diversification of the genus in 
the Canary Islands and Madeira are reviewed and discussed as a 
whole. 
 
Introduction 
 
 The observations of Darwin [1] and Wallace [2] about diversification 
processes on island biotas meant an outstanding contribution to the origins of  
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modern evolutionary biology. From that moment, island radiations have 
become the object of numerous studies focusing on plants and animals 
from archipelagos all over the world [3, 4]. This interest on islands relies 
in the number of characteristics they possess, which make them attractive 
to researchers in the field –such as their relative small size, the existence of 
clear boundaries, the ecological simplicity compared to the continent, and 
the high diversity they usually harbour– making them natural laboratories 
where it is easier to observe, test and interpret general evolutionary 
patterns [5]. In recent times, Macaronesian archipelagos (Azores, Madeira, 
Canaries, Selvagens and Cape Verde, which constitute, together with a 
small nearby fraction of the African continent, the Macaronesian 
biogeographic region) and particularly the Canary Islands have become 
one of the favorite scenarios for researchers working on plant 
diversification processes (e.g. [6–9]). In this sense, many of the groups that 
have shown higher insular endemism levels -and therefore offering better 
possibilities to analyse island radiation processes- have been targeted (e.g. 
Argyranthemum Webb [10]; Aeonium Webb & Berthel. [11]; Bystropogon 
L.Hér. [12]; Sideritis L., [13]; Sonchus L. alliance [14]; Echium L. [15]; 
Tolpis Adans. [16]; Pericallis Webb & Berthel., [17]; Cheirolophus Cass. 
[18, 19]). 
 Among them all, in this review we will focus in the genus 
Cheirolophus Cass., whose diversification in the Canary Islands is 
considered as one of the top ten explosive plant radiations in this oceanic 
archipelago [20]. In addition to that, the Macaronesian representatives of 
this genus feature several typical traits of plants that have been able to 
diversify on insular environments, such as e.g. increasing woodiness [3], 
larger inflorescences and both showier flowers and inflorescences [21], 
reduction in genome size [7, 22] and small population size [23], thus 
making Cheirolophus a perfect model to study radiations on oceanic 
islands. Until recently, however, comprehensive understanding of the 
diversification of the genus in Macaronesia was missing. Based in previous 
phylogenetic reconstructions, it had been hypothesized that the radiation of 
Cheirolophus in the Canary Islands was a considerably fast and recent 
process [24, 25]. Unfortunately, those early studies lacked of a                                
solid temporal frame, so it was neither possible to estimate speciation rate 
nor to establish comparisons with other well-known cases of explosive 
radiations in Macaronesia (e.g. [15]) or in other oceanic archipelagos               
(e.g. [26]).  
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Figure 1. Morphological and ecological diversity found on the genus Cheirolophus 
a) Ch. arbutifolius (Svent.) G.Kunkel., b) Ch. burchardii Susanna, c) Ch. canariensis 
(Willd.) Holub, d) Ch. crassifolius (Bertol.) Susanna, e) Ch. falcisectus Svent. ex 
Montelongo & Moraleda, f) Ch. intybaceus (Lam.) Dostál, g) Ch. junonianus (Svent.) 
Holub, h, i) Cliffs in Madeira with Ch. massonianus (Lowe) A.Hansen & Sunding, j) 
Ch. tagananensis (Svent.) Holub, k) Ch. teydis (C.Sm.) G.López, l) Ch. uliginosus 
(Brot.) Dostál. (Images: L. Barres, T. Garnatje, D. Vitales, 
http://commons.wikimedia.org). 
 
 The genus Cheirolophus has also been pointed out to represent a 
paradigmatic example of non-adaptive radiation on islands [4]. Indeed, 
most of the Macaronesian species of the genus exploit similar ecological 
niches, showing at the same time mostly inconspicuous morphological 
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differences. Nevertheless, Macaronesian Cheirolophus show as well a few 
cases of ecological adaptations to particular habitats (e.g. Ch. teydis from 
subalpine zone of Tenerife and La Palma; or Ch. junonianus from the 
southern arid part of La Palma island; see Figure 1). These and other 
questions that have been found to play an important role on island 
diversification -such as hybridisation and among population gene flow      
[10, 11, 17]; colonisation and dispersal patterns among islands [9, 27]; or 
reproduction biology factors [28, 29]– have been the subject of some 
recent studies focusing on Cheirolophus radiation [18, 19, 25, 30]. In this 
chapter, we will present different methodological approaches employed to 
disentangle the evolutionary history of this genus, discussing the results 
obtained from a holistic perspective. 
 
1. Brief overview of the genus Cheirolophus 
 
 First of all, we must circumscribe Cheirolophus (Asteraceae, 
Cardueae, Centureineae) within a taxonomic and phylogenetic context. 
The genus was first described by Cassini [31] based on the segregation of a 
group of species formerly included in the genus Centaurea L. Afterwards, 
Boissier [32] included additional species to those previously segregated by 
Cassini, grouping them all in a new genus, Ptosimopappus Boiss., which 
comprised species from sections Cheirolophus Cass. and Microlophus 
(Cass.) DC., that had been described within the genus Centaurea. 
Moreover, this author proposed the inclusion of Centaurea arguta Nees 
and Centaurea uliginosa Brot. to this new genus, describing as well some 
new species such as Ptosimopappus bracteatus Boiss. and Ptosimopappus 
arboreus Boiss. [33]. 
 These taxonomic reorganisations have been in some cases 
conflicting. In fact, while authors like Pomel [34], Holub [35], Dostál 
[36], or Bremer [37] continued considering Cheirolophus as an 
independent genus, Dittrich [38] or Talavera [39], among others, preferred 
maintaining it as a section of Centaurea. Nonetheless, the most recent 
revisions of the Cardueae tribe based on molecular phylogenetic data 
(e.g.[40, 41]), clearly supported the segregation of Cheirolophus as an 
independent taxonomic entity, revealing the position of the genus as a 
basal lineage within subtribe Centaureinae.  
 This genus contains approximately 27-30 species, depending on the 
authors consulted, distributed along the western Mediterranean basin as far 
as Malta, and the Macaronesian archipelagos of Madeira and Canary 
Islands (Figure 2). Some of the species have a wide distribution, such as 
Ch. intybaceus (Lam.) Dostál or and Ch. sempervirens Pomel (Fig. 2). 
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Figure 2. Approximate geographical distribution of the genus Cheirolophus on 
Western Mediterranean, North Africa and Macaronesia. 
 
 Others, however, are more restricted geographically, and limited in 
many cases to very few populations, such as Ch. duranii (Burchard) Holub 
from El Hierro island or Ch. tagananensis (Svent.) Holub from Anaga 
peninsula in the northern part of Tenerife (Fig. 2). Indeed, most of the 
endemic Cheirolophus species from Macaronesia present extremely 
restricted distributions. To date, 20 species, one subspecies and one variety 
have been described in the Canarian archipelago [42], plus another species 
endemic to the islands of Madeira and Porto Santo. The low number of 
populations as well as the small population size reported for some of these 
species was a key factor for many of them to be included in                        
different national and international red lists of endangered flora (e.g. Libro 
Rojo de la Flora Vascular Amenazada de España [43]; or the IUCN Red 
List [44]).  
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2. Molecular phylogenetic studies in Cheirolophus 
 
 The pioneering molecular systematic studies in Cheirolophus employed 
isoenzyme electrophoresis technique to analyse the genetic variability 
among populations of different species [45, 46]. This methodological 
approach provided little resolution on the evolutionary relationships among 
species, but served to propose for the first time a recent origin for the 
diversification of the Macaronesian members of the genus. Sometime later, a 
phylogenetic reconstruction based on the internal transcript spacer (ITS) of 
the nrDNA allowed a taxonomic delimitation of Cheirolophus, including the 
species Ch. crassifolius (Bertol.) Susanna and confirming the monophyly of 
the Macaronesian grade [24]. This question was also readdressed afterwards 
with a combined approach consisting on genome size data and sequencing of 
both the ITS and external transcript spacer (ETS) regions [25]. As mentioned 
above, this study indentified Ch. crassifolius as the sister species to the rest 
of the members and evidenced the existence of two main lineages, the 
Macaronesian and the Mediterranean clades. Unfortunately, none of these 
works were able to accurately reconstruct the evolutionary history of 
Cheirolophus, and the interspecific relationships within the Macaronesian 
group remained particularly unresolved. 
 A recent reconstruction of the evolutionary history of the genus [18] has, 
however, provided a relevant contribution to former phylogenetic works. 
This new study has been based on the analysis of two nrDNA regions (ITS 
and ETS) as well as four cpDNA regions (rpl32-trnL, rpoB-trnD, rps16-
trnK and trnS-trnC), to analyse the whole specific and virtually all 
infraspecific diversity within the genus. 
 The results showed a significant phylogenetic incongruence among 
nuclear and plastid markers, a pattern usually explained by phenomena like 
incomplete lineage sorting (ILS), hybridisation or polyploidy, among others 
[47]. Incongruent position of species within the Mediterranean clade was 
explained by the slow evolutionary rate of plastid markers, preventing us 
from tracking accurately the speciation events in this group. A different 
hypothesis was proposed for the conflicting position of Ch. massonianus 
(Lowe) A.Hansen & Sunding between the plastid and nuclear trees. In this 
case, the placement of this Madeiran endemic in each phylogenetic 
reconstruction is so discordant that phenomena related to sharing alleles 
were discarded. Moreover, Ch. massonianus shows an intermediate genome 
size (though not exclusive) half way between that of the continental and the 
remaining insular species [25], hence constituting another evidence of 
potential hybridisation in this species.  
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 Regardless of this incongruence, both markers resulted useful to 
reconstruct the phylogeny when analysed independently (see Vitales et al. 
[18]). As it had been reported in former studies (e.g. [48]), whereas nuclear 
DNA provided resolution to the backbone of the phylogeny as well as for 
generating a temporal frame for the evolutionary history, plastid markers 
resulted more helpful unravelling the phylogeographic relationships among 
closely related species. Both datasets supported the monophyly of the 
genus and the existence of a well-differentiated insular clade. However, as 
a result of the potential hybridisation involving Ch. massonianus, the 
nuclear tree included the endemic species from Madeira within the insular 
clade, while the sampling on the plastid tree was restricted to Canarian 
species. The reconstruction based on ITS and ETS markers also resolved 
the Mediterranean clade, reflecting morphological and geographical 
affinities among the species of this group. Cheirolophus crassifolius, 
endemic to Malta and Gozo Islands, appeared in both analyses as an early-
diverged lineage, and sister to the rest of the members of the genus. In 
relation to Ch. uliginosus, the only hemicryptophyte representative, this 
species is also placed in a basal position relative to the diversification of 
the species within the Mediterranean and the Macaronesian clades -
although not entirely resolved- according to both nuclear and plastid 
datasets. 
 As already mentioned above, the analysis of the nuclear regions was 
particularly useful for studying the early stages of the evolutionary history 
of Cheirolophus, as well as to establish a time frame for the phylogeny 
(Figure 3). The origin of the diversification of the genus was dated to the 
mid-Miocene period. At that time, the Mediterranean basin still featured 
tropical climate characteristics, but a progressive aridification starting in 
the east around 11-9 Ma [49] might had pushed Cheirolophus westwards, 
explaining its current Western Mediterranean and Macaronesian 
distribution. Concerning the radiation of the genus in Macaronesia, the 
time-calibrated phylogeny indicated that Cheirolophus diversified rapidly, 
with c. 20 species arising in less than 1.8 Ma, at a rate of 0.34–2.84 species 
per Ma. Such high speciation rate is only comparable to those exhibited by 
other island radiations such as Hawaiian Bidens L. (0.3–2.3 species Myr−1) 
or Macaronesian Echium (0.4–1.5 species Myr−1), considered as the fastest 
plant radiations on volcanic islands to date [26]. Indeed, taking into 
account the area covered by both the Canary Islands and Madeira               
(8,321 km
2
), Macaronesian Cheirolophus may well represent the highest 
per-unit-area rate of diversification (4.09 × 10
−5
 to 3.41 × 10
−4
 species 
Myr
−1
 km
−2
) observed so far in plants [26, 50, 51].  
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Figure 3. Time-calibrated Bayesian phylogenetic tree inferred from nuclear (ITS and 
ETS) DNA sequences. Bayesian posterior probabilities (PP) above 95% are indicated 
above main interesting branches. Blue bars indicate 95% high posterior density 
intervals (for nodes with posterior probability > 50%) of node ages. 
 
3. Phylogeography of Macaronesian Cheirolophus 
 
 Having provided strong evidence explaining the radiation process, the 
question arose as to which mechanisms were underlying such rapid 
diversification. Another point to further investigate was the role played by 
the phylogeographic history of Macaronesian Cheirolophus in such rapid 
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diversification. The phylogeographic analyses performed by Vitales et al. 
[18] highlighted Tenerife island as the most likely source area of inter-island 
dispersal, with a pivoting role in successive colonisations towards the East 
(from Tenerife to Gran Canaria) and towards the West (from Tenerife to La 
Gomera and la Palma, on the one hand and towards La Gomera and El 
Hierro, on the other hand). During this process, the analyses suggested that 
La Gomera could have been colonised twice. These results are consistent 
with other phylogeographic studies focusing on the Canary Islands (e.g.          
[52–54]), which propose that this central island could had served as a major 
hub for the colonisation of the archipelago. The ancient geological history of 
this island [55], together with its central position in the archipelago and the 
high diversity of habitats, probably explains this central phylogeographic 
role of Tenerife. Moreover, Tenerife harbours the highest genetic diversity 
for Cheirolophus in the archipelago, as observed also in other genera in the 
Canarian area such as Bystropogon [12], Sideritis [13] or Aeonium [11]. The 
higher genetic and taxonomic diversity levels found in Tenerife have also 
been attributed to the complex palaeogeographic history of this island [55]. 
Successive fragmentation and connexion process among the habitats due to 
major climatic and geologic events affecting Tenerife during this period may 
have contributed to the allopatric differentiation among populations. 
 The largest islands -particularly Tenerife and La Palma- experienced 
several cases of intra-island diversification, probably driven by genetic 
isolation, but also due to different processes such as incipient ecological 
adaptation or introgression events. This model of radiation has been 
proposed to be common in other plants and animals that diversified -more or 
less- in the Canary Islands (see Sanmartín et al. [9] for a review). Certainly, 
these typical patterns of colonization, dispersal and differentiation 
experienced by Cheirolophus cannot explain on their own the extraordinarily 
rapid radiation occurred in Macaronesia, so other intrinsic or extrinsic 
factors must have contributed to this spectacular process of island 
diversification. 
 
4. Genomic insights in Cheirolophus 
 
 Several authors have recently proposed that certain genomic factors such 
as the genome size [7, 22, 56] or the number of nrDNA loci [57] could be 
related to the process of diversification on islands. In Cheirolophus, this 
topic has been the subject of different studies [25, 30], addressing genome 
size, karyological and molecular cytogenetic aspects of some Macaronesian 
and continental species of the genus.  
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 Cheirolophus is the only genus within the Centaureinae that has 
radiated in the Canary Islands. Similarly to other closely related genera 
(Callicephalus C.A.Mey, Myopordon Boiss., Oligochaeta K.Koch, 
Rhaponticum Ludw. and Centaurea, see Hidalgo et al. [58, 59] for further 
details), the genus displays the 35S and the 5S nrDNA loci physically 
separated in the chromosomes. By contrast, while those phylogenetically 
related genera contain a relatively low number of 35S loci [60], fluorescent 
in situ hybridisation (FISH) analyses in Cheirolophus revealed a strikingly 
high number of chromomycin bands and 35S loci, predominantly located 
at terminal position. Likewise, a certain trend towards an increasing 
number of 35S loci in Macaronesian species was observed, preliminarily 
suggesting that this unusual number of loci appeared during island 
radiation process. However, other continental species of the genus such as 
Ch. benoistii (Humbert) Holub or Ch. intybaceus showed as well a high 
number of 35S signals, indicating that the abundance of terminal 35S 
predated the radiation in Macaronesia. Finally, Garnatje et al. [30] 
hypothesised a positive effect of the 35S loci pattern promoting the 
radiation of Cheirolophus.  
 In a previous study focusing on genome size variation within the genus 
Cheirolophus, Garnatje et al. [25] evidenced a significant progressive 
genome downsizing since early stages of its evolutionary history,  and 
particularly noticeable within the Macaronesian clade. Some evolutionary 
mechanisms such as homologous recombination and illegitimate 
recombination (see Leitch and Leitch [61], for a review) have been 
proposed to be able to affect both genome size and rDNA loci distribution. 
In Oligochaeta divaricata K.Koch (another species included within basal 
Centaureinae and closely related to Cheirolophus), a deep chromosomal 
restructuring process resulted on a significant loss of DNA associated to an 
increase of 35S loci and the reorganisation of their position in the 
chromosomes. It should be noted, however, that terminal 35S positions in 
Cheirolophus were not affected by genome size reduction. In summary, 
despite that Cheirolophus radiation was not associated to changes in 
chromosome number or ploidy level, the patterns of rDNA loci distribution 
and the reduction of the DNA content evidence certain capacity for 
genomic dynamism in the group. Indeed, the association among genomic 
size changes, nrDNA organisation and cladogenesis has been recently 
discussed by several authors (e.g. [62, 63]), but the precise putative role 
played by these mechanisms on Cheirolophus radiation will require further 
investigation. 
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5. Population genetics study in Macaronesian Cheirolophus 
  
 As stated earlier, the phylogenetic study of Cheirolophus based on 
nrDNA and cpDNA sequences [18] provided valuable information about the 
early evolutionary history of the genus. However, the phylogenetic 
resolution within the Macaronesian lineage was poor due to the rapidity of 
the diversification process and the limited variability of the employed 
markers. For that reason, the radiation of Cheirolophus in the Canary Islands 
and Madeira was subsequently investigated using a population genetics 
approach with AFLP markers [19].  
 First, this methodology was employed to study the taxonomic 
delimitation within the Macaronesian species of the genus, a subject that had 
been already under discussion in earlier studies focusing on Cheirolophus 
evolution [45]. The phylogenetic results obtained from AFLP data provided 
full support to the current taxonomic species’ circumscription. Thus, our 
results corroborate the distinctiveness of these extraordinarily recently 
diverged species and support the suitability of classical diagnostic characters 
employed in the taxonomical delimitation of Macaronesian Cheirolophus. 
 The phylogenetic relationships among the Macaronesian species were 
not entirely reconstructed with the AFLP data, but the diverse analytical 
approaches proved useful to better understand the evolutionary history of 
these insular lineages. The genetic structure of populations showed a 
significant segregation pattern among western islands (La Palma and El 
Hierro) and central/eastern islands (La Gomera, Tenerife, Gran Canaria). 
The important role played by allopatric differentiation became even more 
evident when considering additional genetic clusters: most of the populations 
grouped geographically, either among the islands or within the islands. Here 
again, the genetic structure found in Tenerife populations was particularly 
interesting, already reported in other plant groups [12], and suggesting a 
lineage disjunction related to the ancient palaeoislands of Anaga and Teno 
[64].  
 Despite the limited population sampling, the study carried out by  
Vitales et al. [19] also suggested a reduced gene flow among the 
Macaronesian populations. The strong signal of isolation-by-distance, the 
low within-population heterozygosity and the high values of the 
fragmentation indexes indicated a limited genetic flow among the 
populations. These results agreed with the low dispersal capacity of 
Cheirolophus seeds, the geographic isolation of populations and their small 
size, possibly contributing to their progressive genetic differentiation. In 
contrast, the phylogeographic pattern observed in this group -including 
numerous colonisation and recolonisation events, both intra- and inter-island 
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suggest that Macaronesian Cheirolophus showed a considerable ability for 
sporadic long distance dispersal (see Crawford et al. [28] for some 
hypotheses). In this way, authors such as Ellis et al. [65] or Knope et al. [26] 
have proposed that the combination of reduced gene flow and certain ability 
for long distance dispersal may play an important role on radiation processes 
experienced by plants. 
 As mentioned in the introduction section, the Macaronesian 
Cheirolophus have been proposed as an example of non-adaptive radiation 
on islands [4]. In this regard, the correlation analyses among morphological 
and genetic distances performed by Vitales et al. [19] indicated that there is 
not a straightforward association among genetic lineages and the 
ecomorphological traits studied in these species. Clearly, the data and the 
methods employed in this study are preliminary and somewhat insufficient 
to discard an essential role of adaptive selection in the radiation of this 
group. However, these results suggested that ecological adaptation did not 
drive the initial stages of Macaronesian Cheirolophus diversification. The 
examples of adaptations to specific ecological conditions found in some 
species (e.g. Ch. junonianus from the southern extreme of La Palma, or         
Ch teydis from the subalpine zone of Tenerife and La Palma) seem to 
correspond with relatively recent and independent processes of 
ecomorphological differentiation. 
 Another mechanism potentially playing an important role in the 
evolutionary history of Macaronesian Cheirolophus is introgression [18]. We 
have already discussed the case of Ch. massonianus, putatively experiencing 
a chloroplast capture process from a continental taxon. In addition, our 
analyses also suggested some cases of genetic introgression between several 
species from the Canary Islands. Particularly, some evidences of genetic 
admixture were found in Ch. teydis and Ch. arboreus from La Palma, and 
Ch. duranii from El Hierro. In some cases these genetic traces seemed 
supported by morphological data and/or heteromorphic positions found in 
the nrDNA regions of these species. That said, one should bear in mind that 
some of these signals could also be explained by retention of ancestral 
polymorphisms or incomplete lineage sorting (ILS) phenomena, especially 
considering the speed of the radiation. Therefore, the relative importance of 
genetic introgression in the radiation of Macaronesian Cheirolophus should 
be further studied more in detail.  
 
6. Conclusion 
 
 Recent molecular phylogenetic studies have shown that the radiation of 
Cheirolophus in Macaronesia was an extraordinarily recent and rapid process. 
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Phylogeographic analyses indicated that Tenerife Island played an important role 
in this explosive diversification that, according to our data, could have been 
driven by allopatric differentiation, incipient ecological adaptation and 
introgression events. Molecular cytogenetic studies have revealed that 
Cheirolophus has undergone a significant increase in the number of 35S rDNA 
loci, which started just after the diversification of the genus in the Mediterranean 
region. This pattern contrasts with the gradual genome downsizing observed 
during the evolution of the genus, and evidences a certain genomic dynamism in 
the genus, probably related with the ability to radiate on islands. Finally, a 
population genetic approach suggested that the combination of poor gene flow 
capacity and a certain ability for sporadic long-distance colonization could have 
also played an important role enhancing the explosive diversification of this 
genus in Macaronesia.  
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Abstract. The usefulness of the ultrastructural characters of 
spermiogenesis and of the spermatozoon in the interpretation of 
relationships in the Platyhelminthes has been widely demonstrated. 
The present paper provides a review and an update on the 
ultrastructural knowledge on spermiogenesis and on the spermatozoon 
in cyclophyllidean cestodes. For each family of cyclophyllideans the 
pattern of spermiogenesis and the type of sperm cell is provided. 
Moreover, the most interesting characteristics of both spermiogenesis 
and the spermatozoon are compiled and illustrated for each family. 
Finally, new spermatological data on some species of the 
Anoplocephalidae and the Taeniidae are provided. 
 
Introduction 
 
 The utility of ultrastructural characters of spermiogenesis and spermatozoa 
as a valuable tool for the elucidation of phylogenetic relationships in the  
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Platyhelminthes has been widely demonstrated [1-13]. To date, the 
ultrastructure of spermiogenesis and/or the spermatozoon has been studied in 
more than 125 species of eucestodes belonging to the orders 
Bothriocephalidea, Caryophyllidea, Cyclophyllidea, Diphyllidea, 
Diphyllobothriidea, Haplobothriidea, Lecanicephalidea, Proteocephalidea, 
Spathebothriidea, Tetrabothriidea, Tetraphyllidea and Trypanorhyncha                
[14-27]. 
 The Cyclophyllidea is undoubtedly the most extensively studied order, 
and data on the ultrastructure of spermiogenesis and/or spermatozoa is 
available for more than 60 species. According to the Global Cestode 
Database [28], the order Cyclophyllidea is constituted by 14 to 18 families, 
380 to 400 genera and more than 3,000 species. To date, there are 
spermatological data on 12 families of cyclophyllideans, which will be 
analyzed in the present work. The studied families are Anoplocephalidae, 
Catenotaeniidae, Davaineidae, Dilepididae, Dipylidiidae, Gryporhynchidae, 
Hymenolepididae, Mesocestoididae, Metadilepididae, Nematotaeniidae, 
Paruterinidae and Taeniidae. Thus, the aim of the present chapter is to 
provide a review and an update concerning the ultrastructural knowledge on 
spermiogenesis and on the spermatozoon of cyclophyllidean cestodes. 
 
1. Materials and methods 
 
 In the present chapter, new and preliminary spermatological results are 
showed concerning three species, namely Thysanotaenia congolensis, 
Echinococcus granulosus and Echinococcus multilocularis. Other 
illustrations refer to original TEM micrographs of previously published 
studies. These are Gallegoides arfaai [29], Raillietina micracantha [30], 
Molluscotaenia crassiscolex [31], Mesocestoides lineatus [32] and Taenia 
taeniaeformis [33]. 
 Live specimens of T. congolensis were isolated from naturally infected 
black rats (Rattus rattus) from Sao Domingos and Orgaos (Cape Verde). 
Specimens of E. multilocularis were obtained from naturally infected red 
foxes (Vulpes vulpes) from La Roche sur Foron (France). Finally,                       
E. granulosus were isolated from experimentally infected dogs from Sidi 
Thabet (Tunisia). 
 Adult studied tapeworms were immediately rinsed with a 0.9 % NaCl 
solution. Later, they were fixed in cold (4 °C) 2.5 % glutaraldehyde in a 0.1 
M sodium cacodylate buffer at pH 7.4 for a minimum of 2 h, rinsed in 0.1 M 
sodium cacodylate buffer at pH 7.4, post-fixed in cold (4 °C) 1 % osmium 
tetroxide with 0.9 % potassium ferricyanide [K3Fe(CN)6] in the same buffer 
for 1 h, rinsed in milliQ water, dehydrated in an ethanol series and propylene 
Spermiogenesis and spermatozoa in cyclophyllideans 103 
oxide, embedded in Spurr’s resin and polymerised at 60 °C for 72 h. 
Ultrathin sections (60–90 nm thick) of mature segments at the level of the 
vas efferens and testes were obtained in a Reichert-Jung Ultracut E 
ultramicrotome. Sections were placed on copper grids and double-stained 
with uranyl acetate and lead citrate according to the Reynolds [34] 
methodology. The grids were examined in a JEOL 1010 transmission 
electron microscope operated at 80 kV, in the “Centres Científics i 
Tecnològics” of the University of Barcelona (CCiTUB). 
 
2. Spermiogenesis and the spermatozoa in the Cyclophyllidea 
 
 Spermatogenesis in tapeworms is of the rosette type. The primary 
spermatogonium divides mitotically, forming two secondary spermatogonia. 
All further divisions occur simultaneously, resulting in a rosette of four 
tertiary, then eight quaternary spermatogonia and sixteen primary 
spermatocytes. The first meiotic division forms thirty-two secondary 
spermatocytes and after the second meiotic division, sixty-four spermatids 
are formed. 
 The initial stages of spermiogenesis in all cestodes are similar. They 
are characterized by the formation of a zone of differentiation delimited by 
a ring of arched membranes and supported by cortical microtubules, and 
by a change in the density of the nucleus. The zone of differentiation 
contains two centrioles and sometimes an intercentriolar body and striated 
rootlets. A cytoplasmic extension elongates from this zone of 
differentiation and the two centrioles give rise to one or two flagella. Bâ & 
Marchand [7] described four types of spermiogenesis in the Cestoda 
mainly characterized by the formation of one or two flagella and by the 
presence/absence of flagellar rotation and proximodistal fusion between 
the flagellum/a and the cytoplasmic extension. All studied 
cyclophyllideans present spermiogenesis of pattern 3 or 4, except for 
mesocestoidids [32, 35] (see Table 1). 
 The spermatozoa of tapeworms are filiform cells, tapered at both 
extremities and lacking mitochondria. The absence of mitochondria in 
eucestode spermatozoa is a clear spermatological synapomorphy. 
Considering diverse characters, Levron et al. [13] described seven types of 
spermatozoa in the eucestodes. These characters include the presence of one 
or two axonemes, the parallel or spiralled pattern of cortical microtubules 
and nucleus, and the presence/absence of crested bodies, periaxonemal 
sheath and intracytoplasmic walls. All cyclophyllideans exhibit spermatozoa 
of types V, VI or VII, containing only one axoneme, with crested body/ies, 
twisted cortical microtubules and a nucleus spiralled around the axoneme 
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(see Table 2). Some characters such as the presence/absence of a 
periaxonemal sheath surrounding the axoneme and the presence/absence of 
transverse intracytoplasmic walls connecting the layer of cortical 
microtubules and the periaxonemal sheath allow differentiating these three 
types of sperm cells in cyclophyllideans. Mesocestoidids are the unique 
exception in the model of sperm cells within cyclophyllideans, showing a 
parallel disposition of cortical microtubules [32, 35] and thus a type IV 
spermatozoon. 
 
2.1. Family Anoplocephalidae 
 
 In the family Anoplocephalidae there are ultrastructural studies on the 
spermiogenesis and/or the spermatozoon in 16 species belonging to the 
different subfamilies of anoplocephalids. These are Anoplocephaloides 
dentata, Aporina delafondi, Gallegoides arfaai, Moniezia benedenii, Moniezia 
expansa, Monoecocestus americanus, Mosgovoyia ctenoides, 
Paranoplocephala omphalodes and Sudarikovina taterae (Anoplocephalinae) 
[29, 36-44], Inermicapsifer guineensis and Inermicapsifer madagascariensis 
(Inermicapsiferinae) [45, 46], Mathevotaenia herpestis and Oochoristica 
agamae (Linstowiinae) [47, 48], and Avitellina centripunctata, Avitellina 
lahorea, Stilesia globipunctata and Thysaniezia ovilla (Thysanosomatinae) 
[49-52]. The type of sperm cells varies in this family. Thus, the studied 
anoplocephalines and also Thysaniezia [29, 36, 37, 39, 42-44, 52] exhibit the 
type V sperm of Levron et al. [13], which is mainly characterized by the 
absence of periaxonemal sheath and intracytoplasmic walls (Fig. 1a). Both 
Inermicapsifer studied species exhibit type VII sperm, characterized by the 
presence of periaxonemal sheath and intracytoplasmic walls. Moreover, 
preliminary observations on another inermicapsiferine (Thysanotaenia 
congolensis) show the same type VII sperm cells (Fig. 1d). In the Linstowiinae 
the spermatozoon is of type VI with periaxonemal sheath but without 
intracytoplasmic walls. In the subfamily Thysanosomatinae the three studied 
genera exhibit three different types of male gametes: the above mentioned 
Thysaniezia presents a type V spermatozoon [52], whereas Stilesia presents a 
type VI spermatozoon [51] and Avitellina presents a type VII spermatozoon 
[49]. 
 Crested body or bodies always mark the anterior extremity of the 
spermatozoon, constituting a constant character in all cyclophyllideans. In 
this order the number of crested bodies is usually one or two. Most 
anoplocephalids exhibit one or two crested bodies in the anterior 
spermatozoon extremity (see Table 2). However, there are two species 
belonging to the subfamily Anoplocephalinae that exhibit more than two 
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crested bodies, namely A. delafondi [37] with five and S. taterae [44] with 
seven crested bodies. 
 In inermicapsiferines only scarce data on spermatogenesis of I. 
madagascariensis in known [46], and details on spermiogenesis are not 
given. For the Anoplocephalinae in which spermiogenesis has been studied 
[36-38, 40, 42, 44], this process follows the type 4 of Bâ & Marchand [7] 
characterized by the absence of proximodistal fusion. In the Linstowiinae, 
pattern 3 spermiogenesis has been described in M. herpestis [47]. For the 
Thysanosomatinae only data on T. ovilla are known and spermiogenesis 
follows the pattern 4 [52]. 
 
Table 1. Ultrastructural data on spermiogenesis in cyclophyllideans. 
 
Family and 
subfamily  
Character 
 Type* SR IB FR PF 
Anoplocephalidae      
Anoplocephalinae 4 -/vsr - - - 
Inermicapsiferinae ? ? ? ? ? 
Linstowiinae 3 - - - + 
Thysanosomatinae 4 - - - - 
Catenotaeniidae      
Catenotaeniinae 3 - - + (<90º) + 
Skrjabinotaeniinae ? ? ? ? ? 
Davaineidae 3 - - - + 
Dilepididae 4 - - - - 
Dipylidiidae 3 +/vsr - - + 
Gryporhynchidae 4 - - - - 
Hymenolepididae 4 - - - - 
Mesocestoididae 2 + + + (90º) + 
Metadilepididae 3 vsr - - + 
Nematotaeniidae 3 - - - + 
Paruterinidae 3 vsr - + (<90º) + 
Taeniidae      
Echinococcinae 3 vsr ? ? + 
Taeniinae 3 -/vsr - + (<90º)/- + 
 
FR – flagellar rotation, IB – intercentriolar body, PF – proximodistal fusion,           
SR – striated rootlets, vsr – vestigial striated rootlets, ? – unknown data, +/- – 
presence/absence of character, * – type according to Bâ & Marchand [7]. 
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 During spermiogenesis, some anoplocephalids such as A. dentata,                
G. arfaai, M. expansa and M. ctenoides exhibit thin striated rootlets or spiral 
rootlets associated to centrioles [36, 38, 40, 42]. In order to increase 
homogeneity in the designation of the previously described non-typical 
striated rootlets, the common designation of vestigial striated rootlets was 
proposed [see 38]. Similar root-like structures, named as thin, filamentous or 
vestigial striated rootlets, also occur in species from other families 
(Dipylidiidae, Metadilepididae, Paruterinidae and Taeniidae) [21, 53-58].  
 
2.2. Family Catenotaeniidae 
 
 In catenotaeniids only two species were studied, Catenotaenia pusilla 
(Catenotaeniinae) and Skrjabinotaenia lobata (Skrjabinotaeniinae) [59, 60]. 
The spermatozoon has been characterized in both subfamilies and 
corresponds to the type VI [13]. With respect to spermiogenesis, there is data 
concerning only C. pusilla [59] and it follows the pattern 3 [7]. However, a 
flagellar rotation of about 45º was observed in this species [59]. 
 
Table 2. Ultrastructural data on the spermatozoon in cyclophyllideans. 
 
Family and 
subfamily 
Character 
 Type* CB CM N PS IW G 
Anoplocephalidae        
Anoplocephalinae V 2, 5, 7 15-45º Spi - - + 
Inermicapsiferinae VII 2 45º Spi + + - 
Linstowiinae VI 1 40º Spi + - - 
Thysanosomatinae V/VI/VII 1, 2 35-50º Spi +/- +/- +/- 
Catenotaeniidae VI 2 40º Spi + - - 
Davaineidae VII 2 45-60º Spi + + + 
Dilepididae VI 1, 2 30-45º Spi + - + 
Dipylidiidae VI 1 40º Spi + - - 
Gryporhynchidae VI 1 45º Spi + - + 
Hymenolepididae V 6, 8, 9, 10, 12 15-30º Spi - - + 
Mesocestoididae IV 1 0º Spi - - + 
Metadilepididae VII 1 30-40º Spi + + - 
Nematotaeniidae V 1 Spi Spi - - + 
Paruterinidae VII 1 35-40º Spi + + + 
Taeniidae        
Echinococcinae VII 1, 2? Spi Spi + + - 
Taeniinae VII 1 40-50º Spi + + - 
 
CB – number of crested bodies, CM – angle of cortical microtubules, G – electron-dense 
granules, IW – intracytoplasmic walls, N – nucleus, PS – periaxonemal sheath, Spi – 
spiralled, ? – unknown data, +/- – presence/absence of character, * – type according to 
Levron et al. [13]. 
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2.3. Family Davaineidae 
 
 Seven species of davaineids were analysed: Cotugnia polyacantha, 
Paroniella reynoldsae, Raillietina baeri, Raillietina carneostrobilata, 
Raillietina micracantha, Raillietina tunetensis and Raillietina vinagoi [30, 
61-66]. The spermatozoon in this family corresponds to type VII according 
to Levron et al [13] (Fig. 1e). In davaineids, spermiogenesis has been studied 
only in R. micracantha and R. tunetensis [30, 65]. In both cases 
spermiogenesis follows the pattern 3 of Bâ & Marchand [7]. 
 
2.4. Family Dilepididae 
 
 There are spermatological studies concerning five species of Dilepididae. 
These are Anomotaenia quelea, Angularella beema, Dilepis undula, 
Kowalewskiella glareola and Molluscotaenia crassiscolex [18, 31, 67-69]. The 
ultrastructural organization of the mature spermatozoon of dilepidids 
corresponds to the type VI of Levron et al. [13] (Fig. 1c). Available data on 
spermiogenesis concerns only A. beema and M. crassiscolex [31, 67], 
corresponding to the pattern 4 of Bâ & Marchand [7]. 
 
2.5. Family Dipylidiidae 
 
 There are ultrastructural studies on the spermiogenesis and the 
spermatozoon of Dipylidium caninum, Joyeuxiella echinorhyncoides and 
Joyeuxiella pasqualei [53, 54, 70, 71]. The ultrastructural organization of 
their spermatozoa corresponds to the type VI [13]. Spermiogenesis in these 
species is also well described and follows the pattern 3 [7]. However, 
striated rootlets are described in these species. In the case of Joyeuxiella spp. 
two well-developed striated rootlets associated to both centrioles were 
observed [71]. In D. caninum there are several thin striated rootlets [53, 54]. 
 
2.6. Family Gryporhynchidae 
 
 In this family, only Valipora mutabilis [72] has been studied. 
Spermiogenesis follows the pattern 4 of Bâ & Marchand [7] and the mature 
spermatozoon is of type VI of Levron et al. [13]. 
 
2.7. Family Hymenolepididae 
 
 Numerous species of this family have been the subject of 
spermatological studies. To our knowledge these are Cladogynia 
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guberiana, Cladogynia serrata, Dicranotaenia coronula, Diorchis 
parvogenitalis, Echinocotyle dolosa, Hymenolepis diminuta, Hymenolepis 
sulcata, Monorcholepis dujardini, Rodentolepis fraterna, Rodentolepis 
microstoma, Rodentolepis myoxi, Rodentolepis nana and Rodentolepis 
straminea [73-85]. 
 However, most of them consist in incomplete and partial analyses of 
the spermatozoon. There are consistent studies of the spermatozoon in the 
case of C. serrata, E. dolosa, R. microstoma, R. nana and R. straminea 
[74, 77, 83-85] and the ultrastructural organization of sperm cells for all 
these species corresponds to the type V [13]. 
 Spermiogenesis is well known for R. microstoma and R. nana [83, 84], 
corresponding to the pattern 4 of Bâ & Marchand [7]. 
 In hymenolepidids the high number of crested bodies present in the 
spermatozoon is particularly interesting (see Table 2). There are six crested 
bodies in C. serrata [74], up to eight in E. dolosa and R. straminea [77, 85], 
up to nine in H. sulcata and R. myoxi [81], up to 10 in R. fraterna [81] and 
12 in H. nana [84].  
 
2.8. Family Mesocestoididae 
 
 The spermiogenesis and the ultrastructural organization of the 
spermatozoon of two mesocestoidids (Mesocestoides lineatus and 
Mesocestoides litteratus) have been studied [32, 35]. 
 In contrast with the remaining cyclophyllideans, these species show a 
parallel arrangement of cortical microtubules in the spermatozoon and 
thus, the sperm cell is of type IV of Levron et al. [13] (Fig. 1b). 
 With respect to spermiogenesis, the pattern is also particular in 
comparison with the remaining cyclophyllideans. Mesocestoidids follow 
the pattern 2 of Bâ & Marchand [7], which is characterized by the 
formation of a single flagellum that rotates and fuses proximodistally with 
a cytoplasmic extension. Both species also exhibit a reduced intercentriolar 
body and well-developed striated rootlets associated to centrioles in the 
zone of differentiation [32, 35]. 
 Both the parallel arrangement of cortical microtubules in the mature 
spermatozoon and the pattern 2 of spermiogenesis with their associated 
characteristics are unique within cyclophyllideans and constitute the 
plesiomorphic condition of these characters. These ultrastructural results 
are in agreement with other morphologic and molecular data, confirming 
the problematic systematics of mesocestoidids [see 32, 35]. 
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2.9. Family Metadilepididae 
 
 Only Skrjabinoporus merops has been analysed in this family [55]. The 
spermatozoon is of type VII of Levron et al. [13], containing both 
periaxonemal sheath and intracytoplasmic walls. Spermiogenesis has also 
been described and follows the pattern 3 of Bâ & Marchand [7]. 
Additionally, vestigial striated rootlets associated to centrioles were 
observed [55]. 
 
 
 
Figure 1. Longitudinal and cross-sections of spermatozoa of a) Gallegoides arfaai, 
b) Mesocestoides lineatus, c) Molluscotaenia crassiscolex, d) Thysanotaenia 
congolensis, e) Raillietina micracantha, and f) Taenia taeniaeformis. CB – crested 
bodies, CM – cortical microtubules, IW – intracytoplasmic walls, PS – periaxonemal 
sheath. Scale bars = 0.3 m. 
 
2.10. Family Nematotaeniidae 
 
 To date, spermatological data from nematotaeniids are available 
concerning only Cylindrotaenia hickmani and Nematotaenia chantalae [86-
88]. In C. hickmani there are two ultrastructural studies on the cirrus pouch 
and sperm ducts [86, 87] in which some sections of spermatozoa are shown. 
As in N. chantalae [88], the ultrastructural organization of the spermatozoon 
seems to be of type V [13]. Concerning spermiogenesis, only data on                  
Jordi Miquel et al. 110 
N. chantalae exists [88] and this process corresponds to pattern 3 of Bâ & 
Marchand [7]. 
 
2.11. Family Paruterinidae 
 
 Three paruterinids were the subject of ultrastructural studies on 
spermiogenesis and on the mature spermatozoon: Anonchotaenia globata, 
Notopentorchis sp. and Triaenorhina rectangula [21, 56, 57]. All three 
paruterinids exhibit a type VII spermatozoon according to the Levron et al. 
models [13] and the pattern 3 spermiogenesis of Bâ & Marchand [7]. As 
mentioned above, paruterinids present vestigial striated rootlets associated 
to centrioles. Moreover, a non-parallel development of the free flagellum 
was described and thus, a flagellar rotation occurs before the proximodistal 
fusion between flagellum and cytoplasmic extension. 
 
 
 
Figure 2. Spermiogenesis and the spermatozoon of Echinococcus spp.                            
a) Spermatozoon of E. granulosus, b) Spermatozoon of E. multilocularis,                             
c and d) Spermatids of E. granulosus, and e) Zone of differentiation of                              
E. multilocularis. CB – crested bodies, CE – cytoplasmic extension, CM – cortical 
microtubules, F – flagellum, IW – intracytoplasmic walls, N – nucleus, PS – 
periaxonemal sheath, vsr – vestigial striated rootlets. Scale bars = 0.3 m. 
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2.12. Family Taeniidae 
 
 In this family there are spermatological studies on eight species of the 
genus Taenia, namely T. crassiceps, T. hydatigena, T. mustelae, T. parva,                    
T. pisiformis, T. saginata, T. solium and T. taeniaeformis [27, 33, 58, 89-96], 
and in two species of the genus Echinococcus, namely E. granulosus and              
E. multilocularis [97-99]. However, for some of these species, the 
spermatological data are only partial [89, 90, 93, 94, 96, 97-99]. 
 In the genus Taenia, a type VII permatozoon of Levron et al. [13] was 
described (Fig. 1f). Spermiogenesis follows the pattern 3 of Bâ & Marchand 
[7], although good descriptions are published concerning only two species, 
T. parva and T. taeniaeformis [58, 93]. In both species a flagellar rotation 
was described and in the case of T. taeniaeformis, additionally, the presence 
of vestigial striated rootlets was illustrated [58]. 
 In the genus Echinococcus there are some published papers that show 
scarce results on E. granulosus and E. multilocularis [97-99]. Nevertheless, 
new preliminary observations on these two species indicate a pattern 3 
spermiogenesis of Bâ & Marchand [7] with the presence of vestigial striated 
rootlets associated to centrioles in both species (Fig. 2d,e). Concerning the 
spermatozoon, the presence of both periaxonemal sheath and transverse 
intracytoplasmic walls characterize the sperm cell as belonging to the type 
VII of Levron et al. [13] (Fig. 2a,b). In the case of E. multilocularis, two 
crested bodies have been observed during spermiogenesis, but this fact is 
still to be confirmed in the mature spermatozoon (Fig. 2c). 
 
3. Conclusion 
   
 The present review highlights the usefulness of spermatological data for 
the systematics and phylogenetics of cestodes. Indeed, the last decade of 
ultrastructural research on spermiogenesis and sperm structure provided 
extensive information. This fact leads to a considerable increase in the 
existing dataset of characters suitable for the assessment of phylogenetic 
relationships of cestodes. In the case of Cyclophyllidea, future research 
should be focused on species belonging to those families lacking 
spermatological studies (Acoleidae, Amabiliidae, Dioecocestidae and 
Progynotaeniidae), but also on other families that have been poorly studied. 
 In cyclophyllideans, both spermiogenesis patterns and sperm models are 
quite homogeneous, with the exception of anoplocephalids, for which an 
important variability is observed. In this Order, the suitability of sperm 
characters is clearly shown in mesocestoidids or in inermicapsiferines. The 
plesiomorphic characters present during spermiogenesis and in the mature 
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spermatozoon of Mesocestoides are unique within cyclophyllideans and they 
are also observed in other primitive groups of tapeworms. Thus, these 
spermatological data support the separation of the Mesocestoididae from the 
Cyclophyllidea [see 32, 35]. On the other hand, the available data on the 
spermatozoa of Inermicapsifer and Thysanotaenia indicate their proximity to 
davaineids. However, as it is generally accepted, all these spermatological 
data should be combined with molecular studies to obtain a more robust 
phylogeny of cestodes [10-12]. 
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8. Dietary spray-dried animal plasma 
alleviates mucosal inflammation in 
experimental models     
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Institut de Recerca en Nutrició i Seguretat Alimentària, Universitat de Barcelona, Spain 
 
Abstract. The intestinal and bronchoalveolar mucosae contribute to 
homeostasis by preventing the entrance of biological and chemical 
agents that could alter the stability of the system. In this review, we 
summarise the main effects of dietary supplementation with                 
spray-dried plasma (SDP), a complex mixture of biologically active 
functional components, on two models of acute inflammation; a 
murine model of intestinal inflammation, based on the 
administration of S. aureus enterotoxin B (SEB), and a model of 
acute lung inflammation, using mice challenged with 
lipopolysaccharide from E. coli (LPS). Oral SDP modulates the 
immune response of the intestinal mucosa and restores the barrier 
function of the epithelium, preventing most of the effects of SEB on 
defensin expression, tight-junction permeability and mucosal 
cytokine production. In the lung, SDP supplementation partially 
prevents the LPS-induced release of pro-inflammatory cytokines, an 
effect that involves the participation of the common mucosal 
immune system. In both models, the effects of SDP are mediated by 
an increased T-reg response and enhanced release of anti-
inflammatory cytokines that contribute to mucosal homeostasis. 
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Introduction 
 
 Spray-dried plasma (SDP) is a protein-rich product obtained from the 
industrial fractionation of blood from porcine and bovine animals 
slaughtered for human consumption. Blood is collected with an 
anticoagulant, centrifuged to separate blood cells and spray-dried using high 
pressure and a temperature over 80ºC for a very short period of time. With 
this procedure, proteins are not denaturalised and their biological activity is 
mostly preserved [1]. 
 At the end of the last century, SDP was initially proposed as a protein 
source for piglets [2]. Since then, many studies have demonstrated that SDP 
improves piglet and calf performance, and today it is widely used as an 
alternative to the use of antibiotics as growth promoters [3]. Numerous 
studies have shown that feeding SDP of either bovine or porcine origin 
reduces mortality and morbidity in various animal species challenged with 
pathogenic bacteria (E. coli, Salmonella), viruses (rotavirus, coronavirus, 
white spot syndrome virus) or protozoa (C. parvum) [4;5;6]. 
 In addition, a greater efficacy of SDP has been described in younger 
pigs which have a less mature immune system [7], or in pigs kept under less 
hygienic conditions [8]. 
 
1. Effects of SDP on acute intestinal inflammation 
 
 The gastrointestinal tract provides a protective interface between the 
internal milieu and the permanent challenge resulting from microorganisms 
and antigens derived from food present in the lumen. The intestinal mucosa 
regulates the penetration of luminal antigens and the generation of 
immunologic responses in the gut, and dysregulation of these barrier 
mechanisms causes intestinal inflammation [9]. 
 Since the host’s immune responses can be modulated by diet [10], the 
dietary approach offers a therapeutic potential in conditions associated with 
gut barrier dysfunction and inflammatory response. 
 
1.1. Intestinal barrier 
 
 A key function of the intestinal epithelium is to serve as a selective 
barrier allowing the uptake of nutrients while excluding toxins and 
microorganisms. Mucosal permeability mainly depends on the capacity of 
tight-junctions to efficiently seal the apical poles of epithelial cells. The 
Animal plasma and inflammatory diseases 119 
space between cells is occupied by interlocking proteins such as claudins, 
occludin or E-cadherin that bind scaffolding proteins such as ZO-1 and            
β-catenin which, in turn, link them to the cellular cytoskeleton [11]. An acute 
change of the intestinal barrier function contributes to disease pathogenesis, 
especially when the intestine is challenged by luminal antigens. Several 
bacterial products, such as Clostridium and Vibrio toxins, change the 
localisation of several tight-junction proteins [12] or reduce the number of 
strands in the tight-junction [13]. 
 Staphylococcal enterotoxin B (SEB) reduced the expression of β-catenin 
in a rodent model of intestinal inflammation [14] and SDP supplementation 
prevented this effect (Figure 1A). Moreover, SEB treatment significantly 
increased the flux of 4 kD FITC-dextran (FD4, a fluorescent tracer of 
paracellular permeability) across the intestinal wall and SDP 
supplementation prevented this effect (Figure 1B). The effects of SEB on 
intestinal permeability were similar to those described in SEB-injected mice 
(15). β-catenin expression was negatively correlated with FD4 flux, 
suggesting that the increases in dextran flux are paralleled by a reduction in 
β-catenin expression (Figure 1C). These results indicate that the increase in 
FD4 flux induced by SEB treatment is associated with a reduction in the 
tightness of the epithelial junction complex and that SDP dietary 
supplementation resulted in complete recovery. The effects of SDP 
supplementation in reducing a toxin-induced increase in mucosal 
permeability may prevent the passage of microbial and food antigens to the 
interstitial space, thereby avoiding local inflammation [16]. 
 Enterotoxins can also have indirect effects by inducing the release of 
pro-inflammatory cytokines such as IFN-γ and TNF-α. Both cytokines 
increase epithelial permeability by reducing the expression of β-catenin [17]. 
SEB also stimulates the secretion of IFN-γ and TNF-α from lymphocytes 
[18;19], which can disassemble tight-junction protein complexes [20] or 
reduce their expression [21;22], thus enhancing paracellular permeability of 
microvascular endothelial cells.  
 Mucosal homeostasis is also protected by mucosal defensins secreted by 
both Paneth cells and enterocytes. These are antimicrobial peptides that 
regulate the composition and number of luminal colonising microbes present 
in the small intestine, and they play an important role in reducing pathogen 
concentration in the intestinal lumen. Studies in humans indicate that 
reduced Paneth cell defensin expression may be a key pathogenic factor in 
ileal Crohn's disease, because it changes the profile of the colonising 
microbiota [23]. 
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Figure 1. SDP effects on intestinal barrier function in acute inflammation (with 
permission from Pérez-Bosque et al., 2006). Panel A shows representative images of 
β-catenin immunohistochemical localisation in jejunum from Control, SEB and  
SEB-SDP rats. Panel B shows the FITC-dextran (FD) flux across the intestinal wall 
of rat jejunum measured in an Ussing chamber. Results are expressed as means ± 
SEM (7-10 animals). Symbols indicate significant differences P<0.05; *SEB group 
vs Control group, #SEB-SDP group vs SEB group. Panel C shows the correlation 
between β-catenin expression and FD flux (P<0.001). 
 
 In rats, SEB reduces the expression of cryptdin 4 and β-defensin-1 
(Figure 2). Since cryptdin 4 has the ability to block IL-1β release from           
LPS-activated monocytes [24], decreased expression of this defensin would 
result in increased intestinal IL-1β production, rendering the intestine more 
susceptible to SEB-induced damage and contributing to pathogenesis of 
inflammatory bowel diseases. β-defensin-1 is constitutively expressed by 
enterocytes, and when its expression is reduced, there is increased 
proliferation of several major components of the intestinal microbiota, 
including Candida albicans, Bacteroides fragilis, Enterococcus faecalis and 
Escherichia coli [25]. SDP restored the physiological production of mucosal  
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Figure 2. Effects of SDP supplementation on cryptdin 4 (A) and β-defensin 1 (B) 
expression in acute inflammation. Expression determined by real time PCR. Data 
are the mean ± SEM of 7-8 rats. Symbols indicate significant differences P<0.05; 
*SEB group vs Control group, #SEB-SDP group vs SEB group. 
 
defensins, indicating that plasma protein supplementation may contribute 
to maintenance of intestinal immune homeostasis by maintaining the 
production of natural innate antibacterial agents, as well as by regulating 
the production of pro-inflammatory cytokines. The possible relationship 
between the current effects of SDP on defensin expression, and previous 
observations showing that dietary plasma proteins induce changes in the 
microbiota profile associated with a higher resistance to dysbiosis [26], 
should be further explored. 
 
1.2. Intestinal immune response 
 
 Gut-associated lymphoid tissue (GALT) accounts for up to 80% of the 
mucosal immune system and is distributed along the intestine. It contains a 
broad network of secondary lymphoid organs, as well as a large number of 
lymphocytes, including several intestine-specific subpopulations [27]. Upon 
activation, the intestinal immune system coordinates a strong inflammatory 
response against invasive pathogenic bacteria (thus promoting protection) 
while providing inhibitory mechanisms to prevent an excessive response 
against commensal bacteria (thus promoting tolerance). However, if the 
immune system is stimulated and the response is not controlled, tissue may 
be damaged [18]. 
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 SEB administration induces a recruitment of neutrophils [28] and 
eosinophils [29]. The dietary inclusion of SDP does not modify the SEB-
induced effects on neutrophil infiltration, but does reduce eosinophil 
infiltration and the degree of cell degranulation. The SEB challenge also 
increases the activation of intestinal T-helper lymphocytes present in Peyer’s 
patches (PP), in mucosal lamina propria and in the intraepithelial 
compartment [28;30]. Furthermore, dietary supplementation with SDP 
prevents the SEB-induced activation of T-helper lymphocytes in all the 
above mentioned intestinal compartments (Figure 3A). SDP reduces the 
expression of mucosal pro-inflammatory cytokines [19], which is paralleled 
by a reduction in intestinal activated T cells (Figure 3B), consistent with the 
fact that activated T-helper lymphocytes release pro-inflammatory cytokines 
to amplify the immune response [31]. Bosi et al. [32] observed that pigs 
challenged with E. coli K88 and fed SDP had a lower intestinal expression 
of pro-inflammatory cytokines. The effect of SDP on the mucosal cytokine 
profile reduces mucosal inflammation and prevents changes in mucosal 
permeability and tight-junctional protein expression following SEB 
administration [14]. 
 The inducible regulatory T cell (T-reg) population is another component 
of the mucosal immune system that maintains immunological 
unresponsiveness to self-antigens and suppresses excessive immune 
responses that can be deleterious to the host [33]. T-reg cells mediate 
peripheral T cell tolerance to antigens derived from dietary origin or from 
the commensal flora. In addition, after antigenic stimulation, T-reg 
lymphocytes can specifically inhibit the immune response of activated T-
helper cells [34], through the expression of characteristic cytokines such as 
transforming growth factor-β and IL-10, distinct from either Th1 or Th2 
cells. 
  SDP supplementation increased IL-10 production in SEB-challenged 
rats at both intestinal (Peyer’s patches and intestinal mucosa) and systemic 
levels [19]. Dietary supplementation with plasma proteins increases the 
mucosal expression of IL-10, which suggests the involvement of this anti-
inflammatory cytokine in regulating the production of pro-inflammatory 
cytokines (Figure 3C). This SDP effect on IL-10 contributes to intestinal 
homeostasis, since this cytokine is involved in the control of the intestinal 
pathology caused by T cell and innate immune cell activation. In view of the 
role of IL-10 in the amelioration of intestinal inflammation [35], it is worth 
noting that SDP can also increase mucosal IL-10 in absence of any 
challenge. 
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 The observation that the effects of SEB on the release of systemic           
pro-inflammatory cytokines are small is in agreement with previous    results 
in the spleen [28] and indicates that SEB has little effect on the peripheral 
immune system. However, the increase in IL-10 concentration in serum is 
highly correlated to a reduction in the TNF-α concentration (Figure 3D). 
 
 
 
Figure 3. SDP effects on mucosal immune response in acute intestinal 
inflammation (with permission from Pérez-Bosque et al., 2008). Panel A shows 
activated T lymphocytes in the intestinal lamina propria. Activated T cells were 
immunolocalised with specific antibodies on jejunal slides from Control, SEB and 
SEB-SDP rats. Results are expressed as means ± SEM (5-6 animals). Symbols 
indicate significant differences P<0.05; *SEB group vs Control group, #SEB-SDP 
group vs SEB group. Panel B shows the correlation between the number of activated 
T cells in the intestinal lamina propria and TNF-α mucosal concentration. The 
correlation coefficient was R2=0.6971 (P<0.001). The correlation of TNF-α and IL-
10 concentration in the intestinal mucosa and in serum is shown in panels C and D, 
respectively. 
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2. Effects of SDP on acute lung inflammation 
 
 The observation that SDP not only modulates GALT homeostasis [29] 
but also affects lymphoid tissue populations in peripheral tissues such as the 
spleen [36;28] and lung [37] has led to the hypothesis that plasma 
supplements may also modulate the immune response in non-intestinal 
mucosal tissues. This hypothesis is supported by the existence of the 
common mucosal immune system that connects the lymphoid tissue of the 
gut to the other mucosal areas, that is, nasopharyngeal, bronchoalveolar and 
genitourinary mucosae [38]. 
 
2.1. Common mucosal immune system 
 
 The respiratory and gastrointestinal tracts share some structural 
similarities. Both have an extensive luminal surface area, which is protected 
from commensal bacteria, pathogens and foreign antigens by a selective 
epithelial barrier [39] and an overlying mucus-gel layer [40]. These 
epithelial surfaces cover a mucosa-associated lymphoid tissue composed of 
resident lymphocytes. This lymphoid tissue regulates antigen sampling, 
lymphocyte trafficking and mucosal host defence [38]. Together with the 
genitourinary tract, they represent the main sites of intersection between the 
environment and the host. 
 An additional feature of mucosal barrier tissues is their contact with 
beneficial microbiota. Therefore, these tissues must protect the host from 
pathogenic challenges while at the same time maintaining a peaceful 
coexistence with the resident microbiota [41]. 
 There is much evidence suggesting that the mucosal immune system is a 
system-wide organ. Studies have demonstrated that stimulation in one 
compartment of the mucosal immune system can lead to changes in distal 
areas. For example, intranasal immunisation results in vaginal protection 
against genital infection with herpes simplex virus type 2 [42]. Furthermore, 
the use of antibiotics in neonates has been associated with a greater risk of 
developing asthma [43], which suggests that alterations in the gut microflora 
can have an effect on the lungs. Collectively, such studies suggest that the 
mucosal immune system is actually a large interconnected network with 
individual components efficiently sharing information [44]. 
 
2.2. Pro-inflammatory immune response 
 
 In a mouse model of acute lung inflammation induced by inhalation of 
LPS, the pulmonary response is characterised by leukocyte migration 
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accompanied by a massive release of pro-inflammatory cytokines and 
chemokines (Figure 4A), which recruit monocytes and neutrophils into the 
lung airway and into the lung tissue [45]. Dietary inclusion of SDP reduces 
the innate immune response to LPS inhalation. The reduction in leukocyte 
numbers in bronchoalveolar lavage fluid (BALF) and lung tissue, the lower 
concentration of pro-inflammatory cytokines and chemokines in BALF and 
the lower iNOS expression in lung tissue all suggest a dietary-dependent 
reduction in the chemical mediators responsible for acute lung injury.  
 
 
 
Figure 4. SDP effects on mucosal pro-inflammatory immune response in acute 
lung inflammation (with permission from Maijò et al., 2012a,b). Panel A shows the 
correlation between leukocyte recruitment into lung airway and chemokine CCL2 
concentration in bronchoalveolar lavage fluid (BALF). Panel B and panel C show the 
percentage of activated neutrophils (B) and activated Th lymphocytes (C) in the lung 
airway. Results are expressed as means ± SEM (5-6 animals). Symbols indicate 
significant differences P<0.05; *LPS group vs Control group, #LPS-SDP group vs 
SEB group. Panel D shows the correlation between the number of activated Th 
lymphocytes in BALF and IL-2 BALF concentration. 
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 The LPS challenge increased the percentage of neutrophils by 70% 
[45]. The primary function of neutrophils is to contain and kill invading 
microbial pathogens [46]. In BALF and lung tissue, LPS increased the 
proportion of activated neutrophils (Figure 4B) and of activated 
monocytes [45], as a consequence of the release of large amounts of 
chemokines. SDP supplementation reduces the percentage of activated 
neutrophils and monocytes in the lung airway. The effects of SDP on the 
response of the innate immune system present in the lung are relevant 
because this system plays an important role in mediating defence against 
pathogens, detecting tissue damage and regulating tissue health and 
integrity [47]. Therefore, the lower cell migration and diminished 
activation of inflammatory cells in pulmonary tissue may reduce potential 
damage in respiratory epithelium and vascular endothelium associated with 
the inflammatory response. 
 LPS challenge also promotes the activation of Th lymphocytes at both 
local (lung tissue; Figure 4C) and systemic (blood) levels. These effects 
are accompanied by enhanced release of IL-2 in the lung (Figure 4D); this 
cytokine (almost exclusively produced by activated Th cells) promotes 
proliferation of lymphocytes, macrophages and NK cells [48]. SDP 
supplementation also reduces the percentage of activated Th lymphocytes 
and prevents the release of IL-2. This effect is consistent with the                   
anti-inflammatory response previously described for plasma supplements 
[19]. 
 
2.3. Regulatory response during acute lung inflammation 
 
 The LPS challenge does not modify the percentage of T-reg cells 
(Figure 5A); however, dietary SDP inclusion increases the percentage of 
these cells and also reduces the T-activated:T-reg cell ratio (Figure 5B).              
T-reg cells reduce inflammation by counteracting the effects of other Th 
cells and contribute to suppression of innate and adaptive immune responses 
[49;50]. 
 SDP promotes IL-10 production in the lung of inflamed mice, and the 
increases in the concentration of this cytokine are paralleled by increases in 
the percentage of T-reg cells (Figure 5C). Other studies carried out using a 
LPS model of acute lung inflammation in rats have demonstrated that 
treatment with IL-10 after endotoxin instillation protects against acute lung 
injury, possibly by suppressing pulmonary infiltration of activated 
neutrophils [51]. In the LPS-induced lung inflammation model, as in the 
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SEB model of intestinal inflammation, it has been shown that the dietary 
modulation of intestinal inflammation is mediated by an increase in mucosal 
IL-10 expression, which reduces the release of pro-inflammatory cytokines 
[19;52] (Figure 5D). 
 
 
 
Figure 5. SDP effects on mucosal anti-inflammatory immune response in acute 
lung inflammation (with permission from Maijò et al., 2012b). Panel A and panel B 
show the percentage of the regulatory T lymphocytes (T-reg) (A) and the ratio 
between activated Th lymphocytes and T-reg cells (B) in the lung airway. Results are 
expressed as means ± SEM (5-6 animals). Symbols indicate significant differences 
P<0.05; *LPS group vs Control group, #LPS-SDP group vs SEB group. Panel C 
shows the correlation between T-reg into lung airway and the concentration of the 
anti-inflammatory cytokine IL-10 in bronchoalveolar lavage fluid (BALF). Panel D 
shows TNF-α and IL-10 concentrations in BALF. 
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3. Mode of action of SDP 
 
 SDP is a highly complex mixture of functional peptides and proteins 
such as immunoglobulins and growth factors, with a high proportion                    
of albumin [53]. As summarised by Petschow et al. [54], plasma 
supplements contribute to homeostasis by neutralising endotoxin in the 
intestinal lumen, promoting a stable microbiota, maintaining the gut barrier 
function and preserving the immune balance both in intestinal and 
peripheral tissues. 
 The mechanism by which oral plasma supplements modulate 
peripheral inflammation is not completely understood. However, there is 
increasing evidence that signals initiated in the intestinal lumen of 
different origin (dietary functional components, changes in the microflora, 
the presence of microbial cell wall components and even bacterial secreted 
products) can interact with the intestinal mucosa and have the capacity to 
regulate immune responses outside the gastrointestinal tract [55]. Plasma 
supplements ameliorate the inflammatory response by increasing the 
number of T-regs in the inflamed colon as well as by enhancing                          
IL-10 release [56]. Therefore, there is evidence indicating that plasma 
supplements modulate the abundance of T-regs in the intestine (the 
inductor site) and stimulated blood and lung T-regs in the lung model                      
(the effector site), both interconnected by the common mucosal system 
[55]. 
 The mechanism of action of SDP is probably not unique. SDP contains 
a high proportion of immunoglobulins that can bind a variety of potential 
antigens in the lumen, preventing their attachment to the mucosa [32]. This 
is the mechanism claimed to explain the beneficial effects of SDP in the 
prevention of viral gastroenteritis in children [57], and in the reduction of 
diarrhoea in pigs [58] and in acquired immune deficiency syndrome 
patients infected with C. parvum [59]. However, it must be considered that 
over 250 peptides have been identified in plasma [53] and most of them 
will retain some biological function after spray-drying [1]. SDP may 
contain a fraction of natural antibodies that will contribute to immune 
homeostasis, enhancing anti-inflammatory IL-10 production, as suggested 
by Petschow et al. [60]. The presence of bioactive peptides in SDP may 
also cause changes in the intestinal microbiota profile. For example, SDP 
can inhibit the growth of pathogenic bacteria [61;58]. 
 Animal plasma supplementation can also change the microbiota profile. 
Ovine Ig may alter the intestinal environment through a specific enrichment 
of Lactobacillus strains and depletion of enterobacteria [62], although 
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studies in piglets have yielded conflicting results [6;63]. In rats, the analysis 
of caecal microbiota showed that animals fed porcine SDP presented 
increased richness of the intestinal ecosystem [26]. Finally, it is worth noting 
that animal plasma supplements contain growth factors, cytokines and 
biologically active compounds that may also directly interact with mucosal 
receptors present both in enterocytes and ib dendritic cells, or that can reach 
the subepithelial compartment across the Peyer’s patch M cells, as happens 
with food-derived peptides [64]. This is a largely unexplored area that 
deserves further attention. 
 
4. Conclusions 
 
 Supplements prepared from animal plasma of porcine, bovine or ovine 
origin have been shown to contribute to gut homeostasis and act at luminal and 
mucosal levels. The main targets are the regulation of the intestinal barrier and 
the gut-associated immune system, which connects and modulates other 
mucosal areas, promoting the proliferation of regulatory lymphocytes and the 
expression of anti-inflammatory cytokines which presumably mediate most of 
its beneficial physiological effects. The mechanism by which plasma 
supplements initiate the regulatory responses is probably not unique but 
involves luminal mechanisms, with changes in the microbiota profile, direct or 
indirect interaction with enterocytes or with immune intestinal cells, and steps 
connecting the gut-associated phenomena with peripheral mucosal areas also 
exposed to the external environment. A better insight into the mechanisms 
implicated and a deeper knowledge of the specific plasma components 
involved are necessary to gain acceptance of these products. 
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Abstract. Alanine aminotransferase (ALT) is a sensitive marker of 
dietary protein utilisation in fish. Three ALT isoforms (cALT1, 
cALT2 and mALT) encoded by two genes have been isolated from 
gilthead sea bream (Sparus aurata). Molecular characterization of 
ALT isozymes and gene promoters suggest involvement of cALT1 
and mALT in postprandial use of dietary amino acids, while cALT2 
seems associated to hepatic gluconeogenesis. Inhibition of hepatic 
cytosolic ALT activity stimulates pyruvate kinase and decreases the 
renewal rate of alanine in S. aurata. These findings point to ALT as a 
target to spare protein and improve catabolism of dietary 
carbohydrates in cultured fish. 
 
Introduction 
 
 Feeds supplied to fish in culture typically represent the largest variable 
cost in aquaculture producers’ budget. Nowadays an important concern in 
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aquaculture is to reduce the amount of dietary protein and to increase the 
content of cheaper nutrients to replace fishmeal [1]. In addition, since a 
large quantity of wild-caught fish is used as a source of fishmeal for 
aquafeeds, a reduction in the amount of protein supplied with the diet to 
fish in culture will alleviate pressure and dependence on marine fisheries, 
which are often overexploited [2–4]. Moreover, an excess of protein in the 
diet of farmed fish enhances amino acid degradation and eutrophication of 
local waters as a result of increased excretion of ammonia and organic 
compounds [5,6]. 
 Most fish species produced by aquaculture, such as gilthead sea bream 
(Sparus aurata), turbot and sea bass, are carnivorous ectothermic species 
and efforts to partially substitute dietary protein by other nutrients are 
limited by the metabolic features of these animals. Carnivorous fish 
present low capacity to metabolise dietary carbohydrates [7–9]. The 
metabolism of carnivorous fish is adapted to a preferential use of dietary 
amino acids as the main source for metabolic energy production.  
 Alanine aminotransferase (ALT; EC 2.6.1.2), also known as glutamate 
pyruvate transaminase, plays a major role in amino acid metabolism and 
gluconeogenesis by catalysing the reversible transamination between                 
L-alanine and -ketoglutarate to form pyruvate and L-glutamate. 
Therefore, ALT constitutes an important link between amino acids, 
carbohydrates and energy metabolism (Fig. 1). 
 ALT is a homodimer formed by two subunits of 50 kDa. Each subunit 
binds a molecule of the coenzyme pyridoxal-5-phosphate (PLP), which is 
necessary for enzyme activity. In mammals, the hepatic activity of ALT is 
regulated by hormonal and nutritional status, and its expression levels 
increase in rats fed with high protein diets, during starvation, after 
treatment with cortisol or -adrenergic agonists, and in diabetic animals 
[10,11]. ALT and aspartate aminotransferase (AST) are quantitatively the 
most important aminotransferases in the fish liver [12]. Nevertheless, ALT 
activity is more sensitive to changes in the nutritional status than AST in S. 
aurata and other fish species. 
 In the present review we will address current knowledge of the 
nutritional regulation of ALT expression in fish and its potential use as a 
biotechnological target to enhance carbohydrate catabolism for energy 
purposes, and preserve dietary amino acids for growth in order to spare 
protein and improve the sustainability of aquaculture. 
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Figure 1. Role of ALT in the hepatic metabolism. 
 
1. Hepatic ALT activity as a marker of dietary protein utilisation 
in fish 
 
 Partial substitution of dietary protein by carbohydrates promotes a 
metabolic adaptation that involves stimulation of key enzymes in 
glycolysis and pentose phosphate pathway in the liver of S. aurata [13–17]. 
Furthermore, supply of high protein/low carbohydrate diets increased ALT 
activity, while AST remained unaffected (Fig. 2A) [13,17]. Similar results 
were reported for Atlantic salmon [18] and rainbow trout [19,20]. This 
finding argues for a central role of ALT in the metabolic adaptation to 
changes in dietary nutrient composition. The increase in liver ALT activity 
in fish fed high protein diets may contribute to an efficient use of dietary 
amino acids either for growth or as a substrate for gluconeogenesis.  
 Hepatic ALT activity decreases in S. aurata following long-term 
starvation, whereas AST activity shows a slight tendency to increase                   
[13]. The effect of starvation on ALT and AST activities in other                  
fishes is variable and does not follow a clear pattern among different species.  
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Figure 2. Nutritional regulation of ALT activity in the liver of S. aurata. (A) Effect 
of protein/carbohydrate dietary content on ALT and AST activity. Different letters 
indicate significant differences for ALT activity (lower-case letters) among diets. No 
significant differences were found for AST [17]. (B) Effect of ration size on somatic 
growth rate (SGR, expressed as weight gain percentage per day) and the hepatic 
activity of ALT and AST in S. aurata. Different letters indicate significant 
differences for ALT activity (lower-case letters) and SGR (upper-case letters) among 
ration sizes. No significant differences were found for AST [13].  
 
Feeding Sparus aurata with different energy levels showed that liver ALT 
enzyme activity correlates with ration size and somatic growth rate. In 
contrast, regardless of the ration size no significant differences in AST 
activity were observed (Fig. 2B) [13]. 
 
2. Molecular cloning, subcellular localization, and kinetic 
properties of Sparus aurata ALT isozymes 
 
 Biochemical studies on rat and human ALT suggested the presence of 
soluble isoforms of ALT in cytosol and mitochondria [21–24]. The fact that 
Km for alanine of rat mitochondrial ALT is one order of magnitude lower 
than the value of cytoplasmic ALT, led to the assumption that pyruvate 
formation from alanine is a major function of mitochondrial ALT [25]. 
However, later reexamination of the subject indicated that a considerable 
part of alanine-derived pyruvate originates in cytoplasm and that 
contribution of rat mitochondrial ALT activity during gluconeogenesis is 
negligible compared with that of the cytoplasmic enzyme [26]. In addition, 
presence of several cytosolic ALT and mitochondrial ALT isozymes have 
been demonstrated in mammalian tissues [27–30]. The metabolic function of 
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each ALT isoform in the cell and the molecular mechanism that generates 
ALT isoforms in mammals remain unknown. 
 Similarly as in mammals, distribution of ALT activity in liver extracts 
from S. aurata showed that more than 85 % of total ALT activity localizes to 
the cytosol, whereas mitochondrial ALT corresponds to about 14% of total 
ALT activity [31]. Three ALT isozymes were isolated from S. aurata 
tissues, named cALT1, cALT2 and mALT [31,32]. Alternative splicing of 
cALT gene generates cALT1 and cALT2, while a separate gene encodes 
mALT. Compared to cALT1 messenger, cALT2 mRNA contains an extra 
exon with an upstream translational start site that results in the inclusion of 
23 amino acid residues at the N-terminus of the protein [32]. Considering 
that polyasparagine and polyglutamine regions are involved in protein-
protein interaction through the formation of a polar zipper of hydrogen 
bonds between the side chains [33], presence of an asparagine-rich region in 
cALT2 suggests regulation of the enzyme activity by aggregation or 
interaction with effector proteins. In this regard, aggregation of ALT 
molecules gives rise to active oligomers during the purification of the rat 
liver enzyme [34]. 
 The primary structure of S. aurata mALT protein shares an identity of 
77 and 74 % with cALT1 and cALT2, respectively. Alignment of peptide 
sequences of piscine cALTs and mALT with mammalian ALT1 and ALT2 
shows an identity of 66-71 %. The overall similarity with mammalian ALTs 
suggests a high degree of conservation of structure and reaction mechanism 
in vertebrate evolution. In the rat liver cytosolic ALT, Lys
313
 resides in the 
active site and participates in binding to the coenzyme PLP [35,36]. This 
residue is conserved in S. aurata ALTs and corresponds to Lys
309
, Lys
332
 and 
Lys
372
, in cALT1, cALT2 and mALT, respectively. 
 Subcellular localization of S. aurata ALT isoforms was examined by 
means of confocal fluorescence microscopy and immunodetection after 
expression of enhanced green fluorescent protein (GFP)-fusion proteins in 
transiently transfected eukaryotic cells. Both cALT1 and cALT2 show a 
diffuse distribution in the cell, indicating that both isoforms mostly exhibit 
cytosolic localization. A minor part of the two proteins is also present in 
vesicle-like structures [31,32]. 
 Consistent with the physicochemical properties of a mitochondrial 
targeting signal presequence [37–40], the N-terminus of mALT comprises 
twelve positively charged, seventeen hydroxylated, and many hydrophobic 
residues within the first 70 amino acids. Indeed, fusion of GFP to the                     
C-terminus of mALT (mALT-GFP) leads to colocalization of the fusion 
protein with mitochondrial markers. On the contrary, fusion of GFP to 
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mALT N-terminus or to the C-terminus of a mALT mutant lacking the                       
N-terminal end blocks entry of the protein into mitochondria, and confirms 
presence of a mitochondrial targeting signal at the N-terminus of mALT. 
Immunodetection of CHO cells transfected with mALT-GFP revealed that 
although the protein is mostly found in the mitochondrial fraction, it is also 
detected in cytosol, although to a lesser extend and with higher molecular 
weight [31]. This finding argues for mALT import and processing into 
mitochondria according to the presequence import pathway, where basic N-
terminal presequences are directed into mitochondria through interaction 
with translocases of the outer and inner membranes [41–43]. 
 Expression of cALT1 in S. aurata is mainly found in liver, brain, 
skeletal muscle, intestine and kidney. No expression of cALT1 is detected in 
heart, gill or spleen. In contrast, maximal expression of cALT2 occurs in 
these three organs. Moderate cALT2 expression is observed in intestine, 
kidney and liver, whereas low cALT2 mRNA levels are detected in brain 
and skeletal muscle. mALT is ubiquitously expressed, with the higher levels 
in kidney, followed by liver, and intestine [32,44].  
 The occurrence of various ALT isozymes in tissues such as the liver 
supports the notion that ALT isoforms may play different roles in the cell. 
To unravel the molecular functions of S. aurata ALT proteins, kinetic 
characterisation of ALT isozymes was performed after expression of fish 
enzymes in Saccharomyces cerevisiae (Table 1) [32,44]. Kinetic properties 
of ALT isoforms were determined considering catalysis of the reaction in the 
direction of L-glutamate formation (forward reaction) and the direction of  
L-alanine formation (reverse reaction). Analysis of the forward/reverse ALT 
activity ratio and the fact that the reverse reaction mechanism of cALT2 
followed a ping-pong bireactant system with, in contrast to cALT1, strong 
double substrate inhibition suggest that cALT2 preferentially converts                 
L-alanine to pyruvate. Mutagenesis analysis demonstrated that residues 3-13 
of cALT2 are essential for the reaction direction preference exhibited by this 
enzyme [32].  
 Taking into consideration that cALT1 and cALT2 expression in                          
S. aurata is found in tissues that can undergo both glycolysis and 
gluconeogenesis, such as liver, kidney and intestine, it is conceivable that 
in these particular tissues cALT2 expression can be more restricted to 
metabolic conditions that favour gluconeogenesis. In contrast, cALT1 
prevails during the fed state, which is characterised by elevated glycolysis 
and deviation of excess pyruvate to form L-alanine and provide                      
2-oxoglutarate to replenish the citric acid cycle in a metabolic situation 
where intermediates of this pathway can be used for biosynthetic purposes.  
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Table 1. Kinetic parameters of S. aurata cALT1, cALT2 and mALT [32,44]. 
 
     
  cALT1 cALT2 mALT 
  Forward reaction    
 Km
Ala (mM) 1.8 2.2 2.2 
 Km
2-Oxo (mM) 0.05 0.05 0.21 
 Vmax (mmol/min/g) 57 14697 403 
 Vmax / Km
Ala
 0.03 6.65 0.18 
 Vmax / Km
2-Oxo
 1.18 288 1.89 
     
  Reverse reaction    
 Km
Glu (mM) 15.9 4.5 11.3 
 Km
Pyr (mM) 0.69 0.15 0.32 
 Vmax (mmol/min/g) 11.6 20.9 534 
 Vmax / Km
Glu
 0.001 0.005 0.047 
 Vmax / Km
Pyr
 0.02 0.14 1.68 
 Ki
Glu (mM)  34.9  
 Ki
Pyr (mM)  36.5  
 
cALT2 was the only cALT isoform detected in non-gluconeogenic tissues 
such as heart, gill and spleen. This may be associated with the higher 
regulatory and kinetic versatility exhibited by this enzyme [32]. The 
metabolic function of cALT2 in these tissues seems to differ from the role 
exerted in liver, kidney or intestine, and might be related with processes such 
as amino acid interconversion and deamination. 
 Kinetic characterisation of S. aurata mALT indicates that this enzyme 
preferentially catalyzes the reaction in the pyruvate-forming direction [44].  
 
3. Nutritional and hormonal regulation of cALT1, cALT2 and 
mALT expression 
 
 To analyse the functional role of ALT isozymes in intermediary 
metabolism, the effect of nutritional status and hormonal regulation was 
addressed on the expression of cALT1, cALT2 and mALT in S. aurata. 
Long-term starvation increases cALT2 mRNA levels and reduces cALT1 
expression in liver of S. aurata [32]. Up-regulation of cALT2 expression 
in starved fish is consistent with preference of cALT2 in catalysing the 
production of pyruvate from L-alanine in a metabolic condition with 
decreased levels of hepatic pyruvate [45]. Indeed, alanine is the main 
amino acid released by skeletal muscle and taken up by the liver in 
starvation [46].  
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 Food intake participates in short-term modulation of hepatic cALT1 
and cALT2 expression. Consistent with the expression pattern in starved 
fish, cALT2 mRNA abundance decreased to minimum levels after a 
postprandial period of 4-8 hours. In contrast, the hepatic expression of 
cALT1 reached maximal values 2-8 hours following food intake. Likewise, 
administration of glucose and insulin to S. aurata significantly decreased 
cALT2 mRNA 6 hours after treatment, while cALT1 mRNA levels 
remained unaffected. Considering together kinetic data and nutritional 
regulation of cALTs expression, these observations point to up-regulation 
of cALT2 in conditions associated with increased gluconeogenesis, 
whereas cALT1 seems more involved in postprandial utilisation of dietary 
nutrients [32]. 
 Similarly as for cALT1, starvation decreased mALT mRNA levels in 
liver and kidney of S. aurata [44,47]. Analysis of mALT expression in 
liver of fed S. aurata indicated a tendency to increase at postprandial time 
6 hours [47]. Possibly, in the fed state cooperation of cALT1 and mALT 
allows addressing of dietary amino acids into the mitochondria to provide 
substrates for energy purposes. The fact that feeding S. aurata with high 
protein diets increases hepatic cALT1 expression while does not affect 
mALT [47,48], suggests that mALT is more involved in energy production 
from amino acids to maintain basal metabolism, whereas cALT1 would 
metabolise excess of dietary amino acids in the cytosol. 
 In mammals, type 2 diabetes leads to increased gluconeogenesis in the 
liver [49–51], and among the amino acids, alanine is the most effective 
gluconeogenic precursor [52]. Consistent with up-regulation of cALT2 
expression in gluconeogenic conditions in liver, the diabetogenic action of 
streptozotocin (STZ), a glucosamine-nitrosourea derivative that causes  cell 
necrosis and that is widely used to generate diabetic animal models [53–55], 
leads to a marked increase in the hepatic expression of cALT2 in S. aurata, 
whereas cALT1 and mALT mRNA levels show a tendency to decrease 
[32,47]. The requirement for gluconeogenic substrates may be critical to 
enhance hepatic cALT2 expression in STZ-induced diabetic S. aurata. 
 
4. Transcriptional control of Sparus aurata cALT and mALT 
gene promoters 
 
 To gain insight into the transcriptional regulation of ALT genes in fish, 
the promoter regions of cALT and mALT from S. aurata were isolated and 
characterised. The cALT and mALT promoters were the first ALT gene 
promoters reported for animals others than humans [44,56]. 
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 The S. aurata cALT promoter contains an initiator (Inr)-like element 
that overlaps the transcription start site. Sequential 5’ deletions of promoter 
reporter constructs and analysis of transcriptional activity in sea bass larvae-
derived SBL cells, allowed to conclude that the promoter region within 89 
bp upstream from the transcriptional start constitutes the core functional 
promoter of this gene. Transient transfection experiments and EMSA 
analysis demonstrated that p300, a transcriptional coactivator that modulate 
the activity of a wide array of transcription factors [57,58], confers an 
activating signal on the cALT promoter by forming part of a complex that 
binds to a response element located at position -73 to -60 bp upstream from 
the transcription start site [56]. Recruitment of proteins with histone 
acetyltransferase activity, such as p300, to the Inr element of cALT promoter 
may provide an open DNA configuration that makes the site of 
transcriptional initiation more accessible to other transcription factors and 
the basal transcriptional machinery. In this regard, targeting of p300 to the 
Inr element might enable the recruitment of TFIID to the cALT promoter, as 
suggested for other TATA-less Inr-containing promoters [59,60]. 
 Apart from acetylating histones, p300 acetylates several transcription 
factors in a regulated manner [61]. Transfection experiments in SBL cells 
showed that an acetyltransferase-deficient mutant of p300 failed to induce            
S. aurata cALT promoter activity, indicating that acetyltransferase activity 
of p300 is essential for p300-mediated transcriptional activation of cALT 
[56]. Thus, p300 may induce cALT promoter activity by acetylating histones 
and transcription factors. Indeed, EMSA assays and site-directed 
mutagenesis revealed that c-Myb transactivates S. aurata cALT promoter by 
binding to a c-Myb box at position -52 to -35 bp upstream from the 
transcriptional start. c-Myb-dependent transactivation of cALT occurred 
irrespective of the p300 response element [56]. However, since p300-
mediated acetylation increases DNA binding activity of c-Myb and 
replacement of acetylated residues (lysines) in c-Myb by arginine 
dramatically decreases the transactivating capacity of c-Myb [62,63], p300-
mediated acetylation of c-Myb possibly enhances binding of c-Myb to the             
S. aurata cALT promoter (Fig. 3). 
 Given that conditions associated with increased gluconeogenesis, such 
as starvation and treatment with STZ, result in a marked increase of cALT2 
mRNA levels in the liver of S. aurata, cALT2 up-regulation can be 
responsible for serum increase of ALT activity under conditions associated 
with insulin resistance and development of type-2 diabetes [32]. In 
agreement with cALT2 expression, mRNA abundance of p300 and c-Myb 
increased in starved S. aurata and decreased in fish liver after the 
administration of insulin [56]. 
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Figure 3. Coactivator p300 and c-Myb transactivate the S. aurata cALT promoter. 
Schematic representation of the cALT promoter region, with the DNA wrapped 
around nucleosomes forming histones (depicted in a grey circle). By acetylating the 
histone tails and transcription factors, i.e. c-Myb, p300 can make the DNA more 
accessible to other regulatory proteins. In addition, p300 can form a physical bridge 
between transcription factors and the general transcription factors and RNA 
polymerase II (Pol II). Inr, initiator element. GTF, General Transcription Factors. 
Acetylation is represented by the symbol`l    . Figure adapted from [64]. 
 
 Functionality of the promoter region of S. aurata mALT was assayed in 
human kidney-derived HEK293 cells transfected with fusion constructs 
containing sequencial 5'-deletions of the isolated fragment. The promoter 
region within 49 bp upstream from the transcription start site constitutes the 
core functional promoter for mALT gene. HNF4α transactivates the S. 
aurata mALT gene promoter by binding to a response element located at 
position -63 to -39 bp upstream from the transcriptional start [44]. Tissue 
distribution of S. aurata HNF4α expression, mainly in kidney, liver and 
intestine, correlates well with that observed for mALT [44]. 
 There is increasing evidence suggesting a major role for HNF4  in the 
kidney [65–67], and involvement of this transcription factor in 
transactivation of genes involved in amino acid metabolism such as tyrosine 
aminotransferase and ornithine aminotransferase [68,69]. In the fish kidney, 
dietary amino acids are used as substrates for oxidation and gluconeogenesis 
[70]. Under gluconeogenic conditions, such as starvation and STZ-treatment, 
down-regulation of HNF4  expression correlates with decreased mALT 
mRNA levels in kidney of S. aurata, which suggest a central role of HNF4α 
in the transcriptional regulation of mALT. Expression of mALT in this tissue 
might be mainly involved in the oxidation of amino acids for energetic 
purposes rather than for providing gluconeogenic substrates [44]. 
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5. Effect of ALT inhibition on the intermediary metabolism of 
Sparus aurata 
 
 Bearing in mind the central role of ALT linking amino acids, 
carbohydrates and energy metabolism, ALT was considered a candidate 
gene target to spare protein and improve the metabolic utilisation of 
dietary carbohydrates. To test this hypothesis, the metabolic effect of 
inhibiting cytosolic ALT activity on intermediary metabolism was 
addressed in S. aurata using amino-oxyacetate (AOA), an inhibitor of 
PLP-dependent transaminases [71]. Although in vitro AOA inhibits ALT 
activity in cytosolic and mitochondrial fractions isolated from liver of                  
S. aurata, AOA only affects cytosolic ALT activity in vivo, which suggests 
that AOA does not enter mitochondria and thus cannot inhibit mALT [72]. 
Consequently, the effect of AOA in vivo may be restricted to cytosolic 
ALT activity and, during the fed state, essentially to cALT1, the cALT 
isoform mainly involved in postprandial utilisation of dietary nutrients 
[32]. Considering that mALT activity accounts for as less as about 14 % of 
total ALT activity in the liver of fed S. aurata [31], the use of AOA in vivo 
appeared to be suitable to specifically inhibit ALT activity of cytosolic 
fractions.  
 Dietary AOA supplementation to S. aurata for 30 days causes a 
significant inhibition on ALT activity, without affecting ALT protein 
levels and irrespective of nutrient composition of the diet. The most 
remarkable effects of AOA-dependent ALT inhibition on the intermediary 
metabolism is a significant increase in pyruvate kinase (PK) activity, a key 
enzyme in glycolysis, without affecting the gluconeogenic fructose-1,6-
bisphosphatase activity nor glycemia [44]. 
 It was reported that glutamate behaves as an inhibitor of PK activity, 
while alanine is a strong allosteric inhibitor of hepatic PK [73]. Taking into 
account that dietary AOA supplementation decreased glutamate and 
alanine levels in the liver of S. aurata, increased PK activity in the liver 
after long-term exposure to AOA may result from: i) low glutamate levels 
and the consequent loss of the glutamate-dependent PK inhibition; and ii) 
reduction of alanine concentration as a consequence of ALT inhibition.                 
1
H NMR studies showed that inclusion of AOA to the diet also decreased 
hepatic glycogen. Moreover, 
2
H NMR analysis indicated decreased                
2
H-enrichment level of alanine methyl hydrogens in the liver                       
of fish exposed to AOA irrespective of the composition of the diet [72].  
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Figure 4. Effect of dietary amino-oxyacetate supplementation on the intermediary 
metabolism of S. aurata. 
 
Altogether, these results suggest that AOA-dependent inhibition of 
cytosolic ALT activity in the liver stimulates glycolysis and decreases the 
renewal rate of alanine, which in turn may improve metabolism of dietary 
carbohydrates and spare protein (Fig. 4). 
 
6. Conclusion 
 
 Molecular characterisation of S. aurata ALT isozymes including 
cloning and subcellular localisation of ALT isoforms, nutritional and 
hormonal regulation of ALT expression, enzyme kinetics, and 
transcriptional regulation of cALT and mALT gene promoters led to 
hypothesize that inhibition of cytosolic ALT activity could be useful to 
improve the use of dietary carbohydrates and spare protein in 
aquaculture. Preliminary studies showed that AOA-dependent inhibition 
of cALT activity gave rise to promising results including stimulation of 
PK activity and decreased renewal rate of alanine in the liver. To 
perform a more robust protein-sparing effect in order to promote an 
important increase in the use of dietary carbohydrates for energy 
production and preserve dietary amino acids for growth in cultured fish, 
strategies to apply in future studies should consider: i) use of interference 
RNA (iRNA) to specifically down-regulate the expression of cALT 
messengers; ii) explore the impact of post-translational mechanisms that 
may control ALT activity, such as protein-protein interactions; and iii) 
increase genomic and transcriptomic information available for S. aurata 
and other fish species with commercial interest to identify other 
candidate genes to perform a multifactorial action to improve the 
utilisation of dietary nutrients in fish farming. 
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Abstract. Oxylipins are a family of natural compounds that are 
reported to perform a variety of biological functions. Besides the 
biological properties of such compounds, interest in hydroxy fatty 
acids is increasing, due to the industrial applications of these 
renewable compounds as a starting material for resins, emulsifiers, 
plastics or polyesters. Hydroxy fatty acids are used as thickeners in a 
new generation of emulsifiers and lubricants, to reach new levels of 
performance. When grown in submerged culture with oleic or linoleic 
acid, Pseudomonas aeruginosa 42A2 produced several oxylipins. In 
this study, oxylipin production and its applications are examined. 
 
Introduction 
 
 The main sources of hydroxy fatty acids (HFAs) are plants and a                 
great variety of seed oils, particularly castor oil. In fact, HFAs are ubiquitous 
compounds in nature, as they are found in animals, fungi and bacteria. Classical  
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oleochemistry occurs mainly at the ester functionality of the triglycerides. 
Whereas most native oils contain unsaturated fatty acids, as Biermann and 
collaborators stated, only a few reactions across the double bond of 
unsaturated FA are currently applied [1]. Numerous synthetic problems 
remain unsolved, and solutions must be found. As described in the 
literature, a great number of prokaryotes may be used for 
biotransformation processes. Microorganisms contain a wide range of 
enzymes for biotransformation, e.g. lipases, lipoxygenases, oxidases, 
epoxidases, P450 monooxigenases, that have enormous potential to 
develop new biotechnological processes with unsaturated fatty acids, 
making it possible to obtain a new brand of products with unexplored 
properties. Candida sp. or Bacillus sp. are reported to produce diacids               
( -unsaturated fatty acids), which are important compounds for polyester 
or polyamide synthesis [1], and epoxy fatty acids, which are used as PVC 
stabilizers or as starting materials to produce polyether polyols and are also 
found in reactions produced by the Gaeumannomyces graminis fungus [2]. 
The oxidation of unsaturated fatty acids is now focused on epoxidation, 
hydroxylation and double bond cleavage, to be used in fine chemistry and 
for further polymerization [1]. 
 Microbial transformation is a powerful strategy to develop new lipid 
products. Lipases are the most common enzymes used in oleochemical 
processes. These enzymes do not require cofactors for catalysis, and show 
stereo-, regio- and chemoselectivity, high activity and stability. Most of 
them, e.g. those from Pseudomonas cepacia, Candida antarctica, 
Rhizomucor miehei or Rhizopus delemar, are commercially available. 
Recently, an increasing number of microorganisms producing HFAs have 
been reported as an efficient tool to convert inexpensive unsaturated fatty 
acids into value-added compounds [3]. Oxidative enzymes belonging to the 
P450 superfamily have been involved in α-hydroxylation or in the fatty 
acid synthase and β-hydroxylation systems in the case of β-HFAs; 
cytochrome P450 monooxygenases from different microorganisms, e.g. 
Bacillus or Pseudomonas, can produce -HFAs; and bacterial 
monooxygenases have been heterologously expressed [3]. Mid-position 
hydroxylation on saturated HFAs has been reported by Wallent [4] and 
Volkov [5]. Unsaturated HFAs have also been reported; the resulting 
product might be mono- or poly-HFAs [3]. The enzymes involved in these 
reactions are lipoxygenases and diol synthases [6, 7]. 
 In nature, oxylipins have different functions. They act as signalling 
molecules and biological mediators, and they facilitate the plasticity of cell 
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membranes, the mobilization of lipids [8] and the generation of HFAs that 
are involved in cellular communication and the antibiosis effect. Although 
in minute amounts, polyesters of HFAs have been detected in oily seeds 
and in animal organisms, where they play the role of natural lubricants             
[9, 10]. 
 The antimicrobial activity of such compounds and the functionality of 
the HFAs have attracted attention, leading to the generation of new 
polyesters, called estolides, which form a new class of green emulsifiers and 
lubricants. In this study, the production of hydroxy fatty acid derived from 
oleic acid (OA) and linoleic acid (LA) is described, as well as the 
applications of these compounds. 
 
1. Microbial conversion of oleic acid 
 
 Since the first report of the microbial conversion of OA to                        
10-hydroxystearic acid by a Pseudomonas [4], scarce information has been 
published about the hydroxylation of OA whilst maintaining the unsaturated 
alkyl-chain. Heinz and co-workers reported that Torulopsis sp. produced                   
17-hydroxyoleic acid [11], and Soda and collaborators described the 
conversion of OA into ricinoleic acid (RA) by Bacillus pumilus [12]. Other 
uncommon HFAs have been described, such as 15-, 16-, 17-hydroxy-9Z-
octadecenoic acid by B. pumilus [13] or 3-hydroxy-9Z-octadecenoic acid by 
Alcaligenes sp. 5-18 [14].  
 Although 7S,10S-dihydroxy-8E-octadecenoic acid ((7S,10S)-DiHOME) 
produced by Pseudomonas aeruginosa 42A2 was the first dihydroxylated 
derivative from OA to be described [15], the accumulation of HFAs has also 
been reported for several P. aeruginosa strains [16]. Pseudomonas 42A2 
NCIMB 40045 is a gram negative bacterium with a versatile metabolism, 
which is the reason for its ubiquitous characteristic of being associated with 
other free-living soil microorganisms. It has the ability to transform long-
chain unsaturated fatty acids into oxylipins. 
 
1.1. Batch production 
 
 P. aeruginosa 42A2 accumulates several oxidized fatty acids, namely 
10S-hydroperoxy-8E-octadecenoic acid ((10S)-HPOME), 10S-hydroxy-8E-
octadecenoic acid ((10S)-HOME) and 7S,10S-dihydroxy-8E-octadecenoic 
acid (7S,10S- DiHOME), when it is incubated with OA as a single substrate 
in a minimal mineral medium (Fig. 1). 
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Figure 1. Products obtained from the conversion of OA by P. aeruginosa 42A2. 
 
 Although (10S)-HOME was first identified as the precursor of 
(7S,10S)-DiHOME [17], Martinez and co-workers suggest that the 
precursor of (7S,10S)-DiHOME is (10S)-HPOME, and that (10S)-HOME 
is a by-product obtained from the spontaneous reduction of (10S)-HPOME 
[6]. Subsequently, the two enzymes involved in the reaction were identified 
and the genomic structure of the diol synthase operon was elucidated. 
Thus, OA is transformed into (10S)-HPOME in a first enzymatic reaction, 
in order to produce (10S)-HOME spontaneously, and (7S,10S)-DiHOME is 
generated in a second enzymatic reaction. All of this enzymatic system is 
located in the periplasm of P. aeruginosa 42A2 [18].  
  Most microbial processes require air for cell growth. In some cases, 
foam accumulates during production, and can greatly disturb the process. 
To overcome foam formation in the production of (7S,10S)-DiHOME, 
which has surface activity properties, an innovative non-dispersive 
aeration system was designed. It is based on Higbie’s penetration theory 
applied to a wetted-wall column. Hence, an innovative bioreactor was 
created for a foaming biotransformation [19]. 
Development and applications of DNA markers in Pigeonpea 153 
 The biotransformation kinetics were deduced by varying the substrate 
concentration from 10 to 20 g·L
-1
 to obtain different experimental data sets. 
The typical time course of the OA transformation (Fig. 2) indicated that 
(10S)-HPOME accumulation started soon after inoculation until the end of 
the exponential phase of cell growth. Most (7S,10S)-DiHOME and (10S)-
HOME accumulation occurs during the stationary phase until the end of the 
process (30 h), which confirms the role of these compounds as secondary 
metabolites. A high conversion yield (YP/S) 0.9 was achieved and a cell yield 
(YP/X) of 3.2 was calculated. 10S-HPHOME was not detected at the end of 
the culture. 
 
 
 
Figure 2. Kinetics of OA (♦) conversion by P. aeruginosa 42A2 (OA of 20 g·L-1) 
into (10S)-HPOME (■), (10S)-HOME (▲) and (7S,10S)-DiHOME (x). 
 
 As shown in Table 1, the volumetric productivity (PV) that was 
calculated was substrate dependent. (10S)-HOME followed the same pattern 
as (10S)-HPOME, whereas the accumulation of (7S,10S)-DiHOME 
depended on the reaction of (10S)-HPOME with the hydroperoxy-diol 
synthase enzyme. Therefore, the production rate was proportional to the 
amount of (10S)-HPOME [18, 19]. 
 
Table 1. Effect of oleic acid concentration on volumetric productivity. 
 
OA (10S)-HPOME (10S)-HOME (7S,10S)-DiHOME 
(g·L-1) (g·L-1·h-1) (g·L-1·h-1) (g·L-1·h-1) 
10 0.41 0.15 0.34 
15 0.47 0.21 0.25 
20 0.75 0.29 0.31 
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 As expected, the experimental data fitted the mathematical                            
model proposed by Monod, which corresponds to first-order reactions 
occurring during the biotransformation of OA into these oxidized 
compounds [19]. 
 Due to the nature and functionality of the (10S)-HOME and (7S,10S)-
DiHOME accumulated in the cultures, they might easily be further 
modified to form a new generation of polyesters named estolides (ESTs). 
ESTs are a class of polymeric secondary esters derived from addition 
across an unsaturated bond or with HFAs by a carboxyl moiety of another 
fatty acyl group. 
 
2. Estolide production 
 
 Although in a minuscule amount, ESTs are present in nature in the 
epicuticular wax of some species of Juniperus, Pinus or Coniferae, and in 
the oil seeds of certain plants [20] or fungi [21]. ESTs are also found in the 
animal kingdom, in wool wax, beeswax [22], and in human meibomian 
gland secretion [23]. Furthermore, ESTs have been found in cultures                      
of Pseudomonas aeruginosa 42A2 when cultivated with OA as substrate 
[24]. 
 Yamaguchi and collaborators reported for the first time the esterification 
of castor oil in a two-step enzymatic reaction to obtain ESTs with a high 
yield [25]. This led to a new generation of environmentally friendly 
emulsifiers for a wide range of applications in the food industry. Particularly 
important are the RA ESTs, which are used as intermediates in the 
enzymatic production of polyglycerol polyricinoleate (E-476), as reported by 
Bodalo and co-workers [26, 27].  
 Two types of ESTs were synthesized from (10S)-HOME and (7S,10S)-
DiHOME, using the thermostable commercial lipases Novozym 435 (lipase 
B from Candida antarctica), Lipozyme RM IM (Rhizomucor miehei lipase), 
and Lipozyme TL IM (Thermomyces lanuginosus lipase). Enzymatic 
reactions were carried out at 80 ºC under vacuum conditions to reduce the 
viscosity of HFAs monomers [28]. As shown in Fig. 3, the time course of the 
reaction using Novozym 435 (N435) offered the best performance with both 
HFAs. However, Lipozyme RM IM (L RM IM) behaved in a similar way to 
N435 when the substrate was (10S)-HOME. In contrast, Lipozyme TL IM   
(L TL IM) registered yields that were slightly lower than N435 in the 
polymerization of (7S,10S)-DiHOME. 
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 A B 
 
 
Figure 3. EST enzymatic production with 12% (w/w) of the corresponding lipase at 
80 ºC for 168 h under vacuum conditions. A: (10S)-HOME; B: (7S,10S)-DiHOME. 
 
 Borgdorf and Warwel classified lipases according to their ratio 
competitive factor (RCF) [29]. This factor describes the selectivity of one 
single lipase toward two substrates with the same leaving group, and to two 
acyl groups. 
 
Table 2. Reaction yield (%) in estolide formation from the oxylipin produced by                      
P. aeruginosa 42A2 from oleic acid. 
 
Lipase RCF 
(%) 
(10S)-HOME (%) (7S,10S)-DiHOME 
(%)  
Novozym 435 0.7 71.7 94.7 
Lipozyme RM IM 1.3 68.4 70.8 
Lipozyme TL IM 
 
71.6 88.9 
 
 Although the lipase RCF should be taken into account, no relationship 
with the reaction yield was observed (Table 2). Bodalo and co-workers 
found that sn-1,3 selective lipases are unable to attack secondary alcohols 
[30]. However, the sn-1,3 specific lipases Lipozyme RM IM and Lipozyme 
TL IM had significant reaction yields with both substrates. The non-
specific lipase Novozym 435 was the best catalyst with the highest 
reaction yields (71.7% and 94.7%), which indicates the importance of the 
nature of the lipase and the substrate. 
 There are no reports in the literature on EST synthesis from trans-HFA 
monomers. However, Aguieiras and partners used these enzymes in the 
production of mono-ESTs from OA and methyl ricinoleate, and achieved a 
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reaction yield of 33% after 48 h at 80 ºC using 6% enzyme (w/w) [31]. 
This reaction was also studied by Horchani and collaborators using the 
immobilized lipase of Staphylococcus xylosus. A 65% reaction yield was 
achieved after 55 h at 55 ºC [32]. 
 Liquid chromatography coupled to MS has been found to be a time-
consuming technique, especially the optimization of mass spectrometer 
potentials to obtain a low amount of fragmentation in the mass spectra of 
large molecules. In contrast, MALDI-TOF analyses carried out with a 
proper matrix and stabilization cation, e.g. Li
+7
 or Na
+23
, is a fast technique 
with low fragment mass spectra, which means that the method could 
elucidate the number of oligomers synthesized. Finally, nuclear magnetic 
resonance (NMR) is a good complementary structural technique to 
MALDI-TOF, which provides characteristic chemical shifts to identify 
trans-ESTs. trans-EST structural characterization was carried out by 
MALDI-TOF mass spectrometry and NMR. MALDI-TOF analyses were 
carried out using a 2,5-dihydroxybenzoic acid (DBH) matrix saturated with 
acetonitrile [33]. ESTs from (10S)-HOME (M) are presented in               
Fig. 4A. 
 Some ions stand out from the rest, which means that the oligomers that 
are produced can be identified easier and faster. The following ions were 
detected m/z 601.5, [2M-H2O+Na
23
]
+
; 881.7, [3M-2H2O+Na
23
]
+
; 1162.0, 
[4M-3H2O+Na
23
]
+
 and 1442.2, [5M-4H2O+Na
23
]
+
. Hence, up to oligomers 
of five monomeric units of (10S)-HOME were synthesized. However, 
more ions were detected when (7S,10S)-DiHOME (M’) was the substrate 
used (Fig. 4B): m/z 633.5, [2M’-H2O+Na
23
]
+; 929.7, [3M’-2H2O+Na
23
]
+
; 
1226.0, [4M’-3H2O+Na
23
]
+; 1522.3, [5M’-4H2O+Na
23
]
+; 1819.5, [6M’-
5H2O+Na
23
]
+; 2115.7, [7M’-6H2O+Na
23
]
+
; and in the enlarged region of 
the spectra the following ions were observed 2412.0, [8M’-7H2O+Na
23
]
+
; 
and, 2709.2, [9M’-8H2O+Na
23
]
+
. In this situation, up to oligomers of nine 
monomeric units of (7S,10S)-DiHOME were produced, as expected from 
the reaction yields presented in Table 2.   
 Furthermore, NMR spectroscopy was used to confirm the results 
observed in the MALDI-TOF analysis. Certain chemical shifts are decisive 
in order to identify trans-ESTs. In 
1
H NMR spectra, these are the signals 
2.28 ppm and 5.20 ppm, which correspond to the methylene protons 
(position 2) and to the methine proton (position 10) that are both adjacent 
to an ester group, respectively.  
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B 
 
 
Figure 4. MALDI-TOF mass spectra with a DHB matrix saturated in acetonitrile. 
ESTs produced with Novozym 435 at 80 ºC under vacuum conditions for 168 h. A: 
(10S)-HOME ESTs; B: (7S,10S)-DiHOME ESTs. 
 
 An average number of monomers present in a sample could be 
calculated by integrating the methylene proton signal of 2.28 ppm. For 
13
C 
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NMR spectra the determining signals are 74.50 ppm (position 10) and 
173.17 ppm (position 1), which represent the presence of a tertiary carbon 
and an ester carbonyl, respectively. Fig. 5 represents the structure of ESTs of 
three monomeric units. 
 
 
 
Figure 5. ESTs derived from (10S)-HOME (A) and (7S,10S)-DiHOME (B). 
 
 Finally, some physicochemical properties were determined for the 
produced ESTs: the Arrhenius relationship between viscosity and 
temperature (A and Ea), the glass transition temperature (Tg), and 
decomposition enthalpies ( Hi). 
 According to mass spectrometry analysis, the ESTs analysed were 
considered as oligomers and not strictly polymers, due to their low 
polymerization degree. Such simple molecules were determined as 
Newtonian fluids, because their viscosity remained constant over different 
shear rates. A dynamic or absolute viscosity ( ) determination was run over 
three different temperatures (20, 40 and 60 ºC) when possible, to calculate 
the pre-exponential factor (A) and activation energy (Ea) of the Arrhenius-
type relationship [34]. This equation describes the dependence of viscosity 
on temperature, where A can be considered as the infinite-temperature 
viscosity value and Ea indicates the sensitivity of a substance to temperature 
[35]. 
 
 
 Physicochemical analyses results are listed in Table 3. The parameters 
include A and Ea, density ( ), kinematic viscosity at 40 ºC, reaction yield ( ) 
and oligomer number (ON), which is the maximum number of oligomers 
synthesized.  
A 
B 
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Table 3. Viscosity and characterization parameters from ESTs. 
 
Sample A·10-10  
(Pa·s) 
Ea  
(kJ·mol-1) 
  
(g·mL-1) 
   
(cSt) 
  
(%) 
ON 
(─) 
(10S)-HOME 9.47 49.9 0.96 205 ─ 1 
(7S,10S)-DiHOME n.d. n.d. 0.99 n.d. ─ 1 
       
(10S)-HOME N435 3.48 55.1 0.97 608 71.7 6 
(10S)-HOME RM IM 5.79 53.6 0.97 495 68.4 6 
(10S)-HOME TL IM 24.2 49.3 0.97 402 71.6 6 
       
(7S,10S)-DiHOME N435 3.62 59.1 1.00 2510 94.7 9 
(7S,10S)-DiHOME RM IM 0.14 67.7 1.02 3235 70.8 9 
(7S,10S)-DiHOME TL IM 1.06 62.7 1.00 3000 88.9 10 
 
 As can be seen, the viscosity parameters for the (10S)-HOME ESTs are 
lower than those for (7S,10S)-DiHOME ESTs. The same is true for ON 
values. (7S,10S)-DiHOME ESTs were produced in higher yields; thus, their 
ON values were higher. In addition, the melting point of (7S,10S)-DiHOME 
was 56 ºC, due to the hydrogen bond interaction of the two hydroxyl groups. 
Hence, (7S,10S)-DiHOME EST viscosity parameters had higher values. 
  
Table 4. EST calorimetric parameters. 
 
Sample 
Tg 
(ºC) 
Tonset1 
(ºC) 
H1 
(J·g-1) 
Tonset2 
(ºC) 
H2 
(J·g-1) 
Tonset3 
(ºC) 
H3 
(J·g-1) 
Residue 
(%) 
(10S)-HOME -60 119 -7.08 196 47.33 315 -161.3 0.35 
(7S,10S)-DiHOME -49 185 37.79 277 -56.16 366 147.3 1.23 
         
(10S)-HOME N435 -63   213 33.97 323 -174.1 2.27 
(10S)-HOME RM IM -64   217 35.73 322 -174.0 1.57 
(10S)-HOME TL IM -66   218 27.64 338 -252.9 1.73 
         
(7S,10S)-DiHOME N435 -50 187 34.37 295 -30.18 362 -118.9 1.37 
(7S,10S)-DiHOME RM IM -49 200 28.22 302 -36.23 370 -105.5 1.12 
(7S,10S)-DiHOME TL IM -50 201 18.97 300 -37.07 364 -133.5 2.74 
 
 Finally, thermal analysis, DSC (differential scanning calorimetry) and 
TGA (thermal gravimetric analysis) were used to characterize the new 
polyesters. Thermal parameters are listed in Table 4. Tg could be calculated 
for synthesized polyesters and even for both HFAs, indicating that these 
compounds lacked a crystal structure. EST Tg values were practically the 
Ignacio Martin Arjol et al. 160 
same as their corresponding substrates, which confirmed the simplicity of 
these molecules. Furthermore, onset temperatures and decomposition 
enthalpy values were maintained. These two points suggest that the 
oligomers produced had a larger quantity of dimers and trimers than higher 
polymerized oligomers. 
 
3. Microbial conversion of linoleic acid 
 
 Due to the limited natural HFAs supply, research has focused on 
engineering castor oil production and developing new engineered 
microorganisms for RA production [36] and new processes for the microbial 
transformation of unsaturated fatty acids into HFAs [3, 37, 38]. The 
occurrence of lipoxygenase [39] and diol synthase activity [6, 18] in                   
P. aeruginosa reinforces the versatile metabolic activity of this bacteria to 
produce diverse polyol oxylipins. When cultivated in submerged culture 
with linoleic acid as a substrate, P. aeruginosa 42A2 accumulated HFAs in 
the culture, with different degrees of hydroxylation [40]. 
 Several oxylipins have been characterized from LA acid to date, due to 
the activity of bacterial lipoxygenases. Oxidized LA derivatives are 
hydroperoxides (9S)- and (13S)-HPODE (9S-hydroperoxide-10E,12Z-
octadecadienoic and 13S-hydroperoxide-9Z,11E-octadecadienoic acids, 
respectively). These hydroperoxides can spontaneously transform into their 
corresponding hydroxides ((9S)-/(13S)-HODE), epoxyalcohols or even keto 
fatty acids; these last two by the action of hematin [41]. Recently,                      
10-hydroxy-12,15(Z,Z)-octadecenoic acid produced by a rec-enzyme from 
Stenotrophomonas maltophilia was characterized [42].  
 Scarce information has been reported on the bacterial production of 
dihydroxyl fatty acid. Besides 9,10-hydroxystearic acid, only (7S,10S)-
DiHOME [15, 16] and 9,12-dihydroxy-10E-eicosenoic acid have been 
described [43]. Several trihydroxy-fatty acids have been reported so far from 
the bacterial transformation of RA into 7,10,12-trihydroxy-8E-octadecenoic 
acid [44] and from LA 9,10,13-trihydroxy-11E-octadecenoic ((9,10,13)-
TriHOME) and 9,12,13-trihydroxy-10E-octadecenoic ((9,12,13)-TriHOME) 
[40]. A unique strain of Bacillus has been reported to accumulate 12,13,17-
trihydroxy-9Z-octadecenoic acid [45]. 
 When a complex substrate of fatty acids (60% LA, 40% OA, palmitic, 
stearic and linolenic acid) was supplied into the culture of P. aeruginosa 
42A2, a mixture of compounds was found. The organic extract from the 
culture media contained several oxylipins (Table 5). Liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) was used to allow the 
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direct analysis of products and combine the resolution of LC with the 
detection specificity of MS/MS. This is a direct, fast method for detecting 
and resolving the structure of the products accumulated in the culture 
without the formation of derivatives. 
 
Table 5. Fragment ions detected in the organic extract. 
 
Product                          Fragment ions (m/z) 
(10S)-HOME 
 
                 297 [M-H]-; 279 [M-H-H2O]
-;  
                  154.9 indicating –OH at C10 
(9S)-HODE 
 
                 295 [M-H]-; 277 [M-H-H2O]
-;  
                   171 indicating –OH at C9 
(13S)-HODE 
 
                 295 [M-H]-; 277 [M-H-H2O]
-; 
                  195 indicating –OH at C13 
(9,10,13)-TriHOME 
 
329 [M-H]-; 311.2 [M-H-H2O]
-; 293 [M-H-2H2O]
-; 
           127 indicating –OH at C9 and C10 
(9,12,13)-TriHOME 
 
329 [M-H]-; 311.2 [M-H-H2O]
-; 293 [M-H-2H2O]
-; 
           129 indicating –OH at C12 and C13 
  
 In this case, isomers (9,10,13)-TriHOME and (9,12,13)-TriHOME are 
present in the ratio 3:1, which differs from that reported by Kim and 
partners (1:1) from the P. aeruginosa strain PR3 [46]. Due to the difficulty 
of separating these isomers, a multiple reaction monitoring (MRM) 
analysis was undertaken, in which the acquisition mode was based on the 
injection of the sample containing the ion to be studied, m/z 329, into the 
first quadrupole (Q1), fragmentation in the collision cell (Q2), and 
scanning of the product ions in the third quadrupole (Q3). The result is an 
MS/MS spectrum free of interferences where the most appropriate product 
ions are selected in the third quadrupole (Q3), m/z 127 and 129, to perform 
relative quantification and confirmation. Thus, it was seen (Fig. 6) that for 
((9,10,13)-TriHOME) the characteristic transition was m/z 329–127, and 
for the other isomer, ((9,12,13)- TriHOME), the characteristic transition 
was m/z 329–129. 
 TriHOME compounds belong to a class of oxylipins with antifungal 
activity similar to those isolated from a variety of rice plant (9,12,13-
trihydroxy-10E,15-octadecadienoic and 9,12,13-trihydroxy-10E-octadecanoic 
acids) suffering from black rot disease [47, 48] and involved in the 
defensive mechanism of plants [49, 50]. The presence of lipoxygenases                       
in environmental bacteria [39] and diol synthase enzymes [18] suggests                    
the involvement of the microbiota in the interaction with eukaryote 
organisms. 
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Figure 6. MRM analysis of trihydroxylated isomers derived from LA. 
 
 Although the mechanism of action of oxylipins is not yet understood, 
it has been suggested that the inhibition of growth may be due to the 
chemical or physical properties of oxylipins, rather than the interactions 
with specific cellular targets [50]. The oxylipins derived from OA, (10S)-
HOME and (7S,10S)-DiHOME, could inhibit the growth of 
phytopathogenic fungal strains such as Colletotrichum gloeosporioides, 
Fusarium oxysporum and Drechslera teres and produce an antibacterial 
effect against Escherichia coli and Micrococcus luteus (MIC 64 μg·mL-1); 
Staphylococcus aureus (MIC 32 and 8 μg·mL-1 (10S)-HOME and (7S,10S)-
DiHOME, respectively) and Bacillus subtilis (MIC 32 and 128 μg·mL-1 
(10S)-HOME and (7S,10S)-DiHOME, respectively) [51].    
 It was found that the oxylipins derived from LA cultures, those 
described in Table 5, were able to inhibit bacterial growth (Table 6), 
similarly to those described (9,10,13-TriHOME and 9,12,13-TriHOME) 
from the mildew fungus in barley, Blumeria graminis, which reduced 
infection by up to 42% when applied in vivo [52], or 10-hydroxy-8-
octadecenoic and 10-hydroxy-8,12-octadecenoic acids, which were found 
in the stomata of timothy grass after being infected with Epichloe typhina 
[53]. 
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Table 6. Minimal inhibitory concentration of the HFAs described in Table 5. 
 
Microorganism 
 
MIC 
(mg·ml-1) 
Bacillus subtilis ATCC 6333 64 
Enterococcus hirae ATCC 10541 32 
Micrococcus luteus ATCC 9341 64 
Arthroderma uncinatum ATCC 15082 32 
Aspergillus brasiliensis ATCC 14404 140 
Aspergillus repens IMI 016114 140 
Macrophomina phaseolina IMI 48561 32 
Penicillium chrysogenum ATCC 9480 140 
Penicillium funiculosum CECT 2914 32 
Tricophyton mentagrophytes ATCC 18748 64 
Verticillium dahliae 49507/A 32 
 
4. Conclusion 
 
 The transformation of unsaturated fatty acids by P. aeruginosa 42A2 
produced several oxylipins with different degrees of hydroxylation. Further 
polymerization of oxylipins obtained from OA renders a new family of ESTs 
with properties of Newtonian fluids similar to natural lubricants. New oxylipins 
were produced from LA with biological properties against phytopathogenic 
fungal strains. 
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Abstract. Diabetic cardiomyopathy is characterized by structural and 
functional alterations in the heart muscle of people with diabetes that 
finally lead to heart failure. Metabolic disturbances characterized by 
increased lipid oxidation, intramyocardial triglyceride accumulation 
and reduced glucose utilization have all been involved in the 
pathogenesis of diabetic cardiomyopathy. On the other hand, 
evidences arisen in the recent years point to a potential link between 
chronic low-grade inflammation in the heart and metabolic 
dysregulation. Interestingly, the progression of heart failure and 
cardiac hypertrophy usually entails the activation of pro-inflammatory 
pathways. Therefore, in this chapter we summarize novel insights into 
the crosstalk between inflammatory processes and metabolic 
dysregulation in the failing heart during diabetes. 
 
 Introduction 
 
 The human heart produces, and immediately hydrolyzes, approx. 30 kg of 
ATP every day to carry out the mighty job of pumping more than 7,000  L/day                 
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of blood. Therefore, it is not surprising that any abnormality that deregulates 
its proper working may become life-threatening. In fact, heart disease is the 
major cause of death for both men and women in developed countries and, 
according to the World Health Organization, by 2020 it is expected to be the 
leading cause of death throughout the world. Heart disease is often grouped 
with metabolic disorders because it is frequently a consequence of 
uncorrected type 2 diabetes and obesity-related dyslipidemia. Insulin 
resistance, which is a hallmark of type 2 diabetes, is a risk factor of heart 
failure, the leading cause of death in type 2 diabetic patients. Diabetic 
cardiomyopathy, which refers to structural and functional alterations in the 
heart muscle of people with diabetes that finally lead to heart failure, is 
related to disturbances in myocardial energy metabolism. Diabetic 
cardiomyopathy is only said to exist if heart failure is not accompanied by 
coronary artery disease or hypertension that may account for the heart 
muscle disorder. 
 An increasing body of evidence suggests a potential link between 
chronic low-grade inflammation and metabolic disorders that are associated 
with abnormal cytokine production and increased levels of saturated fatty 
acids, such as insulin resistance, type 2 diabetes and obesity. The 
progression of heart disease usually entails a local rise in pro-inflammatory 
cytokines, including interleukin (IL)-6, monocyte chemoattractant protein-1 
(MCP-1) and tumour necrosis factor-α (TNF-α) [1]. These molecules exert 
several autocrine and paracrine effects in cardiac cells via downstream 
activation of the transcription factor nuclear factor (NF)-κB, which may 
contribute to states that are associated with myocardial inflammation, for 
example heart failure and dilated cardiomyopathy. However, the underlying 
mechanisms linking inflammation, heart failure and dilated cardiomyopathy 
are complex, since they are coupled to systemic metabolic abnormalities and 
changes in cardiomyocyte phenotype. In this review we summarize recent 
insights into the crosstalk between inflammatory processes and metabolic 
dysregulation in the failing heart during diabetes. 
 
1. Metabolic regulation in the healthy heart 
 
 Free fatty acids are the preferred energy substrate in the adult heart, 
supplying about 70% of total ATP [2]. However, since the human heart 
requires a constant supply of fuel, other substrates such as glucose (20%) 
or lactate (10%) may provide additional fuel sources in diverse 
physiological and nutritional circumstances. Glucose uptake is mostly 
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regulated by glucose transporters (GLUTs), of which GLUT4 is the most 
abundant in cardiac cells (Fig. 1) [3]. Once inside the cytosol, glucose is 
phosphorylated into glucose-6-phosphate, which can either be stored as 
glycogen or converted into pyruvate, the end product of glycolysis. Then, 
pyruvate enters the mitochondria where it undergoes oxidative 
decarboxylation by the pyruvate-dehydrogenase complex (PDC), which 
catalyses the rate-limiting step of glucose oxidation. Specific PDC kinases 
(PDKs) are responsible for the phosphorylation-induced inactivation of 
PDC. As such, PDK4, the most expressed PDK isoform in the heart, 
decreases glucose oxidation while allowing increased fatty acid -oxidation. 
With regard to the fatty acids, they cross the cardiomyocyte cell membrane 
through passive diffusion or by specific transport proteins, including fatty 
acid translocase (FAT/CD36), fatty acid binding protein (FABP) and fatty 
acid transport protein 1 (FATP1). In the cytoplasm, fatty acids are 
acylated, and either enter the mitochondria by the action of carnitine 
palmitoyl transferase 1 (CPT-1) or are incorporated into the intracellular 
lipid pool in the form of triglycerides. In the mitochondrial matrix, fatty 
acids are oxidized by the β-oxidation pathway to form acetyl-CoA. At this 
point, pathways for glucose and fatty acid oxidation merge, since acetyl-
CoA, which is produced from both pathways, enters the tricarboxylic acid 
(TCA) cycle. Finally, reduced flavin adenine dinucleotide (FADH2) and 
nicotinamide adenine dinucleotide (NADH) generated through β-oxidation 
and the TCA cycle, respectively, carry electrons to the electron transport 
chain, thus driving ATP synthesis by oxidative phosphorylation. 
 Under physiological conditions, glucose utilization is reduced in the 
heart by increased fatty acid oxidation via the Randle cycle. After a high 
carbohydrate supply, insulin activates the protein kinase B (PKB)/Akt 
signalling pathway and subsequent translocation of GLUT4 from 
intracellular vesicles towards the sarcolemma, the cell membrane of 
cardiac cells. As such, insulin promotes glucose uptake and utilization, 
thereby reducing myocardial oxygen consumption and increasing cardiac 
efficiency [4]. Insulin also enhances the uptake of fatty acids, but instead 
of being oxidized, they are stored in the intracellular pool of lipids. The 
AMP-activated protein kinase (AMPK) is another important regulator of 
cardiac energy homeostasis. Conditions leading to energy depletion, for 
instance the failing heart or increased ATP demand, lead to AMPK 
activation, which switches off energy-consuming pathways and stimulates 
ATP-producing pathways such as fatty acid -oxidation and glycolysis. 
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Figure 1. Metabolic regulation in the normal heart. Glucose, after uptake by 
specific transporters (GLUT4), is phosphorylated and can either be stored as 
glycogen or converted into pyruvate (glycolysis). In the mitochondria, pyruvate 
undergoes oxidative decarboxylation by the pyruvate-dehydrogenase complex 
(PDC). Long-chain fatty acids (LCFA) that enter into the cytoplasm by passive 
diffusion or specific transporters (FAT/CD36) are acylated by acyl-CoA synthetase 
(ACS), and either enter the mitochondria (carnitine palmitoyl transferase 1,      
CPT-1), or are incorporated into triglycerides (TG). In the mitochondrial matrix, 
fatty acids undergo β-oxidation to form acetyl-CoA. The acetyl-CoA formed 
during glucose or fatty acid oxidation enters the tricarboxylic acid (TCA) cycle and 
finally generates ATP through oxidative phosphorylation. Initiation of the insulin 
receptor substrate 1 (IRS-1) cascade by insulin induces the phosphatidylinositol 3 
kinase (PI3K), which activates the protein kinase B (PKB)/Akt. AMPK promotes 
myocardial GLUT4 activity and stimulates glycolytic enzymes, while it induces 
CPT-1 activity through acetyl-CoA carboxylase (ACC) phosphorylation-mediated 
inhibition. 
“Reprinted from Palomer et al., International Journal of Cardiology, 168:3160-3172, 
Copyright  (2013), with permission from Elsevier Limited”.  
 
 Cardiac metabolism is mostly regulated at the transcriptional level by 
the peroxisome proliferator-activated receptor (PPAR) transcription factor 
family, which consists of three isoforms, PPAR  (or NR1C1), PPAR /  
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(NR1C2) and PPAR  (NR1C3). The PPAR family of ligand-activated 
nuclear receptors require heterodimerization with another nuclear receptor, 
the 9-cis-retinoic acid receptor (RXR or NR2B), in order to be activated. 
Heterodimerization is then followed by coactivator recruitment and 
subsequent binding to DNA specific sequences called PPAR-response 
elements (PPRE), located within the promoter regions of PPAR target 
genes. Notable among the PPAR target genes with identified PPREs are 
those coding for lipid and glucose homeostasis. PPAR  and PPAR /  are 
the predominant isoforms in the heart, where they share some overlapping 
functions [5]. Transgenic mice with constitutive overexpression of 
PPAR /  in the heart show increased myocardial glucose utilization, do 
not accumulate myocardial lipids and display normal cardiac function [6]. 
Another study has reported that constitutive cardiac overexpression of 
PPAR /  in adult mice results in elevated myocardial oxidative 
metabolism, while myocardial glycogen content and the activity of the 
PDC and AMPK are markedly reduced, overall resulting in improved 
cardiac function [7]. In agreement with this, cardiomyocyte-restricted 
PPAR /  deficiency in mice leads to cardiac pathological development 
[8]. The best-characterized coactivator of PPARs is the cardiac-enriched 
PPAR  coactivator-1 (PGC-1) , which regulates the expression of several 
genes involved in the electron transport chain, mitochondrial biogenesis, 
fatty acid -oxidation and glucose oxidative metabolism, including PDK4. 
PDK4 gene expression is known to be controlled by a plethora of different 
transcription factors. Some of them are coactivated by PGC-1 : PPARs, 
oestrogen-related receptors (ERRs) and the forkhead transcription factor 
(FOXO1 or FKHR); but others acting in a PGC-1 -independent manner: 
E2F1, LXR (liver X receptor) or RXR (retinoid X receptor). 
 
2. Metabolic remodelling in the development of diabetic 
cardiomyopathy 
 
 The heart has the capacity to adapt to various pathophysiological 
conditions by adjusting its relative metabolism of carbohydrates and fatty 
acids. The loss of this metabolic flexibility is associated with pathological 
cardiac hypertrophy and heart failure. During diabetes, the occurrence of 
insulin resistance in the myocardium, together with increased rates of 
systemic lipolysis, means that the heart relies almost exclusively on 
mitochondrial fatty acid -oxidation as the sole fuel source [6]. Reduced 
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myocardial glucose uptake and utilization owing to altered insulin 
signalling may account for the loss of this capacity to switch between 
glucose and fatty acids in insulin-resistant and insulin-deficient forms of 
diabetes. Despite the higher fatty oxidation rate that occurs in the diabetic 
heart, myocardial lipid accumulation is a feature of this disease. The heart 
is not a major site of lipid storage, but fatty acids can be stored as 
triacylglycerols and phospholipids within the cardiomyocyte, particularly 
when they are abundant, as occurs with diabetes or obesity. If this 
accumulation persists over time, the heart will begin to accumulate toxic 
lipid intermediates linked to the development of insulin resistance and 
lipotoxic cardiomyopathy. In fact, there is a strong correlation between 
intracardiac lipid accumulation and heart failure in humans [9]. 
 Metabolic dysregulation occurring in the heart of obese and diabetic 
patients often involves derangements in the activity of both PPARs and 
PGC-1 . The expression and activity of PPAR  and PGC-1  are increased 
in the early stages of insulin resistance in the heart [10], thus promoting 
excessive utilization of fatty acids instead of glucose, and driving diabetic 
cardiomyopathy [6]. In contrast, in overt diabetes the expression and activity 
of PPAR  and PGC-1  are reduced, inducing mitochondrial dysfunction 
and cardiac hypertrophy [11]. Some debate exists about the role of PGC-1  
during diabetes, since it has been reported to be down-regulated in the 
myocardial tissue of streptozotocin-induced diabetic rats, a fact which is 
accompanied by a reduction in left ventricular function [12], but also 
activated in streptozotocin-induced mice [13]. PPAR /  also plays an 
important role in diabetic cardiomyopathy. It has been demonstrated that 
deletion of the PPAR /  gene in the heart results in cardiac dysfunction, 
cardiac hypertrophy and myocardial lipid accumulation [14]. Diabetic 
cardiomyopathy induced with streptozotocin in rats is associated with 
ventricular hypertrophy, intramyocardial lipid accumulation and a marked 
decrease in cardiac PPAR /  protein levels [15]. Furthermore, PPAR /  
protein levels are reduced in neonatal rat cardiomyocytes and rat H9c2 
cardiomyoblasts exposed to hyperglycaemia [15].  
 Transgenic mice with cardiac-specific overexpression of PDK4, and 
thus with chronic suppression of glucose oxidation, exhibit an insulin-
resistant profile characterized by low glucose oxidation rates and high fatty 
acid catabolism [16]. This shift in the substrate preference constrains 
metabolic flexibility and predisposes to cardiomyocyte fibrosis and 
cardiomyopathy. Interestingly, transgenic PDK4 mice are protected against 
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high-fat diet-induced myocyte lipid accumulation, probably owing to their 
increased capacity for mitochondrial fatty acid oxidation. This is related to 
the activation of AMPK and its known target, PGC-1 , and the increased 
capacity for uncoupled mitochondrial respiration. 
 
3. The role of NF- B-induced inflammation in diabetic 
cardiomyopathy 
 
 Under various pathological stimuli, the human myocardium secretes a 
number of pro-inflammatory cytokines and chemokines, which exert several 
pleiotropic effects in cardiac cells. Sustained increases in their levels may 
contribute to states that are associated with myocardial inflammation (i.e. 
heart failure and dilated cardiomyopathy) [17]. Pro-inflammatory cytokine 
expression is under the control of the ubiquitous and inducible transcription 
factor NF-κB, which is itself activated in congestive heart failure and cardiac 
hypertrophy [18]. Several exogenous and endogenous stimuli may induce 
NF- B transcriptional activity, notably the pro-inflammatory cytokines 
themselves, hyperglycaemia, elevated free fatty acid levels in plasma, 
reactive oxygen species, angiotensin II, endothelin 1, lipoproteins and 
anoxia. 
 In mammals, NF-κB consists of five members: p65 (RelA), RelB, c-
Rel, NF- B1 (p50 and its precursor p105) and NF- B2 (p52 and its 
precursor p100), which form either homodimers or heterodimers. The most 
abundant form of the NF- B family is the p65/p50 heterodimer, which is 
often used synonymously for NF-κB. In resting cells, NF- B is present in 
the cytoplasm as an inactive heterodimer bound to an inhibitor protein 
subunit, I B. After stimulation, the canonical or classical pathway of NF-
κB signalling involves the activation of the I B kinase (IKK) complex, 
which specifically phosphorylates I B. Phosphorylation of I B induces its 
subsequent proteasome-mediated degradation, thus releasing the NF- B 
heterodimer, which then translocates to the nucleus and binds to specific 
promoter sequences on its target genes to begin the transcription 
machinery. Furthermore, the p50/p65 heterodimer may undergo a series of 
post-translational modifications including phosphorylation, acetylation and 
methylation, which allow finely-tuned regulation of transcriptional 
activity. 
 The main cardiac responses to diabetes are oxidative stress, 
inflammation, endothelial dysfunction, cardiac fibrosis, hypertrophy and 
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apoptosis, in all of which NF- B may participate. Cardiac inflammation is 
an early and notable response to diabetes and is actively involved in the 
development of heart failure during diabetic cardiomyopathy [19]. Several 
pro-inflammatory cytokines that have elevated levels in circulation in obese 
and diabetic patients, such TNF-  and IL-6, are involved in the 
physiopathological process that relates obesity and insulin resistance in the 
heart [2]. 
   
4. Crosstalk between inflammation and metabolism in the 
diseased heart 
 
4.1. PPAR /  activation blocks lipid-induced inflammation in the heart 
 
 In the heart, excess dietary fat may result in myocardial insulin 
resistance, and is related to a range of direct effects, including 
inflammation, hypertrophy, fibrosis and contractile dysfunction. PPARs 
are capable of limiting myocardial inflammation independently of binding 
to DNA, through a mechanism termed trans-repression. Several 
mechanisms have been proposed to explain these anti-inflammatory 
effects, for example the physical interaction between PPARs and NF- B, 
thereby resulting in a functional cross-inhibition of their transcriptional 
activity. In the heart of mice fed a high-fat diet or in human cardiac AC16 
cells, treatment with the saturated fatty acid palmitate induced the 
expression of TNF- , MCP-1 and IL-6, together with the activity of NF- B 
(Fig. 2A) [20]. Interestingly, the PPAR /  agonist GW501516 abrogated 
this pro-inflammatory profile. Similarly, NF- B-dependent inflammation 
was induced in the heart of PPAR /  knockout mice, a fact which is 
consistent with the anti-inflammatory activity of PPAR /  [20]. This latter 
study reported that PPAR /  activation by GW501516 strongly enhanced 
the physical interaction between the p65 subunit of NF- B and PPAR /  
(Fig. 2B), thereby suggesting that this mechanism may also interfere with 
NF-κB trans-activation capacity in the heart. Furthermore, addition of 
GSK0660 partially blocked the enhanced interaction between p65 and 
PPAR /  in AC16 cells, thus linking this physical interaction with 
PPAR /  availability in the nucleus and its subsequent activity. Likewise, 
PPAR /  activation with its agonists L-165041 or GW0742 inhibits 
phenylephrine- and lipopolysaccharide-induced NF-κB activation in 
cultured neonatal rat cardiomyocytes and H9c2 cells through enhanced 
physical interaction between p65 and PPAR /  [21,22]. Other studies also 
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demonstrate that PPAR /  activation by ligand administration or 
adenoviral overexpression in cultured cardiac myocytes suppresses the     
NF- B signalling pathway and displays potent anti-inflammatory effects 
[13,23]. 
  
therapeutic target to prevent cardiac disease in metabolic disorders. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The PPAR /  agonist GW501516 (GW) prevents inflammation in the heart 
of mice fed a high-fat diet (HFD). (A) mRNA levels assessed by real-time RT-PCR 
(upper panel) and electrophoretic mobility shift assay showing NF- B activity (lower 
panel, Ab, antibody; NE, nuclear extract; IC, immunocomplex). *P<0.05, **P<0.01 
vs. Control; †P<0.05 vs. HFD. (B) Co-immunoprecipitation of nuclear protein extracts 
obtained from AC16 cells treated with palmitate (Pal), GW501516 (GW) and 
GSK0660 (GSK). (C) MCP-1 mRNA levels assessed by real-time RT-PCR in AC16 
cells treated with palmitate, GW501516 and compound C (Comp C). *P<0.05, 
**P<0.01 vs. Control; †P<0.05, ‡P<0.01 vs. Palmitate; &P<0.001 vs. Pal+GW. 
“Reprinted from Álvarez-Guardia et al., Biochimica et Biophysica Acta (BBA) - Molecular and 
Cell Biology of Lipids, 1811:59-67, Copyright  (2011), with permission from Elsevier 
Limited”. 
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Figure 2. The PPAR /  agonist GW501516 (GW) prevents inflammation in the 
heart of mice fed a high-fat diet (HFD). (A) mRNA levels assessed by real-time          
RT-PCR (upper panel) and electrophoretic mobility shift assay showing NF- B 
activity (l wer panel, Ab, antibody; NE, nuclear extr ct; IC, immunoc mplex). 
*P<0.05, **P<0.01 vs. Control; †P<0.05 vs. HFD. (B) Co-immunoprecipitation of 
nuclear protein extracts obtained from AC16 cells treated with palmitate (Pal), 
GW501516 (GW) and GSK0660 (GSK). (C) MCP-1 mRNA levels assessed by real-
time RT-PCR in AC16 cells treated with palmitate, GW501516 and compound C 
(Comp C). *P<0.05, **P<0.01 vs. Control; †P<0.05, ‡P<0.01 vs. Palmitate; 
&P<0.001 vs. Pal+GW. 
“Reprinted from Álvarez-Guardia et al., Biochimica et Biophysica Acta (BBA) - Molecular and 
Cell Biology of Lipids, 1811:59-67, Copyright  (2011), with permission from Elsevier 
Limited”. 
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 It has been reported that GW501516 is able to regulate lipid and 
glucose metabolism in human skeletal muscle by AMPK-dependent, but 
PPAR / -independent, mechanisms [21]. Since activation of AMPK may 
block NF- B signalling pathway through the blockade of IKK activity 
[22], it might be feasible that GW501516 was blocking lipid-induced 
inflammatory pathways in cardiac cells through AMPK-dependent 
mechanisms. An experiment in which the AMPK inhibitor compound C 
was added before GW501516 and palmitate confirmed the anti-
inflammatory role of this kinase in human cardiac AC16 cells (Fig. 2C). 
These results are relevant, especially taking into account that PPAR /  has 
been postulated as a potential target in the treatment of obesity and the 
insulin resistance state. Since chronic low-grade inflammation plays a 
significant role in cardiac hypertrophy and heart failure, and GW501516 
has been shown to ameliorate metabolic disturbances in heart caused by 
high-fat diets, it is tempting to speculate that PPAR /  might serve as a 
therapeutic target to prevent cardiac disease in metabolic disorders. 
 
4.2. The role of the PPAR/PGC-1 /PDK4 axis in the crosstalk between 
inflammatory processes and metabolism 
 
 Cardiac PGC-1  expression, along with its target transcription factors 
PPARs and ERR , are all reduced in animal models of heart failure 
[23,13] and in pathological forms of cardiac hypertrophy [24,25], 
suggesting that this decrease may be responsible for an energetic failure 
that can eventually lead to cardiac dysfunction. Likewise, PGC-1
 
knockout mice exhibit lower cardiac power and increased reliance on 
glucose oxidation [26]. Exposure of human cardiac AC16 cells to TNF-  
inhibited the expression of PGC-1 , a fact which resulted in a reduction in 
PDK4 expression and subsequent increase in the glucose oxidation rate 
(Fig. 3A) [27]. It is worth mentioning that all these changes were 
abrogated with parthenolide, thus demonstrating the involvement of the 
NF- B pathway [28]. In consonance with this, transgenic mice with 
constitutive and specific overexpression of TNF-  in the heart, a well-
characterized model of cytokine-induced cardiomyopathy, displayed 
reduced PGC-1  and PDK4 expression in the heart, and this was 
accompanied an increase in glucose utilization. In a similar way, 
phenylephrine and LPS down-regulate the expression of PGC-1  and 
PDK4 in rat neonatal cardiomyocytes, resulting in an increase in glucose 
utilization and a decrease in fatty acid oxidation, a phenotype which 
resembles that observed during cardiac hypertrophy [28,29]. Interestingly, 
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the PPAR /  agonist L-165041 prevented the reduction in PDK4 
expression induced by both phenylephrine and LPS [22]. Overall data 
suggest the hypothesis that the NF- B-mediated inhibition of PGC-1  
accounts for the shift towards increased glycolysis during cardiac 
hypertrophy and heart failure. 
 An appealing question arose about the specific molecular mechanisms 
by which PGC-1  was down-regulated after NF- B activation in cardiac 
cells. Co-immunoprecipitation studies not only demonstrated that the               
p65 subunit of NF- B interacted with PGC-1  in the basal state, but also this  
 
expression and the subsequent increase in glucose oxidation observed during 
the pro-infla matory state (Fig. 3C) [30]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The p65 subunit of NF- B binds to PGC-1  in cardiac cells. (A) PGC-
1  and PDK4 expression determined by RT-PCR and [U-14C]-glucose oxidation 
rate in  
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Figure 3. The p65 subunit of NF- B binds to PGC-1  in cardiac cells. (A) PGC-1  
and PDK4 expression determined by RT-PCR and [U-14C]-glucose oxidation rate in 
AC16 cells treated with TNF-  and the NF- B inhibitor parthenolide (Parth). (B) 
Co-immunoprecipitation of nuclear protein extracts obtained from AC16 cells treated 
with TNF-  and/or parthenolide. (C) Co-immunoprecipitation (left panel) of nuclear 
protein extracts obtained from AC16 cells transfected with PGC-1 , PGC-1 L2/3A 
or lacZ (Control); analysis of PDK4 gene expression determined by RT-PCR (middle 
panel, † P<0.01 vs. Control; ‡ P<0.01 vs. PGC-1 ; # P<0.01 vs. TNF- ; & P<0.001 
vs. PGC-1 +TNF- ); and [U-14C]-glucose oxidation rate expressed as a percentage 
with respect to control cells (right panel, *P < 0.05, **P < 0.01  vs. Control). 
“Reprinted from Palomer et al., Cardiovascular Research, 81:703-712, Copyright  (2009); 
and Álvarez-Guardia et al., Cardiovascular Research, 87:449-458, Copyright  (2010), with 
permission from Oxford University Press”. 
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binding was increased after stimulation of NF- B activity, and owing to 
p65 accumulation in the nucleus (Fig. 3B) [30]. Modulation of the PGC-1  
protein levels by means of overexpression or gene silencing demonstrated 
that the main factor limiting the degree of association between p65 and 
PGC-1  is the amount of p65 present in the nucleus. 
 PGC-1  binds nuclear receptors through three leucine-rich LXXLL 
motifs (named L1, L2 and L3), which are located within the N-terminus of 
the coactivator, and it is widely recognized that PGC-1  associates with 
other co-regulators via these LXXLL motifs [31]. Given that NF- B also 
requires the binding to specific LXXLL motifs located within the sequence 
of specific coactivators to drive gene expression [32], we investigated 
whether these motifs were responsible of the modulation of PGC-1  
activity by p65. On the basis of co-immunoprecipitation studies, and using 
a mutated form of PGC-1 , we reported that the L2 and L3 motifs play a 
crucial role in p65 binding (Fig. 3C) [30]. Therefore, in cardiac cells, the 
increased physical interaction between p65 and the L2/L3 motifs of PGC-
1  after NF- B activation might reduce PGC-1  expression, thereby 
leading to a reduction in PDK4 expression and the subsequent increase in 
glucose oxidation observed during the pro-inflammatory state (Fig. 3C) 
[30]. 
 
4.3. PPAR-independent mechanisms in the regulation of PDK4 during 
inflammation  
 
 Other mechanisms might also account for the down-regulation of 
PGC-1  after NF- B activation. For instance, NF- B activation may 
indirectly stimulate PKB/Akt [30] and, since PGC-1  contains a consensus 
binding site for PKB/Akt phosphorylation that reduces its stability, it may 
result in a diminution in its transcriptional activity [33]. PKB/Akt also has 
the capacity to phosphorylate the FOXO1 transcription factors [34], 
thereby inducing their ubiquitination-dependent degradation and 
eventually leading to a decrease in the expression of their target genes           
(i.e. PGC-1 ) [35]. 
 We have also recently proposed a novel mechanism by which the 
inflammatory processes driven by NF- B can down-regulate PDK4 through 
inhibition of the E2F1 transcription factor in a PPAR- and ERR -
independent manner. E2F1 is known for its major role in regulating the G1/S 
phase transition during cell cycle progress, hence acting as a critical 
regulator of cell survival and proliferation [36]. However, it has also been 
demonstrated that it may regulate PDK4 expression through specific sites 
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located within the promoter of the gene that encodes for the latter [37]. 
Protein co-immunoprecipitation analyses revealed that PDK4 
downregulation entailed enhanced physical interaction between the p65 
subunit of NF- B and E2F1 (Fig. 4A) [38]. The association between p65 and 
E2F1 has already been established in human [39] and murine fibroblasts 
[40]. Chromatin immunoprecipitation analyses demonstrated that p65 
translocation into the nucleus prevented the recruitment of E2F1 to the 
PDK4 promoter and its subsequent E2F1-dependent gene transcription in 
human cardiac cells (Fig. 4B), thus influencing glucose oxidation (Fig. 4C). 
Interestingly, the NF- B inhibitor parthenolide prevented the inhibition of E2F1. 
 
left ventricular hypertrophy leading to heart failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The interplay between NF- B and E2F1 regulates metabolism in 
cardiac cells. (A) Co-immunoprecipitation of nuclear protein extracts obtained 
from AC16 cells treated with or without TNF-  and transfected with LacZ- or 
E2F1-carrying  
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Figure 4. The interplay between NF- B and E2F1 regulates metabolism in cardiac 
cells. (A) Co-immunoprecipitation of nuclear protein extracts obtained from AC16 
cells treated with or without TNF-  and transfected with LacZ- or E2F1-carrying 
plasmids. (B) Chromatin immunoprecipitation demonstrating the E2F1-site fold 
enrichment at the PDK4 promoter and (C) [U-14C]-glucose oxidation rate in AC16 
cells overexpressing the human LacZ-control or the E2F1 genes incubated with TNF-
. *P<0.05, **P<0.01, ***P<0.001 vs. LacZ; †P<0.01 vs. E2F1; &P<0.01 vs. 
LacZ+TNF- . 
“Reprinted from Palomer et al., PLoS ONE, 6, e19724, Copyright  (2011), with permission 
from PLoS – Public Library of Science, and following the Creative Commons Attribution (CC 
BY) license”. 
Xavier Palomer et al. 180 
Based on these findings, we envision a model for the regulation of PDK4 
expression and cardiac cell metabolism by NF- B and E2F1, in which NF-
B might serve as a molecular switch that regulates E2F1-dependent 
PDK4 gene transcription. As inappropriate PDK4 activity would have 
catastrophic consequences in high-metabolic-rate organs, the basal 
repression of E2F1-dependent PDK4 expression by NF- B might be 
crucial for normal cardiac function. Since E2F1 plays an important role in 
cardiac myocyte growth and is also involved in metabolism regulation 
through PDK4 modulation, targeting this transcription factor could provide 
us with an effective therapy for treating detrimental left ventricular 
hypertrophy leading to heart failure.  
 There are several other pathways that may account for the interplay 
between inflammation and metabolic responses in the heart. For instance, 
the heart of obese mice fed a high-fat diet display a reduction in glucose 
metabolism, GLUT and AMPK activity, which is accompanied by 
macrophage infiltration and enhanced inflammation [41]. A similar profile 
is observed after IL-6 administration in mice, whereby this cytokine 
suppresses the glucose metabolism and induces insulin resistance owing to 
AMPK activity and IRS-1 inhibition [42]. In accordance with this, AMPK 
activation diminishes NF- B signalling, attenuates cardiac hypertrophy 
and improves cardiac function in rats subjected to trans-aortic constriction 
or in rat neonatal cardiomyocytes induced with angiotensin II [42]. 
 Enhanced saturated free fatty acid (e.g. palmitate) levels up-regulate 
the lipid intermediates ceramides and diacylglycerol (DAG), the latter 
being a powerful activator of protein kinase C (PKC) . Likewise, 
hyperglycaemia activates the glycolytic pathway and increases the 
production of the PKC/DAG pathway [43]. PKC activation may provoke 
insulin resistance by means of IRS-1 inhibition and inflammation through 
NF- B induction [44]. On the other hand, ceramides are lipotoxic 
molecules that modulate cellular energy metabolism and are enhanced in 
several models of lipotoxic cardiomyopathy. They are necessary and 
sufficient intermediates linking saturated fats to the inhibition of insulin 
signalling and enhanced inflammation [45]. In transgenic mice prone to 
dilated cardiomyopathy owing to ceramide accumulation in the heart, there 
is an up-regulation of fatty acid oxidation while glucose oxidation is down-
regulated [46]. This has been related to the ceramide-dependent increase in 
the expression of genes such as PDK4, and the fatty acid transporters 
FAT/CD36, FATP1 or ACS [46]. 
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 Finally, recent studies have revealed an important link between sirtuin 
1 (SIRT1), energy metabolism and inflammation [46]. The main reason for 
this link is perhaps that besides its ability to inhibit NF- B activity, SIRT1 
may associate with and deacetylate PGC-1 , leading to enhanced 
transcriptional activity of the latter. A paradigmatic example of this is 
given by the overexpression of SIRT1 in transgenic mice fed a high-fat 
diet, which show lower lipid-induced inflammation along with better 
glucose tolerance [47]. This study reported that the beneficial effects of 
SIRT1 were due both to the induction of the antioxidant proteins via 
stimulation of PGC-1 , and lower activation of pro-inflammatory 
cytokines, owing to NF- B activity down-modulation. Similarly, SIRT1 
inhibition in primary myotubes down-regulates PGC-1  and its target 
mitochondrial transcriptional regulators, ERR  and mtTFA, along with the 
expression levels of mitochondrial and fatty acid utilization genes [48]. On 
the other hand, both the activation of SIRT1 with resveratrol and 
overexpression of SIRT1 reduced phenylephrine-induced hypertrophy and 
the down-regulation of fatty acid oxidation genes in neonatal rat cardiac 
myocyte [49]. According to a study by Planavila et al. [50], SIRT1 
overexpression led to enhanced PPAR  binding to the p65 subunit of    
NF- B and subsequent p65-deacetylation, thus blocking NF- B activity. 
Consistent with this, isoproterenol-induced cardiac hypertrophy, metabolic 
dysregulation and inflammation were prevented by resveratrol in wild-type 
mice, but not in PPAR -null mice. Moreover, SIRT1 overexpression led to 
deacetylation of PGC-1  [50] and phosphorylation-induced AMPK 
activation [50]. In fact, besides the PPAR/PGC-1  pathway, SIRT1 
modulates the activity of a number of proteins involved in cardiac 
metabolic homeostasis. For instance, it has been reported an important role 
of SIRT1 in regulating the ERR transcriptional pathway during the 
progression of heart failure, thus promoting mitochondrial dysfunction 
[51]. 
 
5. Conclusion 
 
 Free fatty acids are the preferred energy substrate in the adult heart, 
although other substrates such as glucose or lactate may provide additional 
fuel sources in diverse circumstances. At the transcriptional level, cardiac 
metabolism is mostly regulated by the PPAR/PGC-1 /PDK4 axis. The 
PGC-1  co-activates PPAR , PPAR /  and ERR  to regulate the 
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expression of genes involved in the electron transport chain, mitochondrial 
biogenesis, fatty acid -oxidation and glucose oxidative metabolism. One 
of its key target genes, PDK4, may promote insulin resistance through the 
inhibition of efficient glucose utilization. During diabetes, and owing to 
the insulin resistance and the dysregulation in the activity of both PPARs 
and PGC-1 , the myocardium relies almost exclusively on mitochondrial 
fatty acid -oxidation as the main fuel source. As a consequence, one of the 
hallmarks of diabetic cardiomyopathy is myocardial lipid accumulation, 
which is related to the development of lipotoxic cardiomyopathy. During 
diabetic cardiomyopathy, the excess of fatty acid oxidation in 
mitochondria induces the formation of reactive oxygen species and the 
accumulation of lipid intermediates, promoting NF- B activation and, as a 
result, contributing to cardiac inflammation and subsequent development 
of heart failure. 
 In this review, we report that PPAR activation is capable of limiting 
myocardial inflammation by means of trans-repression through several 
mechanisms, including the physical interaction between PPARs and pro-
inflammatory NF- B. Notably, PPAR  and PPAR /  activation might 
prevent metabolic disturbances occurring during diabetic cardiomyopathy, 
while inhibiting inflammatory processes in the heart. This is relevant, 
especially taking into account that PPARs have been postulated as 
potential targets in the treatment of obesity and the insulin resistance state. 
On the other hand, several studies point to PGC-1  as a potential 
contributor to cardiac dysfunction and heart failure in metabolic disorders 
with an inflammatory background. Here, we have described several well-
known and new mechanisms by which PGC-1  activity is modulated after 
NF- B induction, for instance the sequestration of PGC-1  protein by p65, 
the PKB/Akt-mediated phosphorylation of PGC-1 , or FOXO inhibition              
(Fig. 5). PGC-1  down-regulation often results in diminished PDK4 
expression, a crucial step in determining the rates of glucose and fatty acid 
oxidation in the heart. However, other mechanisms may account for PDK4 
down-regulation, including the inhibition of E2F1. 
 In summary, an increasing body of evidence suggests a potential link 
between chronic inflammation and metabolic disturbances in the heart. 
Gaining more insight into the mechanisms by which cardiac inflammatory 
processes may deregulate metabolic homeostasis in the heart may assist in 
devising new therapeutic strategies to restore cardiac function during insulin 
resistance and diabetes. 
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Figure 5. Crosstalk between inflammation and metabolism in the diseased heart. 
PPAR activation is capable of limiting myocardial NF- B activity through several 
mechanisms, such as its physical interaction with the p65 subunit of NF- B, or the 
inhibition of MAPK phosphorylation. PPAR  is also capable of inhibiting NF- B 
activity by inducing I B  expression. After NF- B activation, the increased physical 
interaction between p65 and PGC-1  reduces the transcriptional activity of the latter, 
thus diminishing its target gene expression (ACS, CPT-1, FAT/CD36, GLUT4, and 
PDK4). NF- B may also down-regulate PDK4 through inhibition of the E2F1 
transcription factor. SIRT1 down-regulates NF- B activity through p65 deacetylation 
and enhances the activities of PGC-1  and AMPK. AMPK also diminishes NF- B 
signalling due to IKK inhibition and the subsequent lowering of IkB  degradation. 
NF- B activation may also indirectly stimulate PKB/Akt, which catalyzes the 
phosphorylation-mediated inhibition of PGC-1 , and also has the capacity to 
phosphorylate FOXO1, thereby inducing its degradation and finally leading to a 
decrease in the expression of PGC-1 . 
 “Reprinted from Palomer et al., International Journal of Cardiology, 168:3160-3172, 
Copyright  (2013), with permission from Elsevier Limited”. 
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